<SEC-DOCUMENT>0001171843-15-005108.txt : 20150910
<SEC-HEADER>0001171843-15-005108.hdr.sgml : 20150910
<ACCEPTANCE-DATETIME>20150910093054
ACCESSION NUMBER:		0001171843-15-005108
CONFORMED SUBMISSION TYPE:	20-F/A
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150910
DATE AS OF CHANGE:		20150910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		20-F/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		151100191

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F/A
<SEQUENCE>1
<FILENAME>gff20fa_090915.htm
<DESCRIPTION>FORM 20-F/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>FORM 20-F/A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Amendment No. 1)</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">OR</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD STYLE="text-align: justify">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">For the fiscal year ended December 31, 2014</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 3.15in; margin: 0pt 0">OR</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 3.15in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">OR</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3pt"></TD><TD STYLE="width: 32.45pt"><FONT STYLE="font-family: Wingdings">o</FONT></TD><TD STYLE="text-align: justify">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Date of event requiring this shell company report ________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Commission file number <U>001-35773</U></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.1pt solid; text-align: center; width: 100%">RedHill Biopharma Ltd.</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">(Exact name of Registrant as specified in its charter)</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.1pt solid; text-align: center">N/A</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">(Translation of Registrant&rsquo;s name into English)</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.1pt solid; text-align: center">Israel</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">(Jurisdiction of incorporation or organization)</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.1pt solid; text-align: center">21 Ha&rsquo;arba&rsquo;a Street, Tel Aviv 64739, Israel</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">(Address of principal executive offices)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">Ori Shilo, Deputy Chief Executive Officer Finance and Operations&nbsp;</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">21 Ha&rsquo;arba&rsquo;a Street, Tel Aviv 64739, Israel</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.1pt solid; text-align: center">Tel: 972-3-541-3131; Fax: 972-3-541-3144</td></tr>
<tr style="vertical-align: middle">
    <td style="font-size: 10pt; text-align: center">&nbsp;(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</td></tr>
</table>


<P STYLE="font-size: 10pt; font-style: italic; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Securities registered or to be registered pursuant to Section 12(b)
of the Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: center; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Title of class</U></FONT></TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Name of each exchange on which registered</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">American Depositary Shares, each representing ten Ordinary Shares
<SUP>(1)</SUP> </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Nasdaq Capital Market</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Ordinary Shares, par value NIS 0.01 per share<SUP> (2)</SUP></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Evidenced by American Depositary Receipts.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Not for trading, but only in connection with the listing of the American Depositary Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: justify; margin: 0pt 0"><FONT STYLE="font-style: normal">Securities
registered or to be registered pursuant to Section 12(g) of the Act:</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><U>None</U>&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Title of Class)</P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: justify; margin: 0pt 0"><FONT STYLE="font-style: normal">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act:</FONT></P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: justify; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 100%; text-align: center; border-bottom: Black 1.1pt solid">None</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; font-style: italic; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: center; margin: 0pt 0"><FONT STYLE="font-style: normal">(Title of Class)</FONT></P>

<P STYLE="font-size: 10pt; font-style: italic; text-align: left; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-style: italic; text-align: left; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Indicate the number of outstanding shares of each of the issuer&rsquo;s
classes of capital or common stock as of the close of the period covered by the annual report: 127,029,294</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 3pt">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Yes &#9744;&nbsp; &nbsp;&nbsp;No&nbsp;&#9746;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 3pt; text-indent: 40pt">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange
Act 1934.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Yes &#9744;&nbsp; &nbsp;No&nbsp;&#9746;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 3pt; text-indent: 40pt">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to
such filing requirements for the past 90 days.&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&#9746;&nbsp;Yes&nbsp;&nbsp;&nbsp;No&nbsp;&#9744;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-right: 9.05pt; margin-bottom: 3pt; font-size: 10pt; text-align: left; text-indent: 40pt">Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files).</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><FONT STYLE="color: windowtext">Yes &#9744;&nbsp;&nbsp;No
&#9744;</FONT></P>

<P STYLE="margin: 0pt 9pt 0pt 0; font-size: 10pt; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 3pt; text-indent: 40pt">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;accelerated filer and
large accelerated filer&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 80%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD NOWRAP STYLE="width: 33%; text-align: left">Large Accelerated filer &#9744;</TD>
    <TD NOWRAP STYLE="width: 34%">Accelerated filer &nbsp;&#9744;</TD>
    <TD NOWRAP STYLE="width: 33%">Non-accelerated filer &#9746;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 3pt; text-indent: 40pt">Indicate by check mark
which basis of accounting the registrant has used to prepare the financial statements included in this filing:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 40pt">U.S. GAAP
&#9744;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 40pt">International Financing Reporting Standards as issued by the International
Accounting Standards Board&nbsp;&#9746;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 40pt">Other&nbsp;&#9744;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 3pt; text-indent: 40pt">If &ldquo;Other&rdquo; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Item 17 [ ] &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item 18 [ ]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 3pt; text-indent: 40pt">If this is an annual report, indicate by check
mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Yes&nbsp;&#9744;&nbsp; &nbsp;No&nbsp;&#9746;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 40pt">We are an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, may elect to comply with certain
reduced public company reporting requirements.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 27pt; margin: 0pt 0">This Amendment No. 1 on Form 20-F/A (&ldquo;Amendment&rdquo;)
to Annual Report on Form 20-F for the year ended December 31, 2014 (the &ldquo;Original Form 20-F&rdquo;) of RedHill Biopharma
Ltd. (the &quot;Company&quot;), as originally filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
on February 26, 2015 (the &ldquo;Original Filing Date&rdquo;), is being filed solely to amend Exhibits 4.10, 4.11, 4.16, 4.17,
4.18 and 4.19 (the &ldquo;Exhibits&rdquo;) filed with the Original Form 20-F. The Company had sought confidential treatment under
Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and 17 C.F.R. Section
200.80(b)(4), for portions of the Exhibits and, following correspondence with the Staff of the Commission&rsquo;s Division of Corporate
Finance (the &ldquo;Staff&rdquo;), is re-filing the Exhibits to address comments the Company received from the Staff in response
to its request for confidential treatment.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 27pt; margin: 0pt 0">The Exhibits filed herewith supersede the Exhibits
filed with the Original Form 20-F. Except for the revised Exhibits, this Amendment does not reflect any events that may have occurred
subsequent to the Original Filing Date and does not modify or update any disclosures made in the Original Form 20-F. Additionally,
in connection with the filing of this Amendment, the Company is including new certifications of the Company&rsquo;s Chief Executive
Officer and Deputy Chief Executive Officer Finance and Operations pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange
Act. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18
U.S.C.1350) as no financial statements are being filed with this Amendment.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0pt 0">EXHIBIT INDEX</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The exhibits filed with or incorporated into this Registration Statement
are listed in the index of exhibits below</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><U>Exhibit </U></B></P>
        <P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><U>Number</U></B></P></TD>
    <TD STYLE="width: 93%; text-align: justify; text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Exhibit Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">1.1**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Articles of Association of the Registrant, as amended (unofficial English translation).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Deposit Agreement among the Registrant, the Bank of New York Mellon, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued hereunder (incorporated by reference to Exhibit 1 to the Registration Statement on Form F-6 filed by The Bank of New York Mellon with the Securities and Exchange Commission on December 6, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">2.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of American Depositary Receipt (incorporated by reference to Exhibit 1 to the Registration Statement on Form F-6 filed by The Bank of New York Mellon with the Securities and Exchange Commission on December 6, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.1*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Co- Development and Commercialization Agreement, dated August 26, 2010, by and between the Registrant and IntelGenx Corp. (incorporated by reference to Exhibit 4.3 to Draft Registration Statement on Form DRS disseminated with the Securities and Exchange Commission, dated December 3, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Side Letter Agreement, dated January 31, 2013, by and between the Registrant and IntelGenx Corp (incorporated by reference to Exhibit 4.4 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 25, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.3*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Asset Purchase Agreement, dated August 11, 2010, by and between the Registrant and Giaconda Limited (RHB-104, 105, 106) (incorporated by reference to Exhibit 4.4 to Draft Registration Statement on Form DRS disseminated with the Securities and Exchange Commission, dated December 3, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.4 &dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amendment to Asset Purchase Agreement by and between the Registrant and Giaconda Limited (RHB-104, 105, 106) dated February 27, 2014.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.5*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">License Agreement, dated September 15, 2011, by and between the Registrant and University of Central Florida Research Foundation (incorporated by reference to Exhibit 4.5 to Draft Registration Statement on Form DRS disseminated with the Securities and Exchange Commission, dated October 26, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.6&dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">License Agreement, dated February 27, 2014, by and between the Registrant and Salix Pharmaceuticals, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.7*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Master Service Agreement, dated April 28, 2011, by and between the Registrant and 7810962 Canada Inc. and amendment (incorporated by reference to Exhibit 4.12 to Draft Registration Statement on Form DRS disseminated with the Securities and Exchange Commission, dated October 26, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Second Amendment to Master Services Agreement, dated May 29, 2013 by and between the Registrant and 7810962 Canada Inc. (incorporated by reference to Exhibit 4.9 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 25, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.9*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Manufacturing Agreement, dated October 21, 2012, by and between 7810962 Canada Inc. and the Registrant (regarding RHB-104) (incorporated by reference to Exhibit 4.14 to Draft Registration Statement on Form DRS disseminated with the Securities and Exchange Commission, dated October 26, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.10&dagger;***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Manufacturing Agreement Amendment 1, dated October 29, 2014, by and between 7810962 Canada Inc. and the Registrant (regarding RHB-104).</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">4.11&dagger;***</FONT></TD>
    <TD STYLE="width: 93%"><FONT STYLE="font-size: 10pt">Manufacturing Agreement, dated October 28, 2014, by and between Canadian Manufacturer and the Registrant (regarding RHB-104).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.12*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Clinical Services Agreement, dated June 15, 2011, by and between RedHill and 7810962 Canada Inc. and amendment (regarding RHB-104) (incorporated by reference to Exhibit 4.15 to Draft Registration Statement on Form DRS disseminated with the Securities and Exchange Commission, dated December 3, 2012).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.13*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Second Amendment to Clinical Services Agreement, dated January 19, 2014, by and between the Registrant and 7810962 Canada Inc. (incorporated by reference to Exhibit 4.13 of the Annual Report on Form 20-F/A filed with the Securities and Exchange Commission on July 7, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.14&dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Third Amendment to Clinical Services Agreement, dated December 7, 2014, by and between the Registrant and 7810962 Canada Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.15&dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Fourth Amendment to Clinical Services Agreement, dated December 17, 2014, by and between the Registrant and 7810962 Canada Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.16&dagger;***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Master Service Agreement and Extension to Master Service Agreement, dated July 5, 2011 and Manufacturing Agreement, dated July 5, 2011, by and between 7810962 Canada Inc. and the Registrant, as amended (regarding RHB-105).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.17&dagger;***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">First Amendment to Manufacturing Agreement, dated August 17, 2011, by and between the Registrant and 7810962 Canada Inc. (regarding RHB-105)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.18***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Second Amendment to Manufacturing Agreement, dated September 30, 2011, by and between the Registrant and 7810962 Canada Inc. (regarding RHB-105)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.19&dagger;***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Third Amendment to Manufacturing Agreement, dated April 19, 2012, by and between the Registrant and 7810962 Canada Inc. (regarding RHB-105)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.20&dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Clinical Services Agreement, dated October 29, 2012, by and between RedHill and Clinipace, Inc. and (regarding RHB-105).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.21&dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amendment 1 to Attachment A-1, dated August 12, 2014, of the Clinical Services Agreement by and between RedHill and Clinipace, Inc. (regarding RHB-105).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.22&dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Clinical Trials Global Master Service Agreement, dated December 27, 2012 by and between the Registrant and Quest Diagnostics (regarding RHB-104).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.23**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Global Master Service Agreement amendment, dated June 20, 2014 by and between the Registrant and Quest Diagnostics (regarding RHB-104).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.24&dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Master Agreement Work Order, dated May 13, 2014, by and between the Registrant and Quest Diagnostics (regarding RHB-104).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.25&dagger;**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Change Specification Forms by and between Registrant and Quest Diagnostics (regarding RHB&nbsp;&nbsp;104) dated August 9, 2013, October 14, 2013, October 21, 2013, December 23, 2013, March 30, 2014, July 7, 2014, July 14, 2014, and December 18, 2014.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.26</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Letter of Exemption and Indemnity adopted on July 2013 (unofficial English translation) (incorporated by reference to Exhibit B to Exhibit 99.1 to Form 6-K disseminated with the Securities and Exchange Commission, dated June 26, 2013).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.27**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">2010 Stock Option Plan, as amended.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">4.28</FONT></TD>
    <TD STYLE="width: 93%"><FONT STYLE="font-size: 10pt">Securities Purchase Agreement, dated December 30, 2013 by and between the Registrant and OrbiMed Israel Partners Limited Partnership (together with Form of Warrant attached as Exhibit A) (incorporated by reference to Exhibit 4.17 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 25, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.29</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Securities Purchase Agreement, dated December 31, 2013 by and between the Registrant and Broadfin Healthcare Master Fund, LTD (together with Form of Warrant attached as Exhibit A) (unofficial English translation). (incorporated by reference to Exhibit 4.18 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 25, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.30</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Share Purchase Agreement, dated January 13, 2014 by and between the Registrant and each of the investors (together with Form of Warrant attached as Exhibit A) (unofficial English translation) (incorporated by reference to Exhibit 4.19 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 25, 2014).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.31</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Underwriting Agreement, dated February 10, 2015, between the registrant and Wells Fargo Securities, LLC as representative of the several Underwriters (incorporated by reference to Exhibit 1.1 to the Form 6-K submitted to the Securities and Exchange Commission on February 13, 2015).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">12.1***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">12.2***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">13**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certification by Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">15.1**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of Independent Registered Public Accounting Firm.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Confidential treatment granted with respect to certain portions of this Exhibit.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">**</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Previously filed with the Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 26, 2015.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">***</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Filed herein with this Amendment No. 1 on Form 20-F/A</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&dagger;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><U>SIGNATURE</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 40pt">The Registrant hereby certifies that it meets
all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual
report on its behalf.</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD COLSPAN="3" STYLE="vertical-align: middle">&nbsp;REDHILL BIOPHARMA LTD.</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom; width: 50%">&nbsp;</td>
    <TD STYLE="width: 3%">&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left; width: 6%">&nbsp;</td>
    <TD STYLE="width: 25%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 16%">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="text-align: justify">By:</td>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: left; border-bottom: Black 1.1pt solid">/s/ Dror Ben-Asher</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">Name:</td>
    <TD STYLE="text-align: justify">Dror Ben-Asher</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD>&nbsp;&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">Title:</td>
    <TD COLSPAN="2">Chief Executive Officer and Chairman of&nbsp;<BR>
the Board of Directors</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="text-align: justify">By:</td>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: left; border-bottom: Black 1.1pt solid">/s/ Ori Shilo</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">Name:</td>
    <TD STYLE="text-align: justify">Ori Shilo</td>
    <TD STYLE="vertical-align: bottom"></td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;&nbsp;</td>
    <TD STYLE="vertical-align: top; text-align: left">Title:</td>
    <TD COLSPAN="2" STYLE="text-align: justify">Deputy Chief Executive Officer Finance and <BR>
Operations</td></tr>
</table>


<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Date: September 10, 2015</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>2
<FILENAME>exh_410.htm
<DESCRIPTION>EXHIBIT 4.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; text-indent: 0pt; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 4.10</B></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>THE SYMBOL &#8220;</B>[****]<B>&#8221;</B> <B>DENOTES
PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</B></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>Project Order # </B>1879 RHB-104 Manufacturing
Amendment 1</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>THIS PROJECT ORDER No. </B>1879 RHB-104 Manufacturing
Amendment 1 is between RedHill Biopharma Ltd. (&#8220;SPONSOR&#8221;) and 7810962 Canada Inc. (&#8220;MANAGER&#8221;) and, upon
execution by both parties, shall be incorporated into the Service Agreement signed on 5July2014 between SPONSOR and MANAGER.</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">SPONSOR agrees that Manager enters into a subcontract with Corealis Pharma on the terms
set out in Amendment 1 of Project Order 1879 to be executed between 7810962 Canada Inc. and Corealis Pharma as shown below in Exhibit
A. For further clarity, SPONSOR agrees with the costs and to the payment schedule as described in Exhibit A.</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>IN WITNESS WHEREOF, this Proposal has been
executed by the parties hereto through their duly authorized officers on the date(s) set forth below.</B></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="background-color: white; width: 100%; font-size: 10pt">
<TR>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>REDHILL BIOPHARMA Ltd.</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>For 7810962 Canada Inc:</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font-size: 10pt">/s/ Dror Ben-Asher</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.1pt solid"><FONT STYLE="font-size: 10pt">/s/ Alain Guimond</FONT></TD>
    <TD STYLE="padding-bottom: 1.1pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Name: Dror Ben-Asher</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Alain Guimond</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title: CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Title: Senior Director of R&amp;D</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Date: 12Aug2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Date: 12Aug2014</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1.1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Ori Shilo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Name: Ori Shilo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Title: VP Finance and Operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Date: 12Aug2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt"><B>&#160;CONFIDENTIAL</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">&nbsp;&#160;</FONT></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>EXHIBIT A</B></FONT></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt"></FONT>&nbsp;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>Service Agreement
- G</B></FONT></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>7810962 Canada
Inc. - COREALIS Pharma Inc.</B></FONT></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>Clinical Trial
Material manufacture of RHB-104 capsules</B></FONT></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>AMENDMENT 1 TO THE SERVICE AGREEMENT G </B>is
made and entered into this twenty-third (23) day of July, 2014 (the &#8220;<B>Amendment</B>&#8221;).</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Client and Corealis entered into a service agreement G (document
143-111207rev11) dated the twenty-eight day of July, 2014 (the &ldquo;<B>Service Agreement G</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Client and Corealis entered into a Master Service Agreement
dated the fifth day of July, 2011 (the &ldquo;<B>MSA</B>&rdquo;).</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt">The Parties hereto wish to describe the services
to be performed in connection with the MSA, subject to the terms and conditions set forth herein and in the MSA.</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt">Unless the context otherwise requires, all capitalized
terms used in this Amendment shall have the meanings attributed to them in the MSA and the Service Agreement G.</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 36pt"><FONT STYLE="font-size: 11pt"><B>I.&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 11pt"><B>DESCRIPTION OF THE EXTRA WORK TO THE SERVICE
    AGREEMENT G</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt">The scope of this work is to identify a RHB-104
degradation product.</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt">The estimated cost is as follow:</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">Part 1</P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 3%">&bull;</TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 94%"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 3%">&bull;</TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 94%"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0 0pt 20pt; font-size: 10pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">Part 2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 3%">&bull;</TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 94%"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 36pt"><FONT STYLE="font-size: 11pt"><B>II.&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 11pt"><B>COST AND PAYMENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 36pt"><FONT STYLE="font-size: 10pt"><B>2.1-&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>The estimated cost of the Services for the Extra Work detailed in section 1 is 6,700 $USD.</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 36pt"><FONT STYLE="font-size: 10pt"><B>2.2-&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>The Client shall pay to&#160;[****] in United-States currency ($USD) upon the reception of invoices.</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt">The Parties hereto have requested that this Service
Agreement be drafted in the English language.&#160;&#160;<I>Les Parties ont exig&#233; que ce contrat de services soit r&#233;dig&#233;
en anglais.</I></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>IN WITNESS THEREOF, the Parties have executed
this Amendment as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention
to bind the Parties they represent.</B></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="background-color: white; width: 100%; font-size: 10pt">
<TR>
    <TD COLSPAN="3">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">Corealis Pharma Inc.</P></TD>
    <TD COLSPAN="3">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">7810962 Canada Inc.</P></TD></TR>
<TR>
    <TD NOWRAP STYLE="width: 2%; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 10pt"><B>Per:</B></FONT></TD>
    <TD STYLE="width: 16%; border-bottom: black 1.1pt solid"><FONT STYLE="font-size: 10pt"><B>/s/</B> </FONT></TD>
    <TD STYLE="width: 34%; padding-bottom: 1.1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 2%; text-align: left; padding-bottom: 1.1pt"><FONT STYLE="font-size: 10pt"><B>Per:</B></FONT></TD>
    <TD STYLE="width: 16%; border-bottom: black 1.1pt solid"><FONT STYLE="font-size: 10pt"><B>/s/ Alain Guimond</B></FONT></TD>
    <TD STYLE="width: 30%; padding-bottom: 1.1pt">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Name: Yves Roy, Ph.D.</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Name: Alain Guimond, Ph.D.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>Title: President</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">Title: Senior Director of <FONT STYLE="font-size: 10pt"><B>Research</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"><BR>
&#160;</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 25%"><P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><FONT STYLE="color: Black"><B>CONFIDENTIAL&#9;</B></FONT></P>

</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="color: Black">PO<B># </B>1879 RHB-104 Manufacturing Amendment 1&#9;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="color: Black">23July2014</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[****]</P>



<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0.25in 0pt 0"><FONT STYLE="color: Black"><I>7810962 Canada Inc.</I></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="color: Black"><I>245 Victoria Avenue, Suite 100, Montreal,
Quebec H3Z 2M6, Canada</I></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="color: Black"><I>Tel: +1 (514) 807-9315, Fax: +1 (514)
315-9029</I></FONT></P>



<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>3
<FILENAME>exh_411.htm
<DESCRIPTION>EXHIBIT 4.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>Exhibit 4.11</B></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD ROWSPAN="3" STYLE="vertical-align: middle; text-align: left; width: 36%"><img src="corealis_logo.jpg"></td>
    <TD STYLE="vertical-align: bottom; width: 11%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 12%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 14%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; border-left: Black 0.5pt solid; width: 27%">&nbsp;&nbsp;&nbsp;200 Armand-Frappier</td></tr>
<tr>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: middle; border: Black 0.5pt solid; text-align: center">CONFIDENTIAL</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: middle; border-left: Black 0.5pt solid; text-align: left">&nbsp;&nbsp;&nbsp;Laval, Quebec, Canada H7V 4A6 <BR>
&nbsp;&nbsp;&nbsp;Tel (450) 973-7505</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD STYLE="border-left: Black 0.5pt solid">&nbsp;&nbsp;&nbsp;www.corealispharma.com</td></tr>
</table>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>THE SYMBOL &#8220;</B>[****]<B>&#8221;</B> <B>DENOTES
PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</B></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>Service Agreement
- Y</B></FONT></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>Manufacture of
resupply of Clinical Trial Material of</B></FONT></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>[****] RHB-104
capsules</B></FONT></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>THIS SERVICE AGREEMENT Y </B>is made and entered
into this ___________ day of October, 2014 (the &#8220;<B>Service Agreement</B>&#8221;).</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE ALIGN="CENTER" BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 99pt; font-size: 10pt; text-indent: 0pt"><FONT STYLE="font-size: 10pt">BETWEEN:</FONT></TD>
        <P STYLE="margin: 0pt 0">COREALIS Pharma, Inc.<FONT STYLE="font-size: 10pt">, a corporation duly incorporated under the laws of
Canada and having its principal place of business at 200 Armand-Frappier, Laval, Qu&eacute;bec, Canada, H7V 4A6;</FONT></P></tr>

</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE ALIGN="CENTER" BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 99.25pt; font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">(hereinafter referred to as<FONT STYLE="font-size: 10pt"> &ldquo;<B>Corealis</B>&rdquo;)</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE ALIGN="CENTER" BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 99pt; text-indent: 0pt"><FONT STYLE="font-size: 10pt">AND</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>RedHill Biopharma Ltd.</B>, a company duly incorporated under the laws of Israel, and having its principal place of business at 21 Ha&#8217;arba&#8217;a St., Tel-Aviv, 64739 Israel;</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE ALIGN="CENTER" BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 99.25pt">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(hereinafter referred to as the &#8220;<B>Client</B>&#8221;)</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE ALIGN="CENTER" BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 99.25pt">&nbsp;</TD>
    <TD>
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">(Corealis</FONT> and the Client are at times referred
        to individually as the &#8220;Party&#8221; and collectively the &#8220;Parties&#8221;)</P></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>RECITALS</B></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 27pt"><FONT STYLE="font-size: 10pt"><B>A.&#160;&#160;</B></FONT></TD>
    <TD>
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">The Client and <FONT STYLE="font-size: 10pt">Corealis</FONT> entered into a Master
        Service Agreement dated on the 7<FONT STYLE="font-size: 10pt; vertical-align: text-top">th</FONT> day of August, 2012 (the &#8220;<B>MSA</B>&#8221;).</P></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 27pt"><FONT STYLE="font-size: 10pt"><B>B.&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">The Parties hereto wish to describe the services to be performed in connection with the MSA, subject to the terms and conditions set forth herein and in the MSA.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 27pt"><FONT STYLE="font-size: 10pt"><B>C.&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Unless the context otherwise requires, all capitalized terms used in this Service Agreement shall have the meanings attributed to them in the MSA.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 36pt"><FONT STYLE="font-size: 10pt"><B>1.&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>INTERPRETATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="text-align: left; margin: 0pt 0 0pt 20pt; font-size: 10pt">The recitals of this Service Agreement
as well as all of its Appendices form an integral part of this Service Agreement.</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0"></P>

<P STYLE="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 36pt"><FONT STYLE="font-size: 10pt"><B>2.&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>DESCRIPTION AND DELIVERABLES</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 20pt; font-size: 10pt">The objective of this Agreement is to GMP manufacture,
the warehousing, the analytical release testing and the stability storage and testing of the RHB-104 CTM resupply.</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 3%"><FONT STYLE="font-size: 10pt"><B>2.1-</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 97%"><FONT STYLE="font-size: 10pt"><B>API, excipients and packaging components reception and storage</B></FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 6%"><FONT STYLE="font-size: 10pt"><B>2.1 a)</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 94%"><FONT STYLE="font-size: 10pt"><B>API sourcing</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 27pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 20pt">It is estimated that sufficient quantities of fully released
GMP clarithromycin API and GMP clofazimine API are available at Corealis and the Client at its own cost will ship to Corealis sufficient
quantities of GMP rifabutin API (collectively the clarithromycin API, the clofazimine API and the rifabutin API are called &ldquo;APIs&rdquo;
and individually &ldquo;API&rdquo;). Upon reception of the GMP rifabutin API Corealis will execute a full release testing of the
material according to GMP requirements. Should additional APIs be required, the sourcing will be the exclusive responsibility of
the Client. Upon request by the Client, Corealis could characterize and analyze the APIs which will be considered Extra Work.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td colspan="2" style="text-decoration: underline; vertical-align: middle"><FONT STYLE="font-size: 10pt">Cost:</FONT></td>
    <TD STYLE="text-align: left; padding-left: 50pt"><FONT STYLE="font-size: 10pt">[****]</FONT></td></tr>
<tr>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">*</FONT></td>
    <td colspan="2" style="vertical-align: middle; text-align: justify"><FONT STYLE="font-size: 8pt">It is estimated that sufficient
    quantities of each of GMP clarithromycin API and GMP clofazimine API are available at Corealis to execute the manufacture
    of the CTM. However the Client will source and ship to Corealis sufficient quantities of GMP rifabutin API for the manufacture
    of the Drug product included in this Agreement.&nbsp;</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <td colspan="2" style="vertical-align: middle; text-align: justify"><FONT STYLE="font-size: 8pt">The cost includes:</FONT></td></tr>
<tr>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; width: 3%; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify; width: 91%"><FONT STYLE="font-size: 8pt">the reception of one lot of GMP rifabutin API (i.e.,
    documentation review, material registration in Corealis inventory, and material sampling following GMP requirements) (If API
    lot is in more than one container then the sampling and ID testing of each of the additional containers will be considered
    Extra Work at 200$/additional container),&nbsp;</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">the full testing for the release of one lot of GMP rifabutin
    API using validated method. (Client will ship the GMP rifabutin API to Corealis with the complete certificate of analysis
    and related documentation to assure API conformity to the appropriate regulatory authorities),</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">the GMP warehousing of the Client&rsquo;s Materials (e.g., API,
    raw material, objects, inactive ingredients) for the period where the Project is active and for a volume not exceeding 1 m<FONT STYLE="font-weight: normal; font-style: normal"><SUP>3</SUP>.
    If the material need to be stored for a longer period of time or the volume of the material is more than 1 m<SUP>3 </SUP>then
    the storage cost will be considered Extra Work or the material shipped at Client.</FONT></FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <td colspan="2" style="vertical-align: middle; text-align: justify"><FONT STYLE="font-size: 8pt">The cost does not include:</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&bull;&nbsp;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The purchase of the analytical reference materials to be used
    as a standard, if needed, reference impurities (synthesis by-products, Related Substances, metabolites) of known purity, HPLC
    columns, and any dedicated peripherals (e.g., guard column) and reagents.</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The release testing of any additional material (i.e., additional
    API) should the Client change the drug product material specifications or API source or any decision taken by the Client that
    requires additional analytical testing.</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The repackaging of material (if required) as well as the shipping
    cost and custom fees, if any.</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The destruction fees of any material after being pre-authorized
    by the Client.</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Documentation fees for the shipment or reception of GMP API or
    GMP drug products at 200$/ event (i.e., reception or reception).</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Sampling fees of 200$/ containers.</FONT></td></tr>
<tr>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;&bull;</FONT></td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The shipping document preparation and shipment of material.&nbsp;</FONT></td></tr>
</table>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: right; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>&#160;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 6%"><FONT STYLE="font-size: 10pt"><B>2.1 b)</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 94%"><FONT STYLE="font-size: 10pt"><B>GMP Materials (excipients and packaging components) storage and handling-</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 27pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 20pt">Corealis will handle the reception, the full release
testing, the shipping and the storage of GMP Materials (i.e., excipients and packaging materials) in its cGMP warehouse. All material
handling operations and storage conditions will respect the ICH GMP requirements.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD>&nbsp;</TD>
    <td colspan="2" style="text-decoration: underline; vertical-align: middle"><FONT STYLE="font-size: 10pt">Cost:</FONT></td>
    <TD STYLE="text-align: left; padding-left: 60pt"><FONT STYLE="font-size: 10pt">[****]</FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 8pt">*</FONT></td>
    <td colspan="2" style="vertical-align: middle; text-align: justify"><FONT STYLE="font-size: 8pt">The cost includes:</FONT></td></tr>
<tr>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; width: 3%; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&bull;</td>
    <TD STYLE="text-align: justify; width: 93%"><FONT STYLE="font-size: 8pt">The reception of 10 lots
    of excipients and packaging components (i.e., documentation review, material registration in Corealis inventory, and material
    sampling following GMP requirements) as well as their full release testing as per the <FONT STYLE="font-weight: normal; font-style: normal">[****]
    (The cost is based on the hypothesis that all GMP material will be received in one single shipment at 200$/ shipment and the
    full release testing of 10 GMP materials at an average cost of [****] of GMP material received. Any additional shipment or
    reception of GMP material will be considered as Extra Work at [****] or reception. Any additional sampling and testing of
    GMP material received will be considered Extra Work at [****] of GMP material received.).&nbsp;</FONT></FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&bull;</td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt; font-weight: normal; font-style: normal">The
    GMP warehousing of the APIs and the drug product until completion of the study. If the material needs to be stored for a longer
    period of time then the storage cost will be [****]/ month.</FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&bull;</td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">All the GMP Materials, APIs and RHB-104
    drug products must have a volume of less than 1 m3.&nbsp;</FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <td colspan="2" style="vertical-align: middle; text-align: justify"><FONT STYLE="font-size: 8pt">The cost does not include:</FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&bull;</td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The cost of APIs.</FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&bull;</td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The purchase cost of the reference materials
    to be used as a standards and reference impurities (synthesis by-products, degradation products, metabolites) of known purity,
    if required.</FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></td>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&bull;</td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Additional packaging or repackaging of
    APIs, Drug Products or any GMP material will be considered Extra Work.</FONT></td></tr>
</table>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 3%"><FONT STYLE="font-size: 10pt"><B>2.2-</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 97%"><FONT STYLE="font-size: 10pt"><B>Manufacturing of the Clinical Trial Material (CTM)</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 18pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in">The CTM manufacturing process, manufacturing, packaging,
equipment calibration and validation, will be done by Corealis GMP laboratory. All the manufacturing, packaging and analytical
equipments that will be used for the CTM will be calibrated, validated and released for their cleanliness prior to their utilization.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 6%"><FONT STYLE="font-size: 10pt"><B>2.2 a)</B></FONT></TD>
    <TD STYLE="text-align: left; width: 94%"><FONT STYLE="font-size: 10pt"><B>Manufacturing and bulk packaging</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 27pt"></P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 20pt">Corealis will manufacture and package the single dose
strength of RHB-104 capsule as per the optimized formulation developed in the execution of Service Agreement N (document 004-140225rev4).</P>



<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 20pt">Specifically with respect to manufacturing, packaging
and bulk labeling, the followings items will be provided by Corealis:</P>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 95%"><FONT STYLE="font-size: 10pt">Recommendation and justification of specific finished product release specifications,</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 95%"><FONT STYLE="font-size: 10pt">Redaction of Master Manufacturing File (MMF)</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 95%"><FONT STYLE="font-size: 10pt">The CTM will be manufactured and packaged in labeled* double lined sealed LDPE bags inserted in hard shell sealed barrels:</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 3%">&bull;</TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 93%"><FONT STYLE="font-size: 10pt">RHB-104 capsule&#160;&#160;&#160;&#160;&#160;&#160;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8211;[****] units</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD>&nbsp;</TD>
    <td colspan="2" style="vertical-align: middle"><U>Cost:</U><FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;145,000$**</FONT></td></tr>
<tr>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 8pt">*</FONT></td>
    <TD STYLE="vertical-align: middle; text-align: justify; width: 94%"><FONT STYLE="font-size: 8pt">The labelling on the bags
    and barrels will include the basic information for GMP drug products (i.e., Name of sponsor, date of manufacturing, Lot number
    and storage conditions). This Agreement does not include preparation of special packaging and labelling which would require
    randomization, patient kits preparation of special shipments of clinical supplies.&nbsp;</FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 8pt">**</FONT></td>
    <TD STYLE="vertical-align: middle; text-align: justify"><FONT STYLE="font-size: 8pt">The cost is based on the assumption that
    one batch of RHB-104 capsules will be manufactured and packaged within the same manufacturing campaign. The cost includes
    the GMP excipients, the GMP packaging materials, the manufacturing, the bulk packaging, the labelling, the cleaning verification
    of the manufacturing suites and the equipments for one manufacturing campaign. The cost does not include the transportation
    cost of the clinical supplies, the broker and custom fees, the cost of the APIs. No manufacturing engineering batch of the
    drug product will have been executed using the new RHB-104 capsule formulation developed by Corealis in the execution of Service
    Agreement N prior to the execution of this GMP manufacturing campaign and thus, Corealis could not be held responsible for
    batch failure unless the failure is du to a Corealis negligence or wilful misconduct. Furthermore, the manufacturing campaign
    will last 10 working days. The manufacturing campaign will start when the APIs are brought in the GMP manufacturing suites
    and will be terminated when the GMP manufacturing suites will have been released for their cleanliness. Should the manufacturing
    campaign be delayed by the Client, the Client&rsquo;s suppliers, the Client&rsquo;s APIs or any other factors outside the
    control of Corealis, every additional day to the GMP manufacturing campaign will be considered Extra Work at <FONT STYLE="font-weight: normal; font-style: normal">[****]/
    day for GMP suite rental and labour cost may also apply in addition to the suite rental.&nbsp;</FONT></FONT></td></tr>
</table>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 6%"><FONT STYLE="font-size: 10pt"><B>2.2 b)</B></FONT></TD>
    <TD STYLE="text-align: left; width: 94%"><FONT STYLE="font-size: 10pt"><B>Packaging and labeling of the Clinical
Trial Material (CTM) (optional)</B></FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="text-align: left; margin: 0pt 0 0pt 40pt; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0 0pt 20pt">Specifically with respect to packaging and labeling,
the followings items will be provided by Corealis:</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 95%"><FONT STYLE="font-size: 10pt">Redaction of Master Manufacturing File (MMF); and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="width: 95%">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">The RHB-104 capsules of the <FONT STYLE="font-size: 10pt">[****]</FONT> units batch
        will be packaged in induction sealed HDPE bottle containing <FONT STYLE="font-size: 10pt">[****]</FONT>; and</P></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="width: 95%">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">Labeling of bottles in a ratio of two RHB-104 bottles to one RHB-104 placebo bottle
        (i.e., <FONT STYLE="font-size: 10pt">[****]</FONT>) using the labels to be provided by the Client.</P></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 40pt"></P>

<P STYLE="text-align: left; margin: 0pt 0 0pt 20pt; font-size: 10pt">The followings items will be provided by the Client
to Corealis:</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="width: 95%">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">About <FONT STYLE="font-size: 10pt">[****]</FONT>; and</P></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 95%"><FONT STYLE="font-size: 10pt">The randomization list; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 5%"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 95%"><FONT STYLE="font-size: 10pt">The labels.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: right; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD>&nbsp;</TD>
    <td colspan="2" style="font-size: 10pt; vertical-align: middle"><U>Cost:<FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;&nbsp;</FONT></U><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[****]</FONT></td></tr>
<tr>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; width: 3%"><FONT STYLE="font-size: 8pt">*</FONT></td>
    <TD STYLE="font-size: 10pt; vertical-align: bottom; width: 94%; text-align: justify"><FONT STYLE="font-size: 8pt">This cost is not included in
    the total cost of the study in section 7 and should Services included in this section required by the Client it will be considered
    Extra Work and invoiced monthly. The cost is based on the assumption that <FONT STYLE="font-weight: normal; font-style: normal">[****]
    RHB-104 capsules will be bottled AND [****] will be labelled with labels to be provided by the Client AND all the bottling
    and the labelling will be executed within the same manufacturing campaign. The cost includes the GMP packaging materials,
    the packaging, the labelling, the cleaning verification of the packaging suites and the equipments. The cost does not include
    the transportation cost of the clinical supplies, the broker and custom fees, the preparation of Patient Kits. If the Services
    included in this Agreement is executed within the same manufacturing campaign as of the manufacturing of the RHB-104 capsule
    (Section 2.2 a)) and the bulk packaging is not required then $[****] will be subtracted from the discounted cost above.&nbsp;</FONT></FONT></td></tr>
</table>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 6%; text-align: center"><B>2.2 c)</B></TD><TD STYLE="text-align: justify; width: 94%"><B>Release testing of CTM and cleaning verification</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 20pt; font-size: 10pt">The validation of the analytical methods for the
release testing of the CTM and for the cleaning verification has already been validated. All analysis will be performed using the
validated methods. Except for the cleaning verification all of the analyses are outsourced to a Corealis qualified third Party laboratory.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0 0pt 20pt; font-size: 10pt">Analyses to be performed on CTM are:</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="width: 3%">&nbsp;</td>
    <TD STYLE="width: 3%; text-align: center">&nbsp;&bull;</td>
    <TD STYLE="width: 94%">appearance,</td></tr>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;&bull;</td>
    <TD>Identification,</td></tr>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;&bull;</td>
    <TD>water content (KF),</td></tr>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;&bull;</td>
    <TD>assay* and degradation products*,</td></tr>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;&bull;</td>
    <TD>microbiology,</td></tr>
<tr>
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;&bull;</td>
    <TD>content uniformity,</td></tr>
<tr style="vertical-align: bottom">
    <TD>&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;&bull;</td>
    <TD>dissolution** and disintegration time.</td></tr>
</table>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD>&nbsp;</TD>
    <td colspan="2" style="vertical-align: middle"><FONT STYLE="font-size: 10pt"><U>Cost:&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10,965$***</FONT></td></tr>
<tr>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 8pt">*</FONT></td>
    <TD STYLE="vertical-align: bottom; width: 94%; text-align: justify"><FONT STYLE="font-size: 8pt">Assay and Related Substances for the three APIs
    for RHB-104.&nbsp;</FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 8pt">**</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 8pt">[****]<FONT STYLE="font-weight: normal; font-style: normal">.</FONT></FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 8pt">***</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 8pt">The cost is not discounted as all of the CTM analyses are
    outsourced to a Third Party qualified laboratory. The cost includes the analysis of [****]
    (i.e., RHB-104 capsules), the analysis of [****] for cleaning verification for one GMP manufacturing campaign. Except for
    the cleaning verification all the analytical methods for release testing have been validated by a third Party Corealis qualified laboratory.&nbsp;</FONT></td></tr>
</table>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 6%; text-align: center"><B>2.2</B></TD><TD STYLE="text-align: justify; width: 94%"><B>d) Stability study of CTM and cleaning verification</B></TD>
</TR></TABLE>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 20pt; font-size: 10pt">The validation of the analytical methods for the
analysis of the CTM has already been validated by a qualified third Party laboratory. All analysis will be performed using the
validated methods.</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The CTM will be stored in cGMP stability chambers at
<FONT STYLE="font-size: 10pt">[****]</FONT>, and the samples analyzed using the Client&rsquo;s validated methods. The single strength
RHB-104 capsule will be characterized for appearance, assay, related substances, dissolution*, disintegration and water content
using the schedule below.</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 27pt">&nbsp;</P>



<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0 0pt 27pt; font-size: 10pt">The following stability testing schedule
will be used and modified per mutual agreement:</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 90%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="text-align: left; border-top: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Storage <BR>
Condition</FONT></TD>
    <TD COLSPAN="10" STYLE="border: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Time point (Month)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 30%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt; width: 7%"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; width: 7%">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="width: 7%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="width: 7%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="width: 7%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="width: 7%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="width: 7%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; width: 7%">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; width: 7%">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="width: 7%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; border-right: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">[****]</P></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">-</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: left; text-indent: 27pt; margin: 0pt 0; font-size: 10pt">X: Sample to be analyzed.</P>

<P STYLE="text-align: left; text-indent: 27pt; margin: 0pt 0; font-size: 10pt">Y: Sample removed from chamber and analyzed only
at the request of Client.</P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD>&nbsp;</TD>
    <td colspan="2" style="font-size: 10pt"><U>Cost:</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;74,120$**</td></tr>
<tr>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; width: 3%"><FONT STYLE="font-size: 8pt">*</FONT></td>
    <TD STYLE="font-size: 10pt; vertical-align: bottom; width: 94%"><FONT STYLE="font-size: 8pt">A dissolution test is <FONT STYLE="font-weight: normal; font-style: normal">[****].</FONT></FONT></td></tr>
<tr>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; vertical-align: top"><FONT STYLE="font-size: 8pt">**</FONT></td>
    <TD STYLE="font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-size: 8pt">The cost is not discounted as all of the
    CTM analyses are outsourced to a Third Party qualified laboratory. The cost is based on the analysis of <FONT STYLE="font-weight: normal; font-style: normal">[****].&nbsp;</FONT></FONT></td></tr>
</table>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 4%"><FONT STYLE="font-size: 10pt"><B>2.3-</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; width: 91%"><FONT STYLE="font-size: 10pt"><B>Reports and submission documentation</B></FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Telephone meetings,</B> <B>Corealis facility and quality audit</B> by Client&rsquo;s or Client&rsquo;s
representative will be held on an as needed basis.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Client or Client&rsquo;s representative</B> meeting in Corealis facility will be held at Client&rsquo;s
request.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Progress reports</B> will be provided on a Monthly basis or as needed.</TD></TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Item reports</B> will be provided as they are completed.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.15pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A <B>final manufacturing report</B> will be provided at the end of the study. It will include all
the necessary regulatory submission documents related to manufacturing and packaging which include (but not limited to):</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.15pt"></TD><TD STYLE="width: 17.85pt">o</TD><TD STYLE="text-align: justify">The finished products release &amp; stability certificate of analysis.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.15pt"></TD><TD STYLE="width: 17.85pt">o</TD><TD STYLE="text-align: justify">In process testing results.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.15pt"></TD><TD STYLE="width: 17.85pt">o</TD><TD STYLE="text-align: justify">QA Reviewed and audited Manufacturing and Packaging/labeling Documents.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.15pt"></TD><TD STYLE="width: 17.85pt">o</TD><TD STYLE="text-align: justify">Certificate of cGMP compliance.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.15pt"></TD><TD STYLE="width: 17.85pt">o</TD><TD STYLE="text-align: justify">Certificate of analysis of raw materials and packaging components.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.15pt"></TD><TD STYLE="width: 17.85pt">o</TD><TD STYLE="text-align: justify">Any atypical report or Out-of-Specification reports.</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD>&nbsp;</TD>
    <td colspan="2" style="font-size: 10pt"><U>Cost:</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0$*</td></tr>
<tr>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; vertical-align: top; width: 3%"><FONT STYLE="font-size: 8pt">*</FONT></td>
    <TD STYLE="font-size: 10pt; vertical-align: bottom; width: 94%"><FONT STYLE="font-size: 8pt">Included in the costs of the
    previous sections.&nbsp;</FONT></td></tr>
</table>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: right; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 36pt"><FONT STYLE="font-size: 10pt"><B>3.&#160;&#160;</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>GENERAL PROJECT TIMELINES</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img src="exh411_1.jpg"></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt; color: Red"><B></B></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 27pt"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>STARTING DATE AND COMPLETION</B></FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Notwithstanding the date of signature of this Service Agreement,
Corealis shall start the performance of the Services within ten (10) business days after Corealis satisfaction of the following:
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">4.1.1</FONT></TD><TD STYLE="text-align: left; width: 92%"><FONT STYLE="font-weight: normal">signature by the Client of this Service Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">4.1.2</FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="font-weight: normal">complete delivery by the Client of all of the items mentioned
at sub-section 6.1 of section 6 hereof entitled &ldquo;REQUIREMENTS&rdquo;. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">This Service Agreement shall be deemed completed upon full delivery
of the Services by Corealis and receipt by Corealis of the final and last payment for the Services.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 27pt"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt"><B>ASSUMPTIONS</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The RHB-104 optimized formulation containing 95 mg Clarithromycin,
45 mg Rifabutin, and 10 mg Clofazimine will be manufactured for clinical supplies.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Any subcontractor that will used within this project will need
to satisfy the Corealis quality audit. Otherwise Extra Work may be required to support subcontractors and/or take actions not to
delay the project (e.g., Corealis to purchase and release material after approval by the Client). Use of subcontractors must be
approved in advance by the Client.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Corealis is not responsible for the qualification of any API
manufacturer, any delays in the manufacturing of the APIs, the delivery of the APIs, and for the quality of the APIs purchased
by the Client.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">If different lots of APIs are utilized in the execution of the
Project and the physical and chemical properties of the different lots are different or, if the physical and chemical properties
of the API intended to be utilized in the execution of this Projects differs from the expected API properties when this Agreement
was signed by both Parties, then additional formulation development and/or manufacturing process adjustments and/or additional
manufacturing time and/or additional sample analysis may be needed and if needed, they will be considered Extra Work and the Project&rsquo;s
time lines adjusted accordingly. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">When a decision is required to move the project forward, the
Client will provide its decision in writing to Corealis within a period of 5 days, or the project may be delayed. Corealis will
develop a final timeline for this project and all deviations will be immediately reported to the Client. Corealis will make its
best efforts to correct all deviations in order to maintain the project timeline. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Any analytical reference materials (e.g., standards and impurities)
and dedicated materials (e.g., HPLC columns, speciality reagents) purchased by Corealis and utilized solely for the execution of
the Client&rsquo;s Project and any other equipments or materials that are damaged by the Client&rsquo;s API or APIs (e.g., corrosion,
unusual ware, staining, contamination, loss of operational functions) or becomes dedicated to the Client&rsquo;s Project or requires
unusual cleaning efforts and resources due to the nature of the Client&rsquo;s APIs will be considered Extra Work and invoiced
at cost to the Client.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Client decided not to execute a stability study of the CTM.
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">All shipments from Corealis to the Client or to a designated
location specified by the Client will be invoiced at cost as per the </FONT>EXW <FONT STYLE="font-weight: normal">(200 Armand-Frappier
boulevard, Laval, Quebec, Canada, H7V 4A6) Incoterms</FONT><SUP>&reg;</SUP><FONT STYLE="font-weight: normal"> 2010. All shipments
from Clients or from a designated supplier of the Client to Corealis will be invoiced at cost as per the </FONT>DDP<FONT STYLE="font-weight: normal">
(200 Armand-Frappier boulevard, Laval, Quebec, Canada, H7V 4A6) Incoterms</FONT><SUP>&reg;</SUP><FONT STYLE="font-weight: normal">
2010. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Client is responsible to verify that the Services and deliverables
provided in the execution of this Service Agreement do not violate or infringe any patent, trade secret or other proprietary or
intellectual property right of any third Party.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">During an audit, Corealis will allow the Client's representatives
to examine the batch records, technical reports, methods and protocols pertaining to the Services. The assistance provided by Corealis
to the Client during an audit will, under no circumstances, give rise to the payment of additional expenses unless the audit last
more than three working days (a working day consist of an 8 hour shift). Should additional time is required for the audit it will
be considered Extra Work.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.11</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Corealis will allow the Client&rsquo;s representatives to assist
to the execution of the Services for a maximum period of one day per manufacturing campaign. Should the Client&rsquo;s representative
need additional time and/or if the normal execution of the Services is disturbed by the presence of the Client&rsquo;s representative
then Corealis may consider it Extra Work. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.12</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">If different lots of APIs are utilized in the execution of the
Project and the physical and chemical properties of the different lots are different or, if the physical and chemical properties
of the API intended to be utilized in the execution of this Project differs from the expected API properties when this Agreement
was signed by both Parties, then additional formulation development and/or manufacturing process adjustments may be needed and
if needed, they will be considered Extra Work and the Project&rsquo;s time lines adjusted accordingly. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.13</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The costs included in this Agreement for GMP manufacturing are
based on the premises that all of the GMP manufacturing operations will be executed within the same manufacturing campaign, unless
explicitly specified in section 2. Should the GMP manufacturing campaign be delayed or split in several manufacturing campaigns
and where the delays or the split is not caused by Corealis or by Corealis qualified suppliers, the additional cost that may apply
will be considered Extra Work. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.14</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">All of the Client&rsquo;s Materials (e.g., API, raw material,
objects, inactive ingredients) stored in Corealis warehouse will not exceed a volume of 1 m<SUP>3</SUP>. Exceeding storage volume
will be considered Extra Work.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="text-transform: uppercase">6.</FONT></TD><TD>REQUIREMENTS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Client shall provide to Corealis, at no cost to Corealis, the
following:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">If the Client send additional APIs to Corealis for the manufacture
of the RHB-104, the GMP APIs, reference materials to be used as a standard, reference impurities (synthesis by-products, degradation
products, metabolites) of known purity, the certificate of analysis, the BSE &amp; TSE statements, the APIs manufacturer GMP certification.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="text-transform: uppercase">7.</FONT></TD><TD><FONT STYLE="font-size: 10pt">COST AND PAYMENTS</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The cost of the Services is 247,701.00 $USD </FONT>[****]<FONT STYLE="font-weight: normal">.
Any amount exceeding a total of 247,701$ requires a pre-approval in writing by the Client. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Client shall pay to Corealis the following installments in
US currency ($USD):</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">7.2.1</FONT></TD><TD STYLE="text-align: left; width: 92%">[****]<FONT STYLE="font-weight: normal"> upon signature of this Agreement; and </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">7.2.2</FONT></TD><TD STYLE="text-align: left; width: 92%">[****]<FONT STYLE="font-weight: normal"> at the completion of the CTM manufacturing; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">7.2.3</FONT></TD><TD STYLE="text-align: left; width: 92%">[****]<FONT STYLE="font-weight: normal"> at the acceptance of the final CTM manufacturing report;
and </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">7.2.4</FONT></TD><TD STYLE="text-align: left; width: 92%"><FONT STYLE="font-weight: normal">Stability study of CTM invoiced monthly. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Each of the above payments is subject to receipt of a non-disputed
invoice from Corealis and subject to the payment terms detailed in the Master Service Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Notwithstanding section 7.1, for any extra work not covered by
this Service Agreement and agreed upon in writing between the Parties (the &ldquo;Extra Work&rdquo;), the Client shall pay to Corealis
the relevant sum as agreed in writing. For any such Extra Work Corealis will apply the hourly rates and other fees indicated in
this Appendix I attached hereto for the performance of the Services (The costs of the Services for the Extra Work and described
in section 7.1 are collectively, the &ldquo;</FONT>Fees<FONT STYLE="font-weight: normal">&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Notwithstanding section 7.2 hereof, Corealis will invoice the
Client for the Extra Work, on a monthly basis for the Services that (i) have been pre-approved in writing by the Client, and; (ii)
that have been delivered or rendered by Corealis.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="text-transform: uppercase">8.</FONT></TD><TD><FONT STYLE="font-size: 10pt">CONFIDENTIALITY</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Confidentiality issues are covered per the Non Disclosure Agreement
and the MSA.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="text-transform: uppercase">9.</FONT></TD><TD><FONT STYLE="font-size: 10pt">REPRESENTATIONS AND WARRANTIES</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 26.95pt"><FONT STYLE="font-weight: normal">9.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Corealis hereby represents and warrants to the Client that: </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">9.1.1</FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="font-weight: normal">it is a duly organized and validly existing corporation under
the laws of the jurisdiction in which it is incorporated; </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">9.1.2</FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="font-weight: normal">it has the necessary corporate power, authority, skills, and
capacity and is properly authorized to enter into this Service Agreement and to perform its obligations as per the terms and conditions
of this Service Agreement. The execution and delivery of this Service Agreement and the performance of the transactions contemplated
hereby have been duly authorized.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 26.95pt"><FONT STYLE="font-weight: normal">9.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Client hereby represents and warrants to Corealis that: </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">9.2.1</FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="font-weight: normal">it is a duly organized and validly existing corporation under
the laws of the jurisdiction in which it is incorporated; </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-weight: normal">9.2.2</FONT></TD><TD STYLE="text-align: justify; width: 92%"><FONT STYLE="font-weight: normal">it has the necessary corporate power, authority, skills, and
capacity and is properly authorized to enter into this Service Agreement and to perform its obligations as per the terms and conditions
of this Service Agreement. The execution and delivery of this Service Agreement and the performance of the transactions contemplated
hereby have been duly authorized; </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="text-transform: uppercase">10.</FONT></TD><TD><FONT STYLE="font-size: 10pt">TERMS AND CONDITIONS</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">10.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">This Service Agreement shall be governed, construed and interpreted
according to the laws in force in the Province of Quebec and the applicable laws of Canada therein, and the courts of the legal
district of Montreal, province of Quebec (Canada) shall have exclusive jurisdiction to hear any and all disputes arising hereunder.</FONT></TD></TR></TABLE>



<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; margin: 0pt 0"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 27pt"><FONT STYLE="font-size: 10pt">10.2&#160;&#160;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">This Service Agreement is subject to the terms and conditions provided in the MSA and bind the parties as well as their respective successors, permitted assigns and legal representatives.</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 27pt"><FONT STYLE="font-size: 10pt">10.3&#160;&#160;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">This Service Agreement may be executed in counterparts, each of which shall be deemed to be an original and which together shall constitute one and the same agreement. This Service Agreement may also be executed between the Parties by exchange of facsimile transmissions or electronic transmissions in legible form, including without limitation in a tagged image format file (TIFF) or portable document format (PDF).</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 27pt"><FONT STYLE="font-size: 10pt">10.4&#160;&#160;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">The Parties hereto have requested that this Service Agreement be drafted in the English language.&#160;&#160;<I>Les Parties ont exig&#233; que ce contrat de services soit r&#233;dig&#233; en anglais.</I></FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0">&#160;</P>

<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><B>IN WITNESS THEREOF, the Parties have executed
this Service Agreement as of the Date written above, by their authorised representatives, who by signing confirm their authority
and intention to bind the Parties they represent.</B></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt">Corealis Pharma Inc.</P></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">RedHill Biopharma Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">Per: </FONT></TD>
    <TD STYLE="width: 16%; border-bottom: black 1.1pt solid; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">/s/</FONT></TD>
    <TD STYLE="width: 44%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="width: 16%; border-bottom: black 1.1pt solid; text-align: left; text-indent: 0pt">/s/ Dror Ben-Asher</TD>
    <TD STYLE="width: 20%; text-align: left; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="padding-left: 18pt; text-align: justify; text-indent: 0pt"><P STYLE="margin: 0pt 0">Yves Roy, Ph.D.</P>


</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Name: Dror Ben-Asher</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD COLSPAN="2" STYLE="padding-left: 18pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-size: 10pt">President</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Title: CEO</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Per: </FONT></TD>
    <TD STYLE="border-bottom: black 1.1pt solid; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">/s/ Ori Shilo</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Name: Ori Shilo</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Title: VP Finance and Operation</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: justify; text-indent: 0pt; margin: 0pt 0; font-size: 10pt">&#160;</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 13</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B><U>CONFIDENTIAL</U></B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - Y</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>RedHill Biopharma Ltd. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Manufacture of resupply of Clinical Trial Material of </B></P><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[****]</FONT><FONT STYLE="font-size: 12pt"><B> RHB-104 capsules</B></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: left; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>Appendix I </B></FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="corealis_logo.jpg"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt; font-variant: normal"><B>Professional
Consultation Rates</B></FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 85%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; border-top: black 1.1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Professional</B></P>
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Chemist or Engineer)</P></TD>
    <TD STYLE="width: 40%; border: black 1.1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Hourly Rate*<FONT STYLE="font-size: 10pt; vertical-align: text-top">,
        </FONT>**</B></P>
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">($USD)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Senior scientist</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Scientist</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Technician</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.1pt solid; border-left: black 1.1pt solid">
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">R&amp;D laboratory overhead</P>
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">( Equipment and supplies)</P></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 12pt"><B>Analytical Services</B></FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 90%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; border-top: black 1.1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Analyses</B></P>
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt"><B>&#160;</B></P></TD>
    <TD STYLE="width: 40%; border: black 1.1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Cost / Sample *</B></P>
        <P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center">($USD)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****] ****</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****] ****</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****] ****</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD>
    <TD STYLE="border-right: black 1.1pt solid; border-bottom: black 1.1pt solid; border-left: black 1.1pt solid; text-align: center; text-indent: 0pt"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="font-size: 10pt; vertical-align: bottom; width: 5%"><FONT STYLE="font-size: 8pt">*</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: left; width: 95%"><FONT STYLE="font-size: 8pt; font-variant: normal">Prices
    can be changed by Corealis<FONT STYLE="font-weight: normal; font-style: normal"> without any prior notice. Prices apply only
    for non GMP work and analysis. GMP prices will be supplied on demand.</FONT></FONT></td></tr>
<tr>
    <TD STYLE="font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-size: 8pt">**</FONT></td>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt; font-variant: normal">All expenses will be
    charged at cost.</FONT></td></tr>
<tr>
    <TD STYLE="font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-size: 8pt">***</FONT></td>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt; font-variant: normal">Will be invoiced in
    addition to the professional fees when laboratory work is required.</FONT></td></tr>
<tr>
    <TD STYLE="font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-size: 8pt">****</FONT></td>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 8pt; font-variant: normal">A set-up charge of
    [****] method will be invoiced in addition to the sample cost.</FONT></td></tr>
</table>


<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0pt 0"></P>

<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-align: center; text-indent: 0pt; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Page 13 of 13</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.16
<SEQUENCE>4
<FILENAME>exh_416.htm
<DESCRIPTION>EXHIBIT 4.16
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt"><B>Exhibit 4.16</B></P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>THE SYMBOL &ldquo;</B>[****]<B>&rdquo;</B> <B>DENOTES PLACES
WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Dror Ben-Asher</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">CEO</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">RedHill Biopharma ltd.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">21 Ha&rsquo;arba&rsquo;a Street</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Tel Aviv 64739</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Israel</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">July, 5<SUP>th</SUP> 2011</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Dear Mr Ben-Asher,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Reference is made to Master Service Agreement executed between 7810962
Canada Inc. and Redhill Biopharma Ltd on 28 April 2011 in relation to RedHill&rsquo;s RHB-104 program.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This letter is to confirm that 7810962 Canada Inc agree to extend
our undertakings and obligations to the development of RHB-105. The extension of our obligations does not oblige 7810962 Canada
Inc. to perform particular studies or services for the development of RHB-105 and any studies or services that we perform for Redhill
Biopharma Ltd will be following our written approval.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This letter agreement shall be construed and enforced in accordance
with, and the rights of the parties shall be exclusively governed by, the laws of the United Kingdom. Any disputes arising out
of this agreement shall be submitted to the exclusive jurisdiction of the courts of London, England and all proceedings shall be
drafted and conducted using only the English language.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Yours sincerely,</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>/s/ Alain Guimond</U>________</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Name: Alain Guimond PhD</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Function: Senior Director of Research</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Date: July 5<SUP>th</SUP>, 2011</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">For acknowledgement and agreement:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="color: Black"><img src="asher_sig.jpg"></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Name: Dror Ben-Asher</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Function: CEO, RedHill Biopharma Ltd.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Date: July 5, 2011</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Exhibit 1: Letter Agreement dated 28 April 2011</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt"><B><U>Exhibit 1 &ndash; Terms
of Service Agreement with 7810962 Canada Inc </U></B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 99.25pt"><FONT STYLE="font-size: 10pt"><B>BETWEEN:</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>7810962 Canada Inc.,</B></FONT> <FONT STYLE="font-size: 10pt">a
corporation duly incorporated under the laws of Canada and having its principal place of business at 5320&nbsp;13<SUP>e</SUP> Avenue,
Montr&eacute;al, Qu&eacute;bec, H1X 2X8;</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 99.25pt"></TD><TD>(hereinafter referred to as &ldquo;<B>7810962</B>&rdquo;)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 99.25pt"><B>AND:</B></TD><TD STYLE="text-align: justify">RedHill Biopharma Ltd., a corporation duly incorporated under the laws of Israel and having its
principal place of business at 21 Ha&rsquo;arba&rsquo;a Street, Tel Aviv 64739, Israel;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 99.25pt">(hereinafter referred to as the &ldquo;<B>Client</B>&rdquo;)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 99.25pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">When signed by both parties, this Exhibit will form an integral
part of the Master Agreement executed between them on the date hereof and will set forth the specific services, details and schedule
as well as the specific payment terms and conditions under which the Client agrees that 7810962 will provide manufacturing development
services for the Client&rsquo;s RHB-105 product.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Terms:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Client agrees that 7810962 enters into a subcontract with Corealis
Pharma Inc. on the terms set out in the Proposal to be executed between 7810962 and Corealis Inc. as shown below in Exhibits 2.
For further clarity, the Client agrees with the cost described in Exhibit 2 and agrees to the payment schedule as described in
Exhibit 2.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">IN WITNESS WHEREOF, this Proposal has been executed by the parties
hereto through their duly authorized officers on the date(s) set forth below.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>For the Client:</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: Red"><B>&nbsp;</B><img src="asher_sig.jpg"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: Red"><B></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Name: Dror Ben-Asher</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Title: CEO</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Date: July 5, 2011</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>For 7810962:</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">/s/ Alain Guimond PhD</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Name: Alain Guimond PhD</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Title: Senior Director of Research</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Date: July 5, 2011</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><U>Exhibit 2</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>Service Agreement - A</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>Formulation development of RHB-105
in oral solid dosage form <BR>
and manufacture of Phase III Clinical Trial Supplies</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>This service Agreement
</B></FONT>is made and entered into this 5th day of July, 2011 (the &ldquo;<B>Service Agreement</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 99.25pt">BETWEEN:</TD><TD STYLE="text-align: justify"><B>COREALIS Pharma, Inc.</B>, a corporation duly incorporated under the laws of Canada and having
its principal place of business at 200 Armand-Frappier, Laval, Qu&eacute;bec, Canada, H7V 4A6;</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 99.25pt"></TD><TD>(hereinafter referred to as &ldquo;<B>Corealis</B>&rdquo;)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 99.25pt">AND:</TD><TD STYLE="text-align: justify"><B>7810962 Canada Inc.,</B> <FONT STYLE="font-size: 10pt">a
corporation duly incorporated under the laws of Canada and having its principal place of business at 5320&nbsp;13<SUP>e</SUP>
Avenue, Montr&eacute;al, Qu&eacute;bec, H1X 2X8;</FONT></TD></TR></TABLE>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 99.25pt"></TD><TD>(hereinafter referred to as the &ldquo;<B>Client</B>&rdquo;)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -99.25pt; margin: 0pt 0 0pt 99.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 99.25pt"></TD><TD STYLE="text-align: justify">(Corealis and the Client are at times referred to individually as the &ldquo;Party&rdquo; and collectively
the &ldquo;Parties&rdquo;)</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>RECITALS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><B>A.</B></TD><TD STYLE="text-align: justify">The Client and Corealis entered into a Master Service Agreement dated July 5, 2011 (the &ldquo;<B>MSA</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="text-transform: none">B.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; text-transform: none">The Parties hereto wish to describe the
services to be performed in connection with the MSA, subject to the terms and conditions set forth herein and in the MSA.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt"><FONT STYLE="text-transform: none">C.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; text-transform: none">Unless the context otherwise requires,
all capitalized terms used in this Service Agreement shall have the meanings attributed to them in the MSA.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">1.</FONT></TD><TD>INTERPRETATION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The recitals of this Service Agreement as well as all
of its Appendices form an integral part of this Service Agreement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">2.</FONT></TD><TD>DESCRIPTION AND DELIVERABLES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.1pt"></TD><TD STYLE="width: 28.9pt"><B>2.1-</B></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">[****]</FONT><B> study </B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The Drug-Drug compatibility study will be limited to
<FONT STYLE="font-size: 10pt">[****]</FONT> and <FONT STYLE="font-size: 10pt">[****]</FONT> since <FONT STYLE="font-size: 10pt">[****]</FONT>
these molecules have <FONT STYLE="font-size: 10pt">[****]</FONT> (i.e. <FONT STYLE="font-size: 10pt">[****]</FONT> and <FONT STYLE="font-size: 10pt">[****]
</FONT>respectively) and thus it is highly probable that they will <FONT STYLE="font-size: 10pt">[****] </FONT>the <FONT STYLE="font-size: 10pt">[****]</FONT>
moleculewhich is very <FONT STYLE="font-size: 10pt">[****]</FONT> in an <FONT STYLE="font-size: 10pt">[****] </FONT>environment.
The <FONT STYLE="font-size: 10pt">[****]</FONT> and <FONT STYLE="font-size: 10pt">[****]</FONT> will be <FONT STYLE="font-size: 10pt">[****]</FONT>
under <FONT STYLE="font-size: 10pt">[****]</FONT> and <FONT STYLE="font-size: 10pt">[****]</FONT> conditions and stored in <FONT STYLE="font-size: 10pt">[****]</FONT>
and <FONT STYLE="font-size: 10pt">[****]</FONT> containers under the following conditions of temperature and humidity: The mixture
will be and for their (and) at each time points</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" ALIGN="CENTER" STYLE="width: 60%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td rowspan="2" style="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Storage <BR>
Condition</td>
    <td colspan="3" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Time point</P>
        <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Day)</P></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Initial</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr>
    <TD STYLE="vertical-align: top; width: 40%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font-size: 10pt">[****]</font></td>
    <TD ROWSPAN="2" STYLE="width: 20%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="vertical-align: top; width: 20%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="vertical-align: top; width: 20%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
</table>
<P STYLE="font-size: 10pt; text-align: left; text-indent: 35.45pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">X: Sample to be
analyzed.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -14.2pt; margin: 0pt 0 0pt 49.65pt"><FONT STYLE="font-size: 8pt">Y:
Sample removed from chamber and analyzed only at the request of Client if the [****] sample fails in stability.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -35.4pt; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 170.1pt"><U>Cost:</U></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[****]</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">*
Cost based on the analysis of the two APIs (i.e., [****] and [****]) for [****] samples ([****] X 4 conditions ([****] [****]
[****] and [****]) X 3 time points) at $ [****]/sample AND [****] analytical set-ups ([****] time points [****]/ time point) at
$[****]/ set-up.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.1pt"></TD><TD STYLE="width: 28.9pt"><B>2.2-</B></TD><TD STYLE="text-align: left"><B>Formulation development</B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">Three drug products will be developed:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[****] </FONT>(<FONT STYLE="font-size: 10pt">[****]</FONT> <FONT STYLE="font-size: 10pt">[****]</FONT>
and <FONT STYLE="font-size: 10pt">[****]</FONT>), and;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[****]</FONT> (<FONT STYLE="font-size: 10pt">[****] [****] </FONT>and
<FONT STYLE="font-size: 10pt">[****]</FONT>), and;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[****]</FONT> (<FONT STYLE="font-size: 10pt">[****]</FONT> <FONT STYLE="font-size: 10pt">[****]</FONT>
and <FONT STYLE="font-size: 10pt">[****]</FONT>).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The following processes will be considered: <FONT STYLE="font-size: 10pt">[****]
</FONT>followed by <FONT STYLE="font-size: 10pt">[****]</FONT>. <FONT STYLE="font-size: 10pt">[****]</FONT> will be <FONT STYLE="font-size: 10pt">[****]</FONT>.
<FONT STYLE="font-size: 10pt">[****]</FONT> will be assessed by <FONT STYLE="font-size: 10pt">[****]</FONT> and <FONT STYLE="font-size: 10pt">[****]</FONT>
profile with <FONT STYLE="font-size: 10pt">[****]</FONT>.The formulation should be <FONT STYLE="font-size: 10pt">[****]</FONT>
in capsule <FONT STYLE="font-size: 10pt">[****]</FONT>. <FONT STYLE="font-size: 10pt">[****]</FONT> will be considered.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -35.4pt; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><U>Cost:</U> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[****]</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -85.05pt; margin: 0pt 0 0pt 106.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.1pt"></TD><TD STYLE="width: 28.9pt"><B>2.3-</B></TD><TD STYLE="text-align: left"><B>Analytical method development and analysis</B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">Corealis will perform the development and optimization
of the analytical methods based on <FONT STYLE="font-size: 10pt">[****]</FONT> The methods are <FONT STYLE="font-size: 10pt">[****]</FONT>,
<FONT STYLE="font-size: 10pt">[****]</FONT>, <FONT STYLE="font-size: 10pt">[****]</FONT>, <FONT STYLE="font-size: 10pt">[****],
[****]</FONT> as well as all necessary methods including, but not limited to, <FONT STYLE="font-size: 10pt">[****]</FONT> and <FONT STYLE="font-size: 10pt">[****]</FONT>
method for the manufacturing of the Phase III CTM (as required by the FDA). Also in support of the formulation development activities
(i.e., section 2.2) the Corealis analytical group will support the formulators by executing the analyses required for rapid development
of the Drug Product.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><U>Cost:</U> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[****]</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.1pt"></TD><TD STYLE="width: 28.9pt"><B>2.4-</B></TD><TD STYLE="text-align: left"><B>Stability of prototype formulations</B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0 0pt 21.3pt">Corealis will provide the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Justification of up to <FONT STYLE="font-size: 10pt">[****]</FONT> for non-GMP stability study;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Manufacturing and packaging of up to <FONT STYLE="font-size: 10pt">[****]</FONT>;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Sample incubation under the following conditions of temperature and humidity: <FONT STYLE="font-size: 10pt">[****]</FONT>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Justification of finished product specifications;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 14.2pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Physico-chemical characterization at each of the following conditions (Includes: Appearance, Assay*,
Degradation Products*, Dissolution* and Water content).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The samples will be placed in Corealis<FONT STYLE="font-size: 10pt">'</FONT>
stability chambers and the following stability testing schedule will be used:</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td rowspan="2" style="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Storage <BR>
Condition</td>
    <td colspan="7" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Time point (<font style="font-size: 10pt">[****]</font>)</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Initial</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 24%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 7%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
</table>
<P STYLE="font-size: 10pt; text-align: left; text-indent: 21.3pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">X: Sample to be
analyzed.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 21.3pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Y: Sample removed
from chamber and analyzed only at the request of Client.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 85.05pt"><U>Cost:</U></TD><TD STYLE="text-align: left">$32,016**</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">* On
the [****] APIs.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -14.15pt; margin: 0pt 0 0pt 35.45pt"><FONT STYLE="font-size: 8pt">**
The decision of testing the highest and lowest strength only and extrapolating the stability results to the middle dosage strength
(bracketing) will be taken by the Client.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -14.15pt; margin: 0pt 0 0pt 35.45pt"><FONT STYLE="font-size: 8pt">***
Based on [****]/ sample using a bracketing study design.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.1pt"></TD><TD STYLE="width: 28.9pt"><B>2.5-</B></TD><TD STYLE="text-align: left"><B>Manufacturing of the Phase III Clinical Trial Material (CTM) </B></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The CTM manufacturing, packaging, equipment calibration
and validation, cleaning and raw material release will be done by Corealis GMP laboratory. All the manufacturing, packaging and
analytical equipments that will be used for this CTM manufacturing project will be calibrated, validated and released for their
cleanliness prior to their utilization.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 28.9pt">2.5</TD><TD STYLE="text-align: left">a)&nbsp;&nbsp; GMP material storage and handling</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">Corealis will handle the reception, the shipping and
the storage of GMP materials in its cGMP warehouse. All material handling operations and storage conditions will respect the ICH
GMP requirements.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 134.65pt"><U>Cost:</U></TD><TD STYLE="text-align: justify">$1,455*</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt"><B>*
The cost includes:</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">the
                                         reception of one lot of each of the three GMP APIs (i.e., documentation review, material
                                         registration in Corealis inventory, and material sampling following GMP requirements)
                                         (If API lot is in more than one container then the sampling and ID testing of each of
                                         the additional containers will be considered Extra Work at [****]/additional container),</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">the
                                         ID testing for the release of the three lots of APIs (one for each API) using validated
                                         methods. (Client will ship the GMP APIs to Corealis with the complete certificate of
                                         analysis otherwise Extra Work may be required to release the GMP APIs.),</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">the
                                         GMP warehousing of the API and the drug product until completion of the study. If the
                                         material needs to be stored for a longer period of time then the storage cost will be
                                         [****].</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">the
                                         shipping document preparation and shipment of material.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -13.65pt; margin: 0pt 0 0pt 42pt"><FONT STYLE="font-size: 8pt"><B>The
cost does not include: </B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The
                                         purchase of the analytical reference materials to be used as a standard, if needed, reference
                                         impurities (synthesis by-products, degradation products, metabolites) of known purity
                                         estimated cost is [****]. Subject to pre-approval in writing by the Client of the purchasing
                                         of the materials, Corealis will order the materials. The cost of the materials and any
                                         related costs (e.g. transportation or custom fees) will be charged at cost to Client
                                         and will not exceed a cap of [****].</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Subject
                                         to pre-approval in writing by the Client, repackaging of material (if required) as well
                                         as the shipping cost and custom fees, if any, provided not exceeding a cap of [****].</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 42pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 28.9pt">2.5</TD><TD STYLE="text-align: left">b)&nbsp; GMP Manufacturing, packaging and labelling</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">Corealis will manufacture and package the CTM from the
selected Drug product formulation. The three dose strengths (<FONT STYLE="font-size: 10pt">[****]</FONT>, <FONT STYLE="font-size: 10pt">[****]</FONT>,
and <FONT STYLE="font-size: 10pt">[****]</FONT> or <FONT STYLE="font-size: 10pt">[****]</FONT>, <FONT STYLE="font-size: 10pt">[****]</FONT>,and
<FONT STYLE="font-size: 10pt">[****]</FONT>) of the selected solid dosage form and its matching placebo will be manufactured using
the cGMP APIs supplied by Client. The placebo blend will be similar to the active blend except for the APIs. In addition to the
CTM manufacture, Corealis will perform all necessary receipt and release of required excipients, packaging components, and labels.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">Specifically with respect to manufacturing, packaging
and labeling, the followings items will be provided by Corealis:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: left">Recommendation and justification of specific finished product release, in&nbsp;process testing, stability
as well as excipients and packaging components specifications,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">Formulation and process information for the redaction of Master Manufacturing File (MMF)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: left">The CTM will be manufactured and packaged/labeled in <FONT STYLE="font-size: 10pt">[****]</FONT> bottles
with induction seal at <FONT STYLE="font-size: 10pt">[****]</FONT> units per bottle:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -0.25in; margin: 0pt 0 0pt 57.3pt"><FONT STYLE="font-family: Symbol">&middot;<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">[****] </FONT>&ndash; <FONT STYLE="font-size: 10pt">[****]</FONT> units*;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -0.25in; margin: 0pt 0 0pt 57.3pt"><FONT STYLE="font-family: Symbol">&middot;<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">[****]</FONT> &ndash; <FONT STYLE="font-size: 10pt">[****]</FONT> units*;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -0.25in; margin: 0pt 0 0pt 57.3pt"><FONT STYLE="font-family: Symbol">&middot;<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="font-size: 10pt">[****] </FONT>&ndash; <FONT STYLE="font-size: 10pt">[****]</FONT> units*;</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -0.25in; margin: 0pt 0 0pt 57.3pt"><FONT STYLE="font-family: Symbol">&middot;<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>RHB-105 placebo &ndash; <FONT STYLE="font-size: 10pt">[****] </FONT>units*.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: left">Monitoring and supervision of the manufacturing, packaging and analytical operations.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 28.35pt"><U>Cost:</U></TD><TD STYLE="text-align: left">$136,875**<SUP>, </SUP>***</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">*
Includes [****] capsules of [****] for the CTM [****] study: [****] bottles of [****] capsules/ time point/ condition and [****]
bottles of [****] capsules for [****] (to be done [****]). It includes also [****] of placebo.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">**Based
on the hypothesis that the [****]. If the [****] then, subject to pre-approval in writing by the Client, the following CTM will
be [****] at an additional cost of [****].</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">[****]
                                         - [****] units;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">[****]
                                         - [****] units;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">[****]
                                         - [****] units;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.3pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font: 8pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">RHB-105
                                         Placebo [****] units.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">This
same additional cost of [****] will apply in case the decision is taken to [****] detailed in [****].</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">***If
the manufacture of the placebo units is not needed then cost will be reduced by [****].</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 28.9pt">2.5</TD><TD STYLE="text-align: left">c)&nbsp;&nbsp; Analytical method validation</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The analytical methods for the three strengths dosages
developed by Corealis will be validated in its GMP laboratory. The method will be validated according to ICH guidelines. The method
for cleaning verification will also require complete validation.</P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -28.35pt; margin: 0pt 0 0pt 49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 28.35pt"><U>Cost:</U></TD><TD STYLE="text-align: left">$75,100*</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">* Includes
analytical method validation of assay and content uniformity, related substances, and dissolution for the three strengths as well
as for cleaning. If required and pre-approved in writing by the Client, the analytical method validation for the microbial limit
will be done at an additional cost of [****].</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0in; margin: 0pt 0 0pt 14.2pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0in; margin: 0pt 0 0pt 14.2pt"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0in; margin: 0pt 0 0pt 14.2pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0in; margin: 0pt 0 0pt 14.2pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0in; margin: 0pt 0 0pt 14.2pt"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0in; margin: 0pt 0 0pt 14.2pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 28.9pt">2.5</TD><TD STYLE="text-align: left">d)&nbsp; Release testing and cleaning verification</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 22.5pt">The release of the CTM will be performed by the Corealis
GMP laboratory as well as the cleaning verification samples (swabs).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 22.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 22.5pt">The placebo will also be tested for the absence of active.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 22.5pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -63.7pt; margin: 0pt 0 0pt 85pt">Analyses to be performed are:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -63.7pt; margin: 0pt 0 0pt 85pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -63.7pt; margin: 0pt 0 0pt 85pt"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="vertical-align: bottom; width: 5%; text-align: center">&nbsp;&bull;</td>
    <TD STYLE="vertical-align: middle; text-align: left; width: 20%"><font style="font-size: 10pt; font-weight: normal; font-style: normal">[****]*,</font></td>
    <TD STYLE="vertical-align: bottom; width: 20%">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 5%; text-align: center">&nbsp;&bull;</td>
    <TD STYLE="vertical-align: middle; text-align: left; width: 50%"><font style="font-size: 10pt; font-weight: normal; font-style: normal">[****]**,</font></td></tr>
<tr>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;&bull;</td>
    <TD STYLE="vertical-align: middle; text-align: left"><font style="font-size: 10pt; font-weight: normal; font-style: normal">[****]*,</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;&bull;</td>
    <TD STYLE="vertical-align: middle; text-align: left"><font style="font-size: 10pt; font-weight: normal; font-style: normal">[****]***,</font></td></tr>
<tr>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;&bull;</td>
    <TD STYLE="vertical-align: middle; text-align: left"><font style="font-size: 10pt; font-weight: normal; font-style: normal">[****],** [****]**,</font></td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;&bull;</td>
    <TD STYLE="vertical-align: middle; text-align: left"><font style="font-size: 10pt; font-weight: normal; font-style: normal">[****]****.</font></td></tr>
</table>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: -63.7pt; margin: 0pt 0 0pt 85pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -63.7pt; margin: 0pt 0 0pt 85pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -63.7pt; margin: 0pt 0 0pt 85pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 28.35pt"><U>Cost:</U></TD><TD STYLE="text-align: left">$23,383*****</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -28.35pt; margin: 0pt 0 0pt 49.65pt"><FONT STYLE="font-size: 8pt">*
Analyse done also on placebo.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -28.35pt; margin: 0pt 0 0pt 49.65pt"><FONT STYLE="font-size: 8pt">**
For the [****] APIs.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -28.35pt; margin: 0pt 0 0pt 49.65pt"><FONT STYLE="font-size: 8pt">***
A dissolution test is [****].</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -28.35pt; margin: 0pt 0 0pt 49.65pt"><FONT STYLE="font-size: 8pt">****
Done only if requested by the Client.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -21.25pt; margin: 0pt 0 0pt 42.55pt"><FONT STYLE="font-size: 8pt">*****
Cost includes the release of one lot of each of the three strengths as well as one lot of placebo. If required and pre-approved
in writing by the Client, the analysis of microbiolgy will be done at an extra cost of [****].</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.1pt; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 28.9pt">2.5</TD><TD STYLE="text-align: left">e)&nbsp;&nbsp; Stability of the CTM</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The CTM will be stored in a cGMP stability chamber at
<FONT STYLE="font-size: 10pt">[****]</FONT>. Two strengths of the finished product (highest and lowest dose strengths)** will be
characterized for appearance, assay, related substances, dissolution* and water content using the schedule below. Placebo will
be placed at <FONT STYLE="font-size: 10pt">[****]</FONT> for appearance, water content and used for degradation products background
subtraction and will be analyzed only if needed.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt">The samples will be placed in cGMP stability chambers
and analyzed using validated methods. The following stability testing schedule will be used and modified per mutual agreement:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td rowspan="2" style="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">Storage Condition</td>
    <td colspan="9" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Time point <font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Initial</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 25%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 7%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 7%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
</table>
<P STYLE="font-size: 10pt; text-align: left; text-indent: -14.15pt; margin: 0pt 0 0pt 35.45pt"><FONT STYLE="font-size: 8pt">X:
Sample to be analyzed for appearance, assay, related substances, dissolution* and water content.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: 21.3pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Y: Sample removed
from chamber and analyzed only at the request of Client.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -49.7pt; margin: 0pt 0 0pt 85pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.3pt"></TD><TD STYLE="width: 141.75pt"><U>Cost:</U></TD><TD STYLE="text-align: left">$88,800***</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">*
A dissolution test is a single time point and six vessels/ time point.</FONT></P>

<P STYLE="font-size: 10pt; text-align: left; text-indent: -14.15pt; margin: 0pt 0 0pt 35.45pt"><FONT STYLE="font-size: 8pt">**
The decision of testing only the highest and lowest dose strength and extrapolating the stability results to the [****] will be
taken by the Client.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -14.15pt; margin: 0pt 0 0pt 35.45pt"><FONT STYLE="font-size: 8pt">***
Based on the analysis of [****] using a bracketing study design. The analyses of placebos [****] will be done only if requested
and pre-approved in writing by the Client and they are not included in the cost above.</FONT><U> </U></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7.1pt"></TD><TD STYLE="width: 28.9pt"><B>2.6-</B></TD><TD STYLE="text-align: left"><B>Reports and submission documentation</B></TD></TR></TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;&bull;</td>
    <td colspan="2" style="font-weight: bold; vertical-align: middle; text-align: justify">Telephone meetings<font style="font-size: 10pt; font-weight: normal; font-style: normal"> will be held on a weekly basis on a specific day of the week and at a specific time agreed to by the Parties.</font></td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;&bull;</td>
    <td colspan="2" style="font-weight: bold; vertical-align: middle; text-align: justify">Client or Client&rsquo;s representative<font style="font-size: 10pt; font-weight: normal; font-style: normal"> meeting in Corealis facility will be held at Client&rsquo;s request.</font></td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;&bull;</td>
    <td colspan="2" style="font-weight: bold; vertical-align: middle; text-align: justify">Corealis facility and quality audit<font style="font-size: 10pt; font-weight: normal; font-style: normal"> by Client&rsquo;s or Client&rsquo;s representative will be held at Client&rsquo;s request.</font></td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;&bull;</td>
    <td colspan="2" style="font-weight: bold; vertical-align: middle; text-align: justify">Progress reports<font style="font-size: 10pt; font-weight: normal; font-style: normal"> will be provided on a weekly basis.</font></td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;&bull;</td>
    <td colspan="2" style="font-weight: bold; vertical-align: middle; text-align: left">Item reports<font style="font-size: 10pt; font-weight: normal; font-style: normal"> will be provided as they are completed.</font></td></tr>
<tr>
    <TD STYLE="text-align: center; width: 5%; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 4%; text-align: center">&nbsp;</td>
    <TD STYLE="padding-left: 18px; font-weight: bold; text-align: left; width: 91%">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;&bull;</td>
    <td colspan="2" style="vertical-align: middle; text-align: left">The<font style="font-size: 10pt; font-style: normal"><b> final development report(s) </b><font style="font-weight: normal">will include the followings:</font></font></td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">o</td>
    <TD STYLE="text-align: justify">&nbsp; The methodology and the results;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">o</td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">The
finished products release &amp; stability specifications, in process specifications and specific APIs, excipients and packaging
specifications. Specifications will be provided, for US submissions;</FONT></td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">o</td>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">The
final formulation and manufacturing process.</FONT></td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;&bull;</td>
    <td colspan="2" style="vertical-align: middle; text-align: justify">A <font style="font-size: 10pt; font-style: normal"><b>final manufacturing process report</b><font style="font-weight: normal"> will be provided at the end of the study. It will include all the necessary submission documents related to manufacturing and packaging which include (but are not limited to):&nbsp;</font></font></td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">o</td>
    <TD STYLE="text-align: justify">The finished products release &amp; stability certificate of analysis.&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">o</td>
    <TD STYLE="text-align: justify">In process results.&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">o</td>
    <TD STYLE="text-align: justify">QA Reviewed and audited Manufacturing and Packaging Documents.</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt; font-weight: normal; font-style: normal">o</FONT></td>
    <TD STYLE="text-align: justify">Certificate of cGMP compliance.</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">o</td>
    <TD STYLE="text-align: justify">Certificate of analysis of raw materials and packaging components.&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; text-align: center">o</td>
    <TD STYLE="text-align: justify">Any atypical report or Out-of-Specification reports.</td></tr>
</table>


<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 21.3pt"><U>Cost:</U> &#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<FONT STYLE="font-size: 10pt">[****]</FONT>*</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 8pt">*
Based on a value of [****] of the sub-total of all invoices before taxes. If [****], [****] and [****] are selected for the manufacturing
of the CTM, then the cost for section 2.6 will be $[****].</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -7.05pt; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">3.</FONT></TD><TD>GENERAL PROJECT TIMELINES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">[****]</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -56.7pt; margin: 0pt 0">&#9; &#9;[****]</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">4.</FONT></TD><TD>STARTING DATE AND COMPLETION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Notwithstanding the date of signature of this Service Agreement,
Corealis shall start the performance of the Services within ten (10) business days after Corealis</FONT>'<FONT STYLE="font-weight: normal">
satisfaction of the following: </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">4.1.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">signature by the Client of this Service Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">4.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">complete delivery by the Client of all of the items mentioned
at sub-sections 6.1 to 6.3 inclusive of section 6 hereof entitled &ldquo;REQUIREMENTS&rdquo;. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">This Service Agreement shall be deemed completed upon full delivery
of the Services by Corealis and receipt by Corealis of the final and last payment for the Services.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">5.</FONT></TD><TD>ASSUMPTIONS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The target formulation of RHB-105 will be the following drug
products with the three actives (The &lsquo;APIs&rsquo;) combined with pharmacopeia excipients and compressed or encapsulated:</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">[****] with [****], [****], and [****]</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">[****] with [****], [****], and [****]</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">[****] with [****], [****], and [****]</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0pt 0 0pt 27pt"><FONT STYLE="font-weight: normal">In
the event that </FONT>[****] <FONT STYLE="font-weight: normal">the </FONT>[****]<FONT STYLE="font-weight: normal"> will be considered
</FONT>[****]<FONT STYLE="font-weight: normal">:</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">[****] with [****], [****], and [****]</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">[****] with [****], [****], and [****]</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">[****] with [****],[****], and [****]</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The best efforts will be made by Corealis to select excipients
and processes that will comply with the anticipated cGMP manufacturing site.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The best efforts will be made by Corealis to reduce the project
timelines. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">When decisions need to be taken to move forward in the project
at the decision time point, the Client will provide its decision in writing to Corealis within a period of 5 days. Otherwise the
project may be delayed. Corealis will develop a final timeline for this project and all deviations will be immediately reported
to the Client. Corealis will make its best efforts to correct all deviations in order to maintain the project timelines. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">5.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">All APIs will be sourced by Client. Non-GMP material can be used
in the development phase however it should be of identical quality as the GMP material that would be use in the GMP manufacturing.
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 14.2pt; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">6.</FONT></TD><TD>REQUIREMENTS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Client shall provide to Corealis, at no cost to Corealis, the
following:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">All the available information on APIs (e.g.: interactions, stability,
impurities). </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The APIs, reference materials to be used as a standard, reference
impurities (synthesis by-products, degradation products, metabolites) of known purity, certificate of analysis and APIs&rsquo;
MSDS. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">6.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">For the formulation development, a minimum quantity of [****]
of [****] [****] of [****] and [****] of [****] as well as sufficient quantities of related substances (standards, references,
impurities) for each APIs. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">6.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">For cGMP manufacturing of CTM, a minimum quantity of [****] of
[****] [****] of [****] and [****] of [****] will be required. </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">7.</FONT></TD><TD><FONT STYLE="font-size: 10pt">COST AND PAYMENTS</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The cost of the Services is up to $[****] ($[****] with a rebate
of $[****])or up to $[****] if the placebo manufacture are not required (section 2.5 b)). Any amount exceeding a total of $[****]
requires a pre-approval in writing by the Client.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Client shall pay to Corealis the following installments in
United-States currency ($USD):</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">7.2.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">$[****] upon signature of this formulation development project Agreement;
and </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">7.2.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">$[****] at the initiation of the stability study for the prototypes;
and </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">7.2.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">$[****] ($[****] if placebo manufacture are not required) at the
initiation of the CTM manufacturing; and </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">7.2.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">$[****] ($[****] if placebo manufacture are not required) at the
completion of the CTM manufacturing report issued by Corealis; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">7.2.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">$[****] at the acceptance of the final CTM manufacturing process
report by the Client in writing as a final report; and</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">7.2.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">Stability studies (prototypes </FONT>[****]<FONT STYLE="font-weight: normal">
(as per section 2.4) and CTM </FONT>[****]<FONT STYLE="font-weight: normal"> as per section 2.5 e) to be invoiced as per the following
schedule of payment.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 42.55pt; margin: 0pt 0"><B>Installments for the stability of prototype formulations</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Expected date that material will be introduced in stability chamber</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">Time Point [****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">0</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">1</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date of pull out</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date Results available</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Month of invoice</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Amount to be invoiced</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr>
    <td style="width: 40%">&nbsp;</td>
    <td style="width: 30%">&nbsp;</td>
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 25%">&nbsp;</td></tr>
</table>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 42.55pt; margin: 0pt 0"><B>Installments for the CTM stability study </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Expected date that material will be introduced in stability chamber</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 14.15pt"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">Time Point [****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">1</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">2</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date of pull out</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date Results available</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Month of invoice</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Amount to be invoiced</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">Time Point [****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date of pull out</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date Results available</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Month of invoice</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Amount to be invoiced</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">Time Point [****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date of pull out</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date Results available</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Month of invoice</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]2</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Amount to be invoiced</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td colspan="3" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">Time Point [****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date of pull out</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Date Results available</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Month of invoice</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><font style="font-size: 10pt">Amount to be invoiced</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr>
    <td style="width: 39%">&nbsp;</td>
    <td style="width: 30%">&nbsp;</td>
    <td style="width: 6%">&nbsp;</td>
    <td style="width: 25%">&nbsp;</td></tr>
</table>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Notwithstanding section 7.1, for any extra work not covered by
this Service Agreement and agreed upon in writing between the Parties (the &ldquo;Extra Work&rdquo;), the Client shall pay to Corealis
the hourly rates and other fees indicated in this Appendix I attached hereto for the performance of the Services (The costs of
the Services for the Extra Work and described in section 7.1 are collectively, the &ldquo;</FONT>Fees<FONT STYLE="font-weight: normal">&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">7.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Notwithstanding section 7.2 hereof, Corealis will invoice the
Client for the Extra Work, on a monthly basis for the Services that have been delivered or rendered by Corealis. The Client shall
pay Corealis for these Services to the extent their performance has been pre-approved in writing by the Client.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">8.</FONT></TD><TD><FONT STYLE="font-size: 10pt">CONFIDENTIALITY</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Confidentiality issues are covered per the Non Disclosure Agreement
and the MSA.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">9.</FONT></TD><TD><FONT STYLE="font-size: 10pt">REPRESENTATIONS AND WARRANTIES</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">9.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Corealis hereby represents and warrants to the Client that: </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">9.1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">it is a duly organized and validly existing corporation under
the laws of the jurisdiction in which it is incorporated; </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">9.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">it has the necessary corporate power, authority, skills, and
capacity and is properly authorized to enter into this Service Agreement and to perform its obligations as per the terms and conditions
of this Service Agreement. The execution and delivery of this Service Agreement and the performance of the transactions contemplated
hereby have been duly authorized.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">9.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Client hereby represents and warrants to Corealis that: </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">9.2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">it is a duly organized and validly existing corporation under
the laws of the jurisdiction in which it is incorporated; </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-weight: normal">9.2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">it has the necessary corporate power, authority, skills, and
capacity and is properly authorized to enter into this Service Agreement and to perform its obligations as per the terms and conditions
of this Service Agreement. The execution and delivery of this Service Agreement and the performance of the transactions contemplated
hereby have been duly authorized; </FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">10.</FONT></TD><TD><FONT STYLE="font-size: 10pt">TERMS AND CONDITIONS</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">10.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">This Service Agreement shall be governed, construed and interpreted
according to the laws in force in the Province of Quebec and the applicable laws of Canada therein, and the courts of the legal
district of Montreal, province of Quebec (Canada) shall have exclusive jurisdiction to hear any and all disputes arising hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">10.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">This Service Agreement is subject to the terms and conditions
provided in the MSA and bind the parties as well as their respective successors, permitted assigns and legal representatives.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">10.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">This Service Agreement may be executed in counterparts, each
of which shall be deemed to be an original and which together shall constitute one and the same agreement. This Service Agreement
may also be executed between the Parties by exchange of facsimile transmissions or electronic transmissions in legible form, including
without limitation in a tagged image format file (TIFF) or portable document format (PDF).</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">10.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Parties hereto have requested that this Service Agreement
be drafted in the English language. Les Parties ont exig&eacute; que ce contrat de services soit r&eacute;dig&eacute; en anglais.
</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>IN WITNESS THEREOF, the Parties have executed this Service Agreement
as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention to bind
the Parties they represent. </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="20%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Corealis Pharma Inc.</font></div>
</div>
</div>
</td>
<td align="left" valign="top" width="34%">&#160;</td>
<td colspan="3" valign="top" width="46%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7810962 Canada Inc.</font></font></div>
</div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="20%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="34%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="top" width="46%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Per: </font></td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/</font></div>
</td>
<td valign="top" width="34%">&#160;</td>
<td valign="top" width="3%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Per:</font></font></div>
</td>
<td nowrap valign="top" width="23%" style="BORDER-BOTTOM: black 1.1pt solid; TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">/s/ Alain Guimond PhD</td>
<td valign="top" width="20%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name: </font></td>
<td valign="top" width="17%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">[****]</font></font></font></div>
</td>
<td valign="top" width="34%">&#160;</td>
<td colspan="3" valign="top" width="46%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name: Alain Guimond PhD</font></font></div>
</div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title: </font></td>
<td colspan="2" valign="top" width="51%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">VP Pharmaceutical R&amp;D</font></font></div>
</div>
</td>
<td colspan="3" valign="top" width="46%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title: Senior Director of Research</font></font></div>
</div>
</td>
</tr></table>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Service Agreement - A</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>7810962 Canada Inc. &ndash; COREALIS Pharma Inc.</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"><B>Formulation development of RHB-105 in oral solid dosage form <BR> and manufacture of clinical supplies</B></P><P STYLE="font-size: 12pt; text-align: center; margin: 0pt 0"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt"><B>APPENDIX
I</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; height: 60px; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="text-align: center; padding-top: 12pt; padding-bottom: 3pt; font-weight: bold; text-indent: 0in"><font style="font-size: 10pt">[****]Contract Formulation and Process <BR>
Development</font></td></tr>
</table>
<P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt; font-variant: normal"><B>Professional
Consultation Rates</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 85%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 60%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal"><b>Professional
        </b></font></P>
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal">(Chemist
        or Engineer)</font></P></td>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal"><b>Hourly
        Rate</b>*<sup>, </sup>**</font></P>
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal">($USD)</font></P></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt; text-align: center"><font style="font-size: 10pt; font-variant: normal">Senior scientist </font></td>
    <td style="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt; text-align: center"><font style="font-size: 10pt; font-variant: normal">$240.00</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt; text-align: center"><font style="font-size: 10pt; font-variant: normal">Scientist </font></td>
    <td style="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt; text-align: center"><font style="font-size: 10pt; font-variant: normal">$200.00</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt; text-align: center"><font style="font-size: 10pt; font-variant: normal">Technician</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt; text-align: center"><font style="font-size: 10pt; font-variant: normal">$110.00</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal">R&amp;D
        laboratory overhead </font></P>
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal">( Equipment
        and supplies)</font></P></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt; text-align: center"><font style="font-size: 10pt; font-variant: normal">$ 75.00***</font></td></tr>
</table>
<P STYLE="font-size: 10pt; font-variant: small-caps; margin: 0pt 0"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><FONT STYLE="font-size: 12pt; font-variant: normal"><B>Analytical
Services</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 85%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <TD STYLE="width: 60%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal"><b>Analyses</b></font></P>
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal">&nbsp;</font></P></td>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal"><b>Cost
        / Sample </b>*</font></P>
        <P STYLE="font-size: 10pt; font-variant: small-caps; text-align: center; margin: 0pt 0"><font style="font-variant: normal">($USD)</font></P></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">XRPD </font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 24pt; font-variant: small-caps; position: relative; top: 1pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">SEM</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">TGA</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">DSC</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Water Content (Karl Fisher)</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Single point dissolution test/ vessel ****</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Assay****</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Related Substances****</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Disintegration</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Hygroscopicity (5 conditions)</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 24pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Solubility in water at pH 2, 4.5 and 7</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Flow, Grinding and Compressibility</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Particle Size and Distribution</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Bulk and Tap Density</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-variant: small-caps; position: relative; top: 1pt"><font style="font-size: 10pt; font-variant: normal">Organoleptic (texture, color, appearance)&nbsp;&nbsp;</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">[****]</font></td></tr>
</table>
<P STYLE="font-size: 10pt; font-variant: small-caps; margin: 0pt 0"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; text-indent: -7.1pt; margin: 0pt 0 0pt 7.1pt"><FONT STYLE="font-size: 8pt; font-variant: normal">*
Prices can be changed by Corealis without any prior notice. Prices apply only for non GMP work and analysis. GMP prices will be
supplied on demand.</FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; margin: 0pt 0"><FONT STYLE="font-size: 8pt; font-variant: normal">**All expenses
will be charged at cost.</FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; margin: 0pt 0"><FONT STYLE="font-size: 8pt; font-variant: normal">***Will
be invoiced in addition to the professional fees when laboratory work is required.</FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; margin: 0pt 0"><FONT STYLE="font-size: 8pt; font-variant: normal">****A set-up
charge of $</FONT><FONT STYLE="font-size: 8pt">[****]<FONT STYLE="font-variant: normal">/ HPLC method will be invoiced in addition
to the sample cost.</FONT></FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; margin: 0pt 0"><FONT STYLE="font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; font-variant: normal">12&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-variant: small-caps; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; font-variant: normal"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; font-variant: small-caps; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; font-variant: normal">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>5
<FILENAME>exh_417.htm
<DESCRIPTION>EXHIBIT 4.17
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Service Agreement &ndash; A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Amendment 1</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>Exhibit 4.17</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>THE SYMBOL &ldquo;</B>[****]<B>&rdquo;</B> <B>DENOTES PLACES WHERE
PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.</B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><FONT STYLE="text-transform: uppercase"><B>Amendment 1 to The service
Agreement A </B></FONT>is made and entered in August 17<SUP>th</SUP>, 2011 (the &ldquo;<B>Amendment</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="text-transform: uppercase">1.</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">DESCRIPTION OF THE EXTRA WORK</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">Approximately 1 g of [****] lot number [****] was received from [****]
[****] for supplier qualification. &nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">A supplier qualification analysis will have to be performed and will
consist of verification of the results included in the certificate of analysis of the supplier.&nbsp;The following tests will be
performed on this lot:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0; color: #1F497D">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt">1.</TD><TD STYLE="text-align: justify">IR (90$),</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify">Assay (130$),</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt">3.</TD><TD STYLE="text-align: justify">Impurities (190$)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt">4.</TD><TD STYLE="text-align: justify">Water content (85$).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -56.7pt; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="text-transform: uppercase">2.</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">COST AND PAYMENTS</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font-weight: normal">2.1</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The cost of the Services for the Extra Work detailed
in section 1 is $495 USD.</FONT></TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt; text-align: left"><FONT STYLE="font-weight: normal">2.2</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Client shall pay to Corealis in United-States
currency ($USD) upon the reception of the invoice.</FONT></TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B>IN WITNESS THEREOF, the Parties have executed this Amendment
as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention to bind
the Parties they represent. </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Corealis Pharma Inc.______</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">7810962 Canada Inc.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Per: <U>/s/</U>___________________</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Per: <U>/s/ Alain Guimond PhD</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Name: Yves Roy, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: Alain Guimond PhD</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Title: President</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title: Senior director of Research</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.18
<SEQUENCE>6
<FILENAME>exh_418.htm
<DESCRIPTION>EXHIBIT 4.18
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 4.18</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.7pt; margin: 0pt 46.05pt 0pt 6.75pt; color: #1C211C">THE SYMBOL
&ldquo;[****]&rdquo; DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT.
SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 3pt"><FONT STYLE="font-size: 12pt"><B>Service Agreement
&ndash; A</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 3pt"><FONT STYLE="font-size: 12pt"><B>Formulation
development of RHB-105 in oral solid dosage form and manufacture of clinical supplies</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt"><B>Amendment
2</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Amendment 2 to The service Agreement A </B></FONT>is
made and entered in September 30<SUP>th</SUP>, 2011 (the &ldquo;<B>Amendment</B>&rdquo;)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #1C211C; text-align: left">1. &#9;DESCRIPTION OF THE EXTRA WORK</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 46.05pt; margin-bottom: 0pt; color: #1C211C; text-align: left">Reception, the shipping and the
storage of one additional Lot of Rifabutin and Omneprazole in Corealis ' GMP warehouse as per section (2.5 a) service agreement
A</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: #1C211C; text-align: left">Charges as per the following table:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="3" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 90%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: middle">
    <TD COLSPAN="2" STYLE="color: #1C211C; text-align: left; border-top: Black 1.1pt solid; border-left: Black 1.1pt solid">Description</td>
    <TD STYLE="color: #1C211C; text-align: center; border-top: Black 1.1pt solid; border-right: Black 1.1pt solid; border-left: Black 1.1pt solid">Amount</td></tr>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="color: #1C211C; text-align: left; border-bottom: Black 1.1pt solid; border-left: Black 1.1pt solid">&nbsp;</TD>
    <TD STYLE="color: #1C211C; text-align: center; border-bottom: Black 1.1pt solid; border-left: Black 1.1pt solid; border-right: Black 1.1pt solid">&nbsp;</TD></TR>
<tr style="vertical-align: middle">
    <TD COLSPAN="2" STYLE="color: #1C211C; text-align: left; border-left: Black 1.1pt solid">Extra Work as per section (2.5 a) service agreement A<font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">:</font></td>
    <TD STYLE="border-right: Black 1.1pt solid; border-left: Black 1.1pt solid">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; width: 3%; vertical-align: top; border-left: Black 1.1pt solid">&nbsp;</td>
    <TD STYLE="font-size: 12pt; text-align: left; width: 77%">&nbsp;</td>
    <TD STYLE="border-right: Black 1.1pt solid; border-left: Black 1.1pt solid; width: 20%">&nbsp;</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top; border-left: Black 1.1pt solid">&bull;</td>
    <TD STYLE="color: #1C211C; text-align: left">Omeprazole customs charges (Ref.: invoice no.&nbsp;&nbsp;407084173 1-01) ($442<font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #484D49">.</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">74 CDN </font><font style="font-size: 12pt; font-weight: normal; font-style: normal; color: #1C211C">x </font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">0</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #484D49">.</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">96 (exchange rate</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">))</font></td>
    <TD STYLE="color: #1C211C; border-right: Black 1.1pt solid; border-left: Black 1.1pt solid; text-align: center">$425.03</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top; border-left: Black 1.1pt solid">&bull;</td>
    <TD STYLE="color: #1C211C; text-align: left">Omeprazole customs charges <font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">&amp; local transportation (Ref</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">.: </font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">invoice no</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">.&nbsp;&nbsp;</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">407084173 1-02) ($ 145</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">.</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">00 CDN </font><font style="font-size: 12pt; font-weight: normal; font-style: normal; color: #1C211C">x </font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">0.96 (exchange </font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">r</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">ate))</font></td>
    <TD STYLE="color: #1C211C; border-right: Black 1.1pt solid; border-left: Black 1.1pt solid; text-align: center">$139.20</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top; border-left: Black 1.1pt solid">&bull;</td>
    <TD STYLE="color: #1C211C; text-align: left">Rifabutin customs charges (Ref<font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">.: </font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">invoice no.407083673 1-01) ($ 105.00 CDN x 0.96 (exchange rate))</font></td>
    <TD STYLE="color: #1C211C; border-right: Black 1.1pt solid; border-left: Black 1.1pt solid; text-align: center">$100.80</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top; border-left: Black 1.1pt solid">&bull;</td>
    <TD STYLE="color: #1C211C; text-align: left">GMP material storage <font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">&amp; handling for 1 additional Lot of Omeprazole</font></td>
    <TD STYLE="color: #1C211C; border-right: Black 1.1pt solid; border-left: Black 1.1pt solid; text-align: center">$200.00</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top; border-left: Black 1.1pt solid">&bull;</td>
    <TD STYLE="color: #1C211C; text-align: left">Technical support 0<font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">.</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">5 hours ($ 250</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #343A36">.</font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">00 </font><font style="font-size: 10pt; font-weight: normal; color: #343A36"><i>I </i></font><font style="font-size: 10pt; font-weight: normal; font-style: normal; color: #1C211C">hours)</font></td>
    <TD STYLE="color: #1C211C; border-right: Black 1.1pt solid; border-left: Black 1.1pt solid; text-align: center">$125.00</td></tr>
<tr>
    <TD STYLE="text-align: center; vertical-align: top; border-left: Black 1.1pt solid; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1.1pt solid; text-align: left">&nbsp;</td>
    <TD STYLE="font-size: 12pt; border-right: Black 1.1pt solid; border-bottom: Black 1.1pt solid; border-left: Black 1.1pt solid">&nbsp;</td></tr>
<TR>
    <TD STYLE="text-align: center; vertical-align: top; border-left: Black 1.1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 12pt; border-right: Black 1.1pt solid; border-left: Black 1.1pt solid">&nbsp;</TD></TR>
<tr>
    <TD STYLE="text-align: center; vertical-align: top; border-left: Black 1.1pt solid; border-bottom: Black 1.1pt solid">&nbsp;</td>
    <TD STYLE="color: #1C211C; border-bottom: Black 1.1pt solid; text-align: right">Total charges&nbsp;&nbsp;($USD)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
    <TD STYLE="color: #1C211C; border-right: Black 1.1pt solid; border-bottom: Black 1.1pt solid; border-left: Black 1.1pt solid; text-align: center">$990.03</td></tr>
</table>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 285.7pt; margin-bottom: 0pt; color: #1C211C">2. COST AND PAYMENTS</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 62.15pt; margin-bottom: 0pt; color: #1C211C">2.1 The cost of the Services for the
Extra Work detailed in section 1 is $ 990.03</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 24.8pt; margin-bottom: 0pt; color: #1C211C">2.2 The Client shall pay to Corealis
the following installments in United-States currency</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 243.9pt 0pt 20pt; color: #1C211C">($USD) upon reception of the invoice.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>IN WITNESS THEREOF, the Parties have executed this Amendment
as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention to bind
the Parties they represent. </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="3" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <TD COLSPAN="2" STYLE="vertical-align: middle">Corealis Pharma Inc.</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD COLSPAN="2" STYLE="vertical-align: middle">7810962 Canada Inc.</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: middle; width: 4%">Per:</td>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.1pt solid; width: 26%">&nbsp;/s/</td>
    <TD STYLE="vertical-align: bottom; width: 14%">&nbsp;</td>
    <TD STYLE="vertical-align: middle; width: 4%">Per:&nbsp;</td>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: Black 1.1pt solid; width: 26%">/s/ Alain Guimond PhD</td>
    <TD STYLE="vertical-align: bottom; width: 26%">&nbsp;</td></tr>
<tr>
    <TD COLSPAN="2" STYLE="vertical-align: middle">Name: Yves Roy, Ph.D.</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD COLSPAN="2" STYLE="vertical-align: middle">Name: Alain Guimond PhD</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <TD COLSPAN="2" STYLE="vertical-align: bottom">Title: President</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td>
    <TD COLSPAN="2" STYLE="vertical-align: middle">Title: Senior director of Research</td>
    <TD STYLE="vertical-align: bottom">&nbsp;</td></tr>
</table>

<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.19
<SEQUENCE>7
<FILENAME>exh_419.htm
<DESCRIPTION>EXHIBIT 4.19
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Service Agreement &ndash; A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Amendment 3</B></P>



<P STYLE="font-size: 10pt; text-align: right; margin: 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><FONT STYLE="text-transform: uppercase"><B>E</B></FONT><B>xhibit 4.19</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>THE SYMBOL &ldquo;</B>[****]<B>&rdquo;</B> <B>DENOTES PLACES WHERE
PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><FONT STYLE="text-transform: uppercase"><B>Amendment 3 to The service
Agreement A </B></FONT>is made and entered in April 19<SUP>th</SUP>, 2012 (the &ldquo;<B>Amendment</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left"><FONT STYLE="text-transform: uppercase">1.</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">DESCRIPTION OF THE EXTRA WORK</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0"><FONT STYLE="font-weight: normal">The
Client requested that the GMP Omeprazole magnesium API and GMP Amoxicillin API and GMP Rifabutin API would be analyzed by Corealis
at their reception at the Corealis</FONT>]<FONT STYLE="font-weight: normal"> facility for full testing and not only ID testing.
</FONT></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">a.</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><U>GMP Omeprazole magnesium API analytical release testing</U></TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B><U>ITEM</U></B></TD>
    <TD STYLE="text-align: right"><B><U>Cost (USD$)</U></B></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>ID testing</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">IR-Method qualification, set-up and analysis*</TD>
    <TD STYLE="text-align: right">0$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right">200$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Assay</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Method qualification</TD>
    <TD STYLE="text-align: right">2,000$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Set-up</TD>
    <TD STYLE="text-align: right">605$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">575$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Related substances</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Method qualification</TD>
    <TD STYLE="text-align: right">2,500$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Set-up**</TD>
    <TD STYLE="text-align: right">0$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">795$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Residual solvents</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><FONT>Method A: [****]</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right"><FONT>14,000$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">1,200$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Water - Karl Fisher Titration (USP &lt;921&gt;)</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right"><FONT>165$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Appearance</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">85$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">[****]</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 34%">Analysis</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT>75$</FONT></TD>
    <TD STYLE="width: 24%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Corealis</TD>
    <TD STYLE="width: 34%; text-align: center">Page 1 of 5</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date: April 19<SUP>th</SUP>, 2012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; margin: 0"></P>



<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Service Agreement &ndash; A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Amendment 3</B></P>



<P STYLE="font-size: 10pt; margin: 0; text-align: justify"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">[****]</TD>
    <TD STYLE="text-align: right">Analysis</TD>
    <TD STYLE="text-align: right">170$</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">[****]</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right"><FONT>550$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"></TD>
    <TD STYLE="text-align: right"></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Report<FONT STYLE="font-weight: normal">****</FONT></B></TD>
    <TD STYLE="text-align: right">688$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"></TD>
    <TD STYLE="text-align: right"><FONT>_______</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"></TD>
    <TD STYLE="text-align: right"></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B>Sub total for section 1. a.</B></TD>
    <TD STYLE="text-align: right"><B>23,608$</B></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="5"><B>b. <U>GMP Amoxicillin trihydrate API analytical release testing</U></B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"></TD>
    <TD STYLE="text-align: right"></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B><U>ITEM</U></B></TD>
    <TD STYLE="text-align: right"><B><U>Cost (USD$)</U></B></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"></TD>
    <TD STYLE="text-align: right"></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>ID testing</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">IR-Method qualification,
set-up and analysis*</TD>
    <TD STYLE="text-align: right">0$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><FONT></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B>Assay</B></TD>
    <TD STYLE="text-align: right"><FONT></FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Method qualification</TD>
    <TD STYLE="text-align: right">2,000$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Set-up</TD>
    <TD STYLE="text-align: right"><FONT>605$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right"><FONT>575$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"></TD>
    <TD STYLE="text-align: right"><FONT></FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Related substances</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"><B></B>Method qualification</TD>
    <TD STYLE="text-align: right"><FONT>2,500$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Set-up**</TD>
    <TD STYLE="text-align: right"><FONT>0$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right"><FONT>795$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>pH</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">85$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Residual solvents</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right">30,000$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right"><FONT>1,800$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Water - Karl Fisher Titration (USP &lt;921&gt;)</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right"><FONT>165$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Appearance</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">85$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B>Crystallinity</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">550$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B>Report****</B></TD>
    <TD STYLE="text-align: right"><B>1,175$</B></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT>_______</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B>Sub total for section 1. b.</B></TD>
    <TD STYLE="text-align: right"><B>40,335$</B></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 34%"></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT></FONT></TD>
    <TD STYLE="width: 24%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: justify; text-indent: 14.2pt"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Corealis</TD>
    <TD STYLE="width: 34%; text-align: center">Page 2 of 5</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date: April 19<SUP>th</SUP>, 2012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Service Agreement &ndash; A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Amendment 3</B></P>



<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"> c. <U>GMP Rifabutin API analytical release testing </U></P>



<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B><U>ITEM</U></B></TD>
    <TD STYLE="text-align: right"><B><U>Cost (USD$)</U></B></TD>
    <TD STYLE="text-align: right"></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>ID testing</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">IR-Method qualification,
set-up and analysis*</TD>
    <TD STYLE="text-align: right"><FONT>0$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right">575$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B>Assay</B></TD>
    <TD STYLE="text-align: right"></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Method qualification</TD>
    <TD STYLE="text-align: right"><FONT>2,000$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Set-up</TD>
    <TD STYLE="text-align: right"><FONT>605$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">575$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B></B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B>Related substances</B></TD>
    <TD STYLE="text-align: right"></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Method qualification</TD>
    <TD STYLE="text-align: right">2,500$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Set-up**</TD>
    <TD STYLE="text-align: right">0$&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">795$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 0pt"><B>Water - Karl Fisher Titration (USP &lt;921&gt;)</B></TD>
    <TD STYLE="text-align: right">165$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right"><FONT></FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"></TD>
    <TD STYLE="text-align: right"></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Limit of N-Iso Butylpiperidone (TLC)</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Qualification,
set-up and analysis</TD>
    <TD STYLE="text-align: right">1,650$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt"></TD>
    <TD STYLE="text-align: right"><FONT></FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Residual solvents</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****].<B></B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****].</TD>
    <TD STYLE="text-align: right"></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">[****]</TD>
    <TD STYLE="text-align: right">24,000$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">1,800$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Qualification
[****]***</TD>
    <TD STYLE="text-align: right">2,000$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Appearance</B></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-indent: 10pt">Analysis</TD>
    <TD STYLE="text-align: right">85$</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Report****</B></TD>
    <TD STYLE="text-align: right"><FONT>1,103$</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">_______</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Sub total for section 1. c.</B></TD>
    <TD STYLE="text-align: right"><B>37,853$</B></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">_______</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2"><B>Total cost of the amendment</B></TD>
    <TD STYLE="text-align: right"><B>101,795$</B></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">* Already included in Service Agreement A.</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 34%"></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT></FONT></TD>
    <TD STYLE="width: 24%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: justify; text-indent: 14.2pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0; text-align: justify; text-indent: 14.2pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Corealis</TD>
    <TD STYLE="width: 34%; text-align: center">Page 3 of 5</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date: April 19<SUP>th</SUP>, 2012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0; text-align: justify; text-indent: 14.2pt"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: justify; text-indent: 14.2pt"></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; text-indent: 0in; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Service Agreement &ndash; A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Amendment 3</B></P>



<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0">** Included in the set-up cost of the Assay.</P>

<P STYLE="font-size: 10pt; text-indent: -14.2pt; margin: 0 0 0 14.2pt">***Analysis to be outsourced to a Corealis qualified vendor.
<B>[****]</B> in Toronto using the validated analytical methods of <B>[****]</B>.</P>

<P STYLE="font-size: 10pt; margin: 0">**** Cost for the documentation and the CofA- 3% of the total cost of the analysis.</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 3pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">2.</FONT></TD><TD><FONT STYLE="font-size: 10pt">COST AND PAYMENTS</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The cost of the Services for the Extra Work detailed in section
1 is:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-weight: normal">2.1.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">$101,795 if the following installments are:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>50% at the signature of this Agreement; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the balance at the completion of the release testing.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0 0 0 0.5in; text-indent: 0in">OR</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-weight: normal">2.1.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">$89,783 if $89,783 is paid within 7 days from the signature of this
Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-weight: normal">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">The Client shall pay to Corealis the following installments in
United-States currency ($USD):</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0 0 0 14.2pt; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-bottom: 3pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">3.</FONT></TD><TD><FONT STYLE="font-size: 10pt">TIMELINES FOR AMENDMENT 3</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 9pt; margin-bottom: 0">[****]</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B>IN WITNESS THEREOF, the Parties have executed this Amendment
as of the Date written above, by their authorised representatives, who by signing confirm their authority and intention to bind
the Parties they represent. </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Corealis</TD>
    <TD STYLE="width: 34%; text-align: center">Page 4 of 5</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date: April 19<SUP>th</SUP>, 2012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Service Agreement &ndash; A</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Formulation development of RHB-105 in oral solid dosage form and manufacture
of clinical supplies</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Amendment 3</B></P>



<P STYLE="font-size: 10pt; text-align: justify; margin: 9pt 0 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Corealis Pharma Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7810962</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Canada Inc.</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Per: <U>/s/</U>___________________</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Per: <U>/s/ Alain Guimond PhD</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Name: Yves Roy, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: Alain Guimond PhD</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Title: President</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title: Senior director of Research</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%">Corealis</TD>
    <TD STYLE="width: 34%; text-align: center">Page 5 of 5</TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date: April 19<SUP>th</SUP>, 2012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>8
<FILENAME>exh_121.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B><U>Exhibit 12.1</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">I, Dror Ben-Asher, certify that:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 20-F/A of RedHill Biopharma Ltd.;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">a)</P></TD>
    <TD>
        <P STYLE="margin: 0pt 0; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including
its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this
report is being prepared;</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">b)</P></TD>
    <TD>
        <P STYLE="margin: 0pt 0; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles;</P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Date: September 10, 2015</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 25%; border-bottom: Black 1.1pt solid">/s/ Dror Ben-Asher</TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>



<P STYLE="margin: 0">Dror Ben-Asher</P>

<P STYLE="margin: 0">Chief Executive Officer</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>9
<FILENAME>exh_122.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B><U>Exhibit 12.2</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">I, Ori Shilo certify that:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 20-F/A of RedHill Biopharma Ltd..;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">a)</P></TD>
    <TD>
        <P STYLE="margin: 0pt 0; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including
its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this
report is being prepared;</P></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">
        <P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0">b)</P></TD>
    <TD>
        <P STYLE="margin: 0pt 0; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles;</P></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.25in; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Date: September 10, 2015</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 25%; border-bottom: Black 1.1pt solid">/s/ Ori Shilo</TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>



<P STYLE="margin: 0">Ori Shilo</P>

<P STYLE="margin: 0">Deputy Chief Executive Officer Finance and Operations</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>corealis_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 corealis_logo.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!*17AI9@  34T *@    @  P$:  4
M   !    ,@$;  4    !    .@$H  ,    !  (           "6     0"6
M     0  _^%%Q6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C
M:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B
M/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP
M=&L](D%D;V)E(%A-4"!#;W)E(#0N,2UC,#,V(#0V+C(W-S Y,BP@1G)I($9E
M8B R,R R,# W(#$T.C$W.C X(" @(" @(" B/@T*"3QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS
M.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^#0H)"0D\
M9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X-"@D)"3QD8SIT:71L
M93X-"@D)"0D\<F1F.D%L=#X-"@D)"0D)/')D9CIL:2!X;6PZ;&%N9STB>"UD
M969A=6QT(CY&<F5N8V@\+W)D9CIL:3X-"@D)"0D\+W)D9CI!;'0^#0H)"0D\
M+V1C.G1I=&QE/@T*"0D\+W)D9CI$97-C<FEP=&EO;CX-"@D)/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&%P/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SIX87!'26UG/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX-"@D)"3QX87 Z0W)E871O<E1O;VP^
M26QL=7-T<F%T;W(\+WAA<#I#<F5A=&]R5&]O;#X-"@D)"3QX87 Z0W)E871E
M1&%T93XR,#$R+3 Y+3$P5#(Q.C X.C W+3 T.C P/"]X87 Z0W)E871E1&%T
M93X-"@D)"3QX87 Z36]D:69Y1&%T93XR,#$R+3 Y+3$Q5# Q.C X.C$V6CPO
M>&%P.DUO9&EF>41A=&4^#0H)"0D\>&%P.DUE=&%D871A1&%T93XR,#$R+3 Y
M+3$P5#(Q.C X.C W+3 T.C P/"]X87 Z365T861A=&%$871E/@T*"0D)/'AA
M<#I4:'5M8FYA:6QS/@T*"0D)"3QR9&8Z06QT/@T*"0D)"0D\<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QX87!'26UG.G=I9'1H
M/C(U-CPO>&%P1TEM9SIW:61T:#X-"@D)"0D)"3QX87!'26UG.FAE:6=H=#XX
M,#PO>&%P1TEM9SIH96EG:'0^#0H)"0D)"0D\>&%P1TEM9SIF;W)M870^2E!%
M1SPO>&%P1TEM9SIF;W)M870^#0H)"0D)"0D\>&%P1TEM9SII;6%G93XO.6HO
M-$%!45-K6DI29T%"06=%0DQ!17-!040O-U%!<U5':'9D1SEZ84<Y=TE$375-
M04$T46ML3D$K,$%!04%!04)!0DQ!04%!045!#0I!445S04%!04%104(O*S1!
M1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#
M=V='0F=G3$1!;TM#=V]+#0I$0D%-1$%W341!=U%$031014$X3T1"351&0E%4
M17AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(
M>#AF#0I(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G055!14%!=T52#0I!04E205%-
M4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+
M0W=%04%G241!445"05%%04%!04%!04%!#0I!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!"#0I5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51
M;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%
M#0HQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F
M2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:#0IQ8FY*,F5N-4MJ
M<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%
M1$)#15--545&55).:$EG6GAG6D5Y#0IO8DAW1DU(4C133D-&5DII8W9%>DI$
M4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95
M,SAQ3WIW>6=P#0HP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O
M85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO#0HK
M1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%1
M04-%44U2040X03E5-'$W1E=.;CAX+TI",65,4TET#0I8:'5.4FUF,#0W93)$
M,T),,$I)<D-R<4M5-VY**TA+<G!J>$1K;$UN-31F;&9'-U)V<DI6,$I6;$YR
M94%G:EEG:C!C;#1-=35(:5):#0I0-60X>39,-6HP-&%L;S%W8G%Y3'1'2G94
M:VIQ>69A2$=656)B-5I#55-$4EI!,FQV;7HX>'9*+VQ7:6%V9G%L,'=Q;&Y%
M1$Q/4C1L#0I&<GA"-T9Q0319-'I,:VE59T]A55A(-7HK5DQF>799*UI:-$PQ
M3E Q0S9E,'1L36-:;$IJ-6-P4V]K<#992U4V.'9B2F5%8G!(:4-R#0I:1#57
M.#9E5R].3FUB<E)B,6)L56]*;U-#:W-:4%HT,F]W*V91.6EC:$M":GI:0U%0
M2C-M:GIR-5HX<E)7.'5V6'8Q3DQP;5=!*VY,#0I,>4M!1G1O:V-I;&4K35E'
M6$I4241M>#<O;&5N-58O.5AV.$$V9&)Z+W%J:R]";#--9D5I;65T9FUH-48P
M45=:,515+W$O-E%T,'4W#0I196AC3UAH:RMY.45J67)8=V%H>4EX>5!*2FU"
M>E1,>3DU=3AT95DT5VTP5%5)<C%5<#9I;U-(5W4T-5)S1F1F<$=#55-/85%1
M95-3#0IA<"MC4#5C-EAQ3GAP,3EQ+V\S;'!),%9X1CE8=5@T=7!O4GE32FQ.
M4%DU25EP2&]X3U%"=E10>F0O3#-5-5I99% Q4G)I5T=*-VE2#0I%=&)U;VEI
M2$HR;UET-D1W>$]+45540E%N+TLY4'ER+T%/<C,O=T)/=#4O,5)W*T1,=5AX
M27-R,$1Z0G!(;41423E5,&EC,TYH35=7#0I+67!*2'E+359A:7E+:F)-2V1-
M<FQ%9S!744YO6'I2-3 X<RM6;UE*=&1V4'%C9'EZ2D$S<'EY.&U55DEP16HP
M-CDX35E'6$I4241M#0IX-R]L96XU5B]W1%8W+S9D8GHO<6IK+T)L,TUF16EZ
M87EV3&$Y<S1,>3)F,4QA-6I384-3:%AK:VEH;$Y'04EQ1#-Y;VEM8D4Y52]/
M#0I(.'5D3#%'-# V*S%F,')Y,&-X6$51=#=L*TQR<U)Y4TIL3E!9-5E-56IV
M5$$U0452-68O0413.&EE66145%1.2#%0-C%F4TMZ<$8V#0I&>$A654974$M3
M3D8V92M#5T]11FQ);41Y6E9K1U1(4$TO-6EE5'9+.3%$838W<4@Q3S1N5#%9
M;R]3;6Q*4W!7=C=P2$$S2&9*>'AM#0I82FI+44A.2TEV>G8O2RM75DEO.6$U
M4U--1E)283-D4U-A068S3U,X1UAC:GA)<W Q,WI&;V5G,F8Q>E=,,DMY=#8P
M5G!7;U=09VEI#0IR369:4FQ9:51Y6D4P:S%V*V%0:V4T,%,V,3)#+V0Y2G-P
M16AU8G-7=#-W4C50<VHK-G%E;W)18E9&96]Y6&AY=6MC67$P="\U6' K#0I6
M9CA!,64O*VY7."\V;S5,=UID>5!%:7IM0V%/94-/94UK>'EQ2%%K1E1X659&
M47="2# U57I8-'$W1EA9<3=&6%EQ*V%F>G$O3FTY#0HQ;E5R:GDW;S@U:#!3
M,5EX6$UK6F]B<5)44G%S4#DQ2V1G=E$Y5#)P;5EC5D-Z>F-F2E!O174O-7@W
M,# S9C5J,C@Y2W)95S Y=S-T#0IY6#!"*TTR2$]F4VI%3C)19C@U0B]L,SE3
M=E X5S9B1B]O;#)W6%9%6&]K-3)75VYH2C!B+TLO,7-J9WED0WEY=S9P.4@U
M=5 U9F9K#0IL;V8Q9%985V14:%IR0E=&84=D:DTP>D-L1'=34F%6-S W6D1H
M-#5N=5IC6$1&."LS9#-D6&PQ3&188WIZ,TTW1C5P<$=,3S=-86MS#0IX,TIZ
M3$%C8VPV3"MA1F10.&QE43E#-DY(<#<S.'DO-58R5F-$-6<X<W!X-WE*8DUN
M24)J4#5D*V%,=GDQ-74P+U592%I95$MS3C5'#0I$45!B>4U"27!R=# S2'5"
M:SAK8D1'17%,,%@O04IY9#%)>6$W;W5M.'9H=')A4S1+*S@X;D1F+T%*15I6
M<'AS4S)::3AB<W)74S=V#0I)3%=095,T:U-*04)5,61G;S(K;DUG;'!!6B\K
M9DXQ1R]W0UE%=&I&45<K;%=L=%IW2T]I<4DO5C0O45IC<7=J,',X<#-1=C5)
M,V0W#0IB+VU8<$%T;4E%-6QJ=49(4F]V4F1M-65W-#AV;4U/665K<FDK<&E7
M=39I,G!A,W%';W-A=&5833%W5"]!35I:0R\X04A*>$9":$DR#0I8<E@O041J
M2'!Z4V599%DQ2&I63&$P4S,U94)N:T0O<6=/56%G-T%.=45*6BME9C5:+S1D
M,50Y3S982%129%)K4'%22TM#,W5',TLP#0HO:V9C<C1B:G=W-&-L:6IZ6$Q#
M=#-U;C5886%D3B],,U%,53 U1S!36F=/>'5+>D5F45I->'-H=5)B;T1:-68O
M04TU0V%V6C9X-50P#0I(54Q-.#=A4SEU;S1P4#5H151%5TAS>%-O>2]!2TIA
M.' R941::W5/*S$O2E1G*U1.0F9O<# V,$\O:#9#6G)P.'DU;S50:F98=%)B
M#0I5.6,Q1%574$IR>35M;DHO-'E/5R]J;7=I2T1H>4YL-G O>FI.<'9Q*V%D
M53%!<E9B4WI%46)W96524U!P-'A.;$=O3WIB:$<W-D]Z#0I%8V@X<V8X04]1
M;7!.9"]M4&-7+TMQ,D9T0F)Q4$1K=G)(+VLW;6)G2'!C8DMD,DXO;'!P,S92
M."]W0V<R<%0Q1DXU1DDV57%#:THY#0I6<6IW-&]A-5!)86E734)U1E0X>2].
M,3<U;C@S6#$U3DEZ5VM-<G=A9D-4.$M127A#,$AI,4]492M/3U!#1FY+>3E&
M+S5X+SAW-EAF#0HV9'%F:U!6:U8T8CA35%<V;B]D9V1!<S!D9D5+;UIF<#A-
M<'IX23E18DU2,G U-7%N:U,K,&XX=S1V2W,V;'I,95%W,CAH04%L:&YK#0I!
M:FLX3C%B9G=.4C)Y-%1U3G1::E5Q9EEO04%O3F=/9WI8=5<W1EA9<3=&6%EQ
M>'HX>&1D;#!,>5!R3W%1<U9N:'0R5T)W4T-S<W!%#0I58D%J=V1W8VYJ:F-G
M1TUJ469'3V)"=S-U9CA!>FI"<&]A-C$W53(V>'AW5S!F=C9H6C,O04])3&U.
M<41Y1&9H2$XW='%7;E=7<%=&#0IX<#DY14HW4S9J84ME2G5J2W=O9CEV35E'
M;3DX=B]N>F5O4$]%1V@R-5 Q4%%,2S-S;U9*<C%14T9J4V=R>%I1865'6FU%
M8E@S=4YL#0I/.5!03$LR939V24Q64'1Z>4I%=F9D,D-J.65817191%!V>C1U
M63(X+W9946XY>'!.<&)754LO>7%S9G%5+S5+-59H*VQN;$\W0DY.#0IG:W5.
M4G1B94U%>5144GAO0C%Q>D%#;$UT4$IG3V).=GHQ,4IB-SAY.51#3GEJ=$9H
M=&Q09U5J5750;V1M>7)#2VEZ>6YD3&9Y;C Q#0IT4B]-8E%9079,:&1,8TU$
M,'!B07I(+VLS:W-P<4I2:DAQ4FYM>GEX-7@X>"MC3E@Q4%0Y178W;3!V8GED
M<E<U5S-L351X2S=+:$5N#0I(:#EL9DA"1U%!071-;VML;C-L3#AS8GIY3C55
M,3=Z6#5G2W@V=6UN,T5D:F%O=V8P1$EH4W)U<#1L,EEG9D-304\Y5'163$IX
M14%.#0IK66-)<W9#37E82&5T+VQT-35T4$E8:T<Y,4YR5U,V,4Q6-WAO<D=0
M:7EW,'0T,2M+4U=L3FUL4'=G.&HW9&-O>5$T<%4S46QW>%IT#0HK55@Q+W=!
M*V%$-6UV+TY4;3EG,6%:3$PP>G-S85%O6D]-2R]S0E=M0E5J=G8Q>79,-E-+
M6G<Y43-:3BMA=FU73'EF*U@X>3)J.$QQ#0IA3F10,#162$E&;#1L*S,R27=4
M6'AP:TUC94M42V-Q1'AR>FA2=GE-.&Q05&-83GEO4'0V:W<O:&U21#9Y,5,K
M9U!,8W5A6#%W3E54#0I4=GE5:'9Y4W9P*U@T:D=E+TYR4E94+VAM1UE.6% T
M=5AF<&9)*UIZ:5!O,R]N1U145$8U83%B551S8G4W5T5E3DQE34Y8-S5J;4IQ
M#0I$=35/16)06DUX,C$X6&5F.5-8579/*W58<4AL2$QE>F5K5#-26$M*+W=!
M2V]Z67=&4D1H>DYK<W<O-7@Q,# S6#5H0S8R-#9F8514#0I64&DO1T5!9E)+
M8W)Z;C!S.$DS67 K66YL838X<RMB=%$P,EI#251),#%N265J,CAJ17AS4&\K
M12LT3U1X>7-7>&Y':6MM;#9N96%8#0IQ3G1Q3FQ*-E8S85-,3D)*,6]Y1V]Q
M3S0X4FMI3$9-46%F575N,D=H+VU(+T%)5C@W,GA71S<P,E5T8W Q8C168FQ!
M9CE39FEY,2]:#0I*4&9-26MW=4QL0W!56&]75DTS67$W1EA9<3=&6&UV+T%$
M:TLX<2]L=D]%<GAA-G1X3%0K6&M4=B]S9TUU=V95,35F<&9,1UIR:79P#0HS
M+VY(2%1V<3-K2U<W6DM09EAS<V=C:C=34G%S42MG36I::#9G*W!Y<U$R6GAR
M9FTO4W1+,6)3.4=D=E8Q6%9P5FIT<E)$.%%J<65C#0IZ+WEO;U4P+VU/=S=K
M5D-*271M4RM6=GI93&XX>"]-2$]T9G)B57(T5490=WI/>&932$9Y9E4W.'%.
M3T]O9FU,;T5!6&QW=6QU0U!A#0HS0FU0+TIV2$MA:59X:C%)3'HY<4LV;#4Q
M,7DY43%J;79:+U1*-CA&8W%N+T%!;T='07%)4DTW;$\O>58X=5,V,RM93VYF
M0U1B86,S#0HQ-C5E;%%"06%X+V9,>$=2>E-Q3$Q'3$Q'+TYU<"]P5'I4<2MO
M.7)U.&YL459R4E=K2E56.6QY55)11$=2<W-Z+TEL1G0O365Q-C0Y#0I/1VEA
M5F1867(P-4%"45!B-%,R5C5U5F0W4$9Z=&PS+T%$:G0U+V(Q<'9+5V]Y,3E5
M=F,V5S=N.7,O1DQ#4&YU-"\R6&IK33A/;UI9#0IP.4=A9FXY<5)S+WDR=DEL
M3D=V<&],64@O6BMQ9G9%4D=6-$(V;651*VPX<5IM=4LK;W9);FM44W1A+TIF
M5&1&,4M+:3-S8C-1;$$K#0I/3U=34C-J;%-V46A703EX=#-Z0VY-:61H>6]X
M=4Y-5SAP-C%C*U=B+U)F>7HP>5I:.5-F535*3F5V64XQ5TY*4WAI:EE'=DIO
M26AZ#0I05E%E4#)Q,'-K3'5267A.5D9J2"]/469M,SE,*V-"<$U$.'),4E9-
M4F]D:F-047EN+UDP0V9-2$HT23!,-S)'5U9M:VHQ;E1V3UDO#0I+,U%T4G9B
M-D-8>7-B<5=,5&)*44)01DM8;35L>C9A:VAJ1R\K-T=Y44DT:C-S5&9$-4U*
M>7AG*VDO4&5R9E9V*V-E9$E23FIF5V5M#0HR9THV+T1':G13;FE)5&U*069V
M0S5-:C9(>G!M5S1Z-C(O22]4;'-V>3 P;F%K;#$V='A*-VU35G5*+S1!3&U$
M;4YY3&PT>#950B]Y#0IS-615.#9A;%HV5DM',%AY>G Y,64S='=U-C-.>$=O
M44E#1"]!2&%C;5!U4EAS1&@X3VAV>DLX9&PX=%-/,&IS-VUR=5-Z2'A*,T]:
M#0IR:5!4+W=!<F)U9E$O269N8GI,8GE'1SAH:71R3S!M2%97;6-Q>$AU0S9K
M6E1K1GE!8G-E=TI:<C5Z<TQ4.#!F>7AT=DY';7AJ.4\V#0I7:D=A1D%#>$M!
M1S1G.%1T*SAJ+T%/8G-R9V5#5DAK>FM/2TYV;FY-<'AN<VXO3TY8;4,X9SAX
M,S)H1FDQ;&57-UA)5'-S,$I58V@T#0IC:UEG+TE::C9I3S%T,D4W,"MJ8WA(
M261I<G-69&ER<U935'IR-6%J.'IE5G12,%(R15IV27%24TAO<W%%4$=X-C="
M,49F8DI1;%)T#0I%:%EP.&1A.35F,6I19%-L,#=6<E8W5S9I2D)6>'-W2#=3
M3C!:5#))>EE2:T-,1&AM2D0S-E!Z.7 S-61F;%9O3FU/1GAR,7I:<E!A#0HR
M3F1L*W-%>F5P3E1C2W!K*V)(661Y35AG-#5(=6-J:319<THO2D-B5E!-9C5R
M=')7<%1.9%AC1G9C6%4P>FYE<F=104%D04(V=$%"#0HP1U=:<45A1$1'8FQA
M868X-4(O;#5Q43%D=DYU;G=.4%I80TEU<$--8VUI:VI89W-H04@R1U)61F5X
M1R]564U'45938W-/<DA0>4E6#0IB9GI,<6UT=4%5,%A3<G$W1F5H64%+069$
M-%,R4WIC<3<R3TQN8D-.13!$6&9-5W!#>C!Q,&MV8GE6<7-%1WDX:CEP,BMY
M:2LW141,#0I424%B=%E"3#97.'%E4W)F.'0O>2LQ93=A4EI.64YP3&18=#)U
M=S5X4DU9-&M*+UI1.5!%;C5$34]5*T]18VU-9450;&)-,7A8<%AK#0IA;6YF
M;%(U,S%9,5=3-RMR86)!+U-V3G8S<40U<$Q5*S)5>C-M03)W,FE3.#DP*R]U
M.5!V<F4K<S5$1&17,&EY=U-R,58P3E%C=4ET#0IR0G V,2MC=FXV,#@P*U-0
M2S@Y<WER2F135%18='-P<C95.$-,1WEN=E-S<F-A.5)M4&EH=WE,8FML641X
M-59:;4-Q2W-X;T%/<$IZ#0I)85@P3BM:=C5N1'EF;T9N-4\P2UE(5V],4T<R
M=7)Q33=7<4I'16]P+W="*TU"="]+3BMT37A-95!I3FYK-4TU,7-(;&XU5S9R
M1F]U#0IU6"]M4V5J3F\Y:&-4=T)T*V1X3E,S:51Q4'1.3G8W5GDO24Q&3E=-
M,&)99F-813EZ8U,S13=M4V5:,FML:V)C<S=M<DUF8VLU63%V#0I5=&5:,B\U
M># X=4$W:$Y8:T$Y:%<W4#9Z;$5F-W<K-710,$(U5&PW53EC+TY,5F8K458K
M461/4FIX;'1X3SAF=D)%:U-K+SAJ1W!L#0I'365O;'5M9E-(:UE"2F].>65G
M>3EP92]F;6HK65(X<F55.5 X:F%3+T16:W-B93,Q1V1$=F)X3$5Q;$9)+S-9
M.4]V6F9C:6U,:G@X#0I2-&DU134P2T1#=DE11VXO04I9965T63-75V5/,S R
M1B]%5%!X;%5F3EI"6$Q*-WE!65$R:5,X,GDU<65M6$HO4FXU0E=C9C):9&0Q
M#0IH-7%D,FEG56]4.&<X2S533CAN=41B>6<Q*U)F;GHO1&YM8V%D95-C9$HQ
M9W)$2U=.1FIN<E-+5&990W T=#='=F)(3D-X831P56%3#0HO=T1/;GEV62M8
M9E!D,6(R2E57=#='=#=(0W!(-V]Y;&=Y8F10:E%L4B]+4FMS37)I:DE+3#!J
M+T%*>#,X9S9J<"\Q;GI2<55*9TXS#0I$.5@P-D=284]9;5E/.'1$,$1C448X
M4EAT4W1/960W0G-X47)D-V1M33-/>%8R2W5X5C)+=7A61&%H<&5M86Q$-D=O
M,FM.-4(Q.4LT#0IJ4U901#=,9VI#0U%T2F10-4HX;5A%;G$S1V=A9$Y)44%8
M:W1)1V%I:6=&4VY90VU(:E!E:FA#2C!Z>3$U9#!M5C5D3#!Q>G-*6D8T#0I3
M4U=T=D9#>DQ7=$-9,55K5G='4E!.44%%>'=*4SE03'9L.41C;$Y-=$9.-FAI
M=D-S15DY84TY56QO=GAR=C!B1'A&1DEI># W5#E0#0IG1G995W-6<$%$55%W
M27-A5F]".6Q!0C!!1TI.<%@S9&YA6'1T2F$S:T5D>F)3:FI,0DUQ>5)S4$)L
M645%9E!!0W%49C1!.&EF.5,U#0IP9CA!,&A7+R].1U,T-60W2&A(8VE6.' K
M5FPP.71.6%)R16%C.&YR3EI#,FA%2FQO0GI-9DAJ>6]!2S!R:GA(;F%E14EB
M+T%(:U0O#0I!2VQZ4R\X07!#="\K84UE3UAE:FA(8W50:U!Y3U5#2'DW<&Y"
M4U=69G%D=E%%,$))2$1V45DX8W4Y945D>E-E42])>4]R<#5D,'A8#0I59W%W
M<S=C145D0T1W>#0U9#8X23=L,'9K6'E43DLX<W9L-U1:2EI#5VMK97IG6FU9
M;7!*2E-P2G@T-60V.$DW;6@U13AK0D=195AT#0I-0U!1=6]S-V5H<#!Q3TAA
M=5!(3'94=VIU5R\T03AI9CE3-7!F+U-&8B\X04Y'4$A,=E)W:G528BM6+TQ,
M-F1(<&HV4EI.<'-4*W!&#0I9=&)X1T)83F9I5TER=T1F160V9#AE23@W5%%1
M;BM!4$EN+U5U85@O04Y)5G8O>E)J>'DW,&-)-VM28RM54$MD,4A"1F1A3%E4
M>#)Q#0IE;&)*3&%W=7-59&$X27=Y;FEV<TUE23DV945+0RM1=DEY<T=8>3=P
M65E';TES<F-%168W1$AJ;#-O-%(S3#4O2DAK=31M965F44Y.#0IM;FQ9=DI,
M2F%133=-9'E767!5:S0X8W4Y4$-/-598>6PU5E=W8E1L,&%X6%0S:SE:-TU7
M,$EH85%#;DUX.&5*86=P5VQC94DY-CA)#0I1,RM!4$EN+T%&3&UL+SA!4T9B
M+T%03D=02$QV4G=J=5)5+VQ4>79C5V1V6E0V4%EZ5V1P>2MQ,C!L=$,P55A)
M,6(P,$LX5G(S;TUE#0I).39A0T8O=T0U12\V;'I3+W=$<$-T+RMA365/6&5J
M:$AC:6TX<2M6,W9H9G1O.6DQ.$-#3',R,$IL<4)19G9/4$Q98F1C94DY-F%#
M#0IA6D9,<U9D:7)S5F1I<G-667@K65AN6"]!06AO.7)Q4#%E1S0K<S-T=EDO
M-E1C9E9)22]R1$9F5FQM.4]B:6E5<3-W.4U647DO;68U#0IA=$Y/=$QN5S<K
M>6AK=D9E5TYT36UM,5,R14-3*VE:;75);TEW:UEC.%=D,591,C%C5E9R;CAZ
M+T%#6&)Z>7=V951U.$XR3E!9=S)6#0HW37)86E5S24DS:6AD6DI#<3%#;U-E
M;FE-5E=7,S5R95%B;%EM:#%-;%IZ8FE!;3-U5D5N,754,%E3;DM)8V=:4559
M:EI7,F%H>%9B#0I$*UIE:3-/=F9O,GE34S=T571B-F4T=319-3-K4UA4-VE+
M,FQG5S)72G!:1'EM-G!8<'17=4MO5R]W1'IC.'5W,W1P83)A5%A!=6].#0I1
M;6MN;&=U;T5T,C Q45I)-VA403AS8F-J4G%P5E)U4G5O6E9--&9Z2#AO3F5W
M861*<4-,9GI,1E9%4V1O5FMM:3E:279836%X:5)O#0HO:59'26-J.6Y&5F9Y
M,34X.'$K6EI41F\Q-#%W-&=3-D%E0V5$;$))4W%Y4BMT2$AZ6&MP56QA,$EO
M9#A6679O9C5W3F12-E9F87AP#0IK3VPV3G)-.35A,F0X=#):>6MT:3!G8C9X
M1S!%26I6>$-X5FQD=F5M2W-L,"]W1$U,>6AQ1#(P9'9F15!E3UDW9$IO2C1#
M>$5"=5%3#0I*;S0K2W9#<&1'86=C1#138U97,F8U:2M4-S(U=#=A,79J2DYD
M>'A3459H;E9+6$-L-$9E4F]X2$<X<4M7:E)Y1UEB9TA&570X=CA!#0HU="M6
M3E-S3DAK=DIX66%H<3!.=DPY5'!,3DA#.3-8,%EP8FQ9>$5J4V-4=SE1<5<W
M1$9695 X04YV.$%,,31P-5)Q=D=+,VEA9#-E#0HS=55$4G!+24AA371%4%4T
M4TAI,T-V2'9I<7)A+VUH-4AU6FUH6%57:6M16$)K1GAB6%9U14YM=G%80T\P
M,%594C0P*TEO,WAC9#95#0IX5EI**V%V:U=/0T=:-RM69EA,<D9!8D\X1G=4
M2$5*>E<S.4@Q9U!264]P2U5:9'A567%R*UA04#)J*UED978Y3# Q2EI)<DLQ
M=$QY#0I/*SE/45%Z4C-I<S8X1UI!=7EH8590>&(P2'=T:7)R>CAY9DHY:V)P
M8C8W;7,S<WI%2C0W;7IV25AP4$XV16)O<VM+=$EJ4R]$>E%&#0IF9D951G%N
M-71E5&)44TI,-D,V835U4%1V1V=S4%%U635J2EEQ5$UK>4=)>5<T5G%+>GEO
M04LT<7EJ4CE1+U-/:U=/;V5N-E@Q>3-I#0IU4%-R>30K<6=F:GEO2S!R,7!I
M<C0Q.#@V;4Y4.#5A,V9Q4U5N=EHR:G(Q-$)Y12\T541.:D%5031C>EI+6F9M
M43=7;FU/,3 K2FEJ#0IA3G Y:EIG<6%&6DDT1FMK;U(P4'%Y3E@S=UDK5$MF
M3E<X-BMA9%@Q:GEL-51T=%1K86%A,VAU<$9N:TI,>7AT4#9+37A057(V0E=V
M#0IT9VA%06UL;$MW2'9(-5$S,F=A3C5%,$A3<G)53%<R,4\X:6$V1FY,3D=K
M.&=U2DAD1T5B3GE.57!48G1M3FQ"36E7*T9!04TX=DY4#0HP,GE+0SAU-&)9
M>3%%46UK5U!L4VQE4$EI=$LU54%Z43%P-6XX=#-T-C%H6C9T6C-..'!93F%1
M,T55:V]+9F%R1W)&=FAP=G1I66YU#0I2654W+W=!,RM5.5!U;G1,+U=R0WIU
M-#9E<&)Z,U5-56DX9T=(2DA934MG9S1216YO<&M%46UU-DDK;R]O>$Y1=&TQ
M3&IZ*W!,3D=:#0HK3D]83#!W961+8CE-2$-E83)H8E1Z;#51=DQH8F%Z,7I4
M-VTU97!31T<V:&MC.%%786EQ>$]Y9VLT5$$Y>3A19&$K8R]*.35.-DYP#0IR
M=6XS13-&;CE/2S9G9'5+2U=D<4LU3D9516YW1TIG935224EV5$YC,%A6:V54
M4SE1='(Y27E"23ER3DA-1DHV0FI'5W P=T5%8S%"#0IT4G503E!L;3)J95,U
M,65Y9VIJ65)Y4$IC4DEQ=6$P5FE71D-E2C)W.$HW;$I#37-D47-.471L=7)#
M-6EU-UHO<U1W3W-K6G T36A)#0IW155L279096=7;7(V9' X;#5Q165M5S)K
M86QA87),8WI"5$=6<S5/9D)M6C1W9V)P>4HR.$1G5FDO;DQY-S5:.#)Z=')&
M:#5R<W)3#0HS,5!46G1(=EIL84<U:FUS-&XK=%,K9S1L4E5K:4A)<R]W05E#
M.58R<FEQ639F.$%L<F%1,CEO,7)Q66$P:#$P95E95T5964Y(.5A-#0I+=V-X
M2G8X04-W8C%0*T9X5DER4#AN3$\X,&92-610.'=X,T-71FQA>&%F9E)13$Q"
M2DIA,W!V56Y)4V%J;S%E2E982&IY>%9T+WEH#0I.:D)+6B].2S)T,68O6&)A
M3S4Y05%"<'14=F]B=F=O.6-&9U1!66I'1W$T63!)>%9#6%@U8V%&;U17,7!E
M96).3S!Y-W4O,'1(2&)Z#0I1>'=,26US>'A23VQV0SEY<E9J94EC5'EA=&%(
M9F9&531J+TIH179K23%C+V]V-C5A-G!.6B]6>#9J6#%N8FE"2%=B,5!H:4Y!
M-U(X#0I#83=C<5EQ;6YK;CAT9CA!1$8W65A0-E(K=6959$=I,%AH-E!P8R]3
M=4AN.6%V<5!3=G%C95 P,7A6:C%T*U0Q<$Y:,C-L8E=.9FAV#0IB3%0P=C=Q
M,7-,940V=&1J.4IM84YP<&U.>$YZ5TUZ=44T>'%+.6$T<6E*4'EQ,%139DDY
M.7 K<6%T6F%B1GIT<% P>&)7;'1P:5%F#0I6=TEG-W-'<3AK<7,V=3AK:#-C
M.%%V5$964T@X=G9+6"]+=S)V-T15=$XK=5!(83-J-E,Q=&$S3CE(1F%1:3-I
M93-M:UHU24E'2' X#0II<V1A9V-81F-6475N+VM3;&YB,CEK3F%,-F4S-DUF
M5EEF<7=%;'A,<$EP0S!5;G%N,%9C06,Q-'8P,DEX5DQT2R]*5%8W+WDO8G!R
M#0HR<&EX;G1B93AT-T\P5T9(*W)I-G9V<DQV3$MK>%=B:W%$:4)X-#$S<6-+
M<'1,*U='9RMA<F$T=7)86&]R-U1B>2\Q4SAA5WI62D9R#0IQ3G Y5$UA>7!+
M>3AO5#A692]39W=+-G@O2T,R,'!.3W5,:E9B2S(K;T<U4C)T=$]G<TE:4')L
M;CE14V]2*U)F:S--=$DW;&U.1C1I#0IG>%909DEF-654*U5R:W5M<$QE5SAM
M;3)/;GI2;3--8FU45#%:16U6>$MW5E=74G%O5DIR5#1U>%99;D8K4S!5,3EE
M5SAN;65+-3%)#0I*84<V<&)6=6I(2&9#.&EL=7$S1'-Z>65K,&9/:7%A5D,W
M1W!636)Z.&QP6'9B*RMS.6)&=F1A:DIQ=W5#.7 V<696=%E)6C1L6#%K#0IO
M.%)(=WE6;V4V-$9:<$U4-6(X;5-%4T-5-DYP>'!+5C1H=G%S2#)U3E13=D-T
M2S113$M#*U!F2RMN3G$S;693.5!/-79B>4=*>69##0I344)I9F].8S)-:E%C
M4T\U97DV="]W030K*UDY9#@T86IQ,G!A;F%7,FXS,3-,3T)!6EIP>$<W:W%L
M2%-*86AA0W9,35E:=T)18FII#0I*3FPU,RMB;'1:5S-N95123DU"*W!A4D)B
M5T9Q;&%N-%EW>E8V8FU34FDS:6%N3'-2.4YL<GEC-E=F;6%R4#4X9E,W9'58
M-D]J=$Y-#0IG659!-5<X16-2<#1F=D%C8V8P,G,O<7!M=C5U95AT2S%R.'A9
M23503F1O:GI#0WI.;38S33@X3&EI1D930T]62W-X-55:,#-0,#58#0II:U)(
M:WIY0WIZ679P,$EF.#=B3S)S6E=E3S(Q:4M"2G$Q6C0W5U5)>D4Y*U-2:VY*
M;C909W@O:E%V;45F-&PO3BLV9U4K;VPY<D%T#0I563=G>&E946<O3&=U1T\P
M4&=G-WEE9U1F:R]R2&QN5F1A.#4V;G$X8W1V65)8;#=:=D5:4')%<WI)+W K
M<GE50E!I659O>E8V92M6#0IE2T-!04=Z9V\R.#4O3&(O045E-C%Z5FIS3DTP
M93AL42]W1$9K-D,Q:D@O0E0U8FLV1'IA.&95=2],>6QT0C5M,5IV*U!(4C=H
M26TX#0I*8GAK=%4O0U9S8VY196%W-FQ/=GEA:$11*V):2G126%-B5G1*93)E
M+VMB:6MC:S=G4FLK+W=!3$%5,SA..&IL-F4Y3TQQ;'-0;"]3#0HY33AL*UED
M5&@Q<415-7!$8F%A<TYO;'ES86U79%HK5%!C4E%C:GAT5%%+0T\O:&MU26U1
M1DEQ9UAQ;B]!1&I*0F-R-5HQ961I9G$X#0IL-'%22U1T>5-)1GE"-S@Q>6I5
M8W<R-&54369Z5C!Z56(S4G1+;'1,85,Y9S W5TQ#+S%+>6A4,5I*<E,S;#53
M<7-8*S=#3FTT9#9:#0IJ=')&9&985CE3=3 Q8E(O3&1X<$Y(,7!O3'5'0U-+
M-W583VU/:TXS3D=);W!96&ML;VMF<69'841P<TU+;T=W9R]-2F1F:'9:1S%O
M#0IQ=7,V6D(V8G1D;3,K;WDV6"]P8DY%5#9:451Q3U1K9D,O8T5M<7%Z>4\O
M;G5/-G-N.'AX95DU<G1B6%14<%5-2FU71C914#ED6%5'#0IM+V-G;5@W6FTO
M93!P-F5+;V)1:#4U,4A666UV=% Q4T]W8E5D1'9K<S=P3E)L5S%K5V%8-C)Q
M>EAZ4T]W:F]V3FPT<#!)1E!I6E90#0HO=T$P8EA625!-53)O-E)P,7IQ1C5C
M869&87HV6F-A63)P85AQ36%4<S9W3DI%5V$Q:U)N3$9P47%%538P=TMX=GI2
M9B]M2%IW-FUH#0I85C=),CDW<D8T>G<O5W9Q<T9I,FIK,G%R8V]"1#9C9'=P
M-$MR9D-W<E%%:D-Q2$=P96%O-61/95<V,3503&0Y<4=J4GIV3$IF0S=M#0IL
M:W-B:#E15S).9EAA1FE&2D50=SAV-W)T:7%V85<S-6<R,FMZ95E,,SE)=U@R
M:S91=#5B,T9W6DDU<%E,4%9*6GAA,V)V.$%A:VMT#0I"4FMF9F-61F-66FAF
M-F)R=7!F:S0O,3%,:2\Q5%=*64PK83%B;D\V2F18,&1W24955F]K34Q"94DR
M054T<7=(4W1'.#<V5')U;V%R#0ID-DIQ1C-01G!S,FMO.$EU-%=A1S!U3$,P
M:FQ783$T>D5T2$1*8T%23GEC5C0T<7%M1#@P<FEW=49E5%@Q3FYP=7-Y5T12
M9E@T5VMM#0II=6MA=T1";656,DU:*T):1UIY=7A,8C1Q:G14+W=#5FI813@R
M;3-5971V.6,Q47I3;4IB<U%F;RMF4U-P:CE72VE)=C%I=C=S16-8#0HW03!X
M5G)427903VY1*U-.3C S5'16<S)S661'1C X:F%P3D1+;'@O=EEK.&90-G)#
M:T)B:7EY2UA5531H5E@T47%Y8E-F365P95-R#0I:3E9G.'DS1W-7,35P.7IR
M>5,O5W9216MD*S-R3EIQ<#E::7-"-40V<41'1D-S4#-G<FER97)4+T%*;4=#
M-W1B6F1D*W112'I++TY%#0IV47!76E9B5$)(24)X8V=!*VM&2C1(655/,D95
M,C%,4W9/:T]R439F851A-&1.:VXX=7).34HW-E)U17-T,&124')->DUO;WDK
M<E)V#0IH2$AO075+<U$Q>EAF3W1H;SEX86%V<4=S5W-T<G!'<'DV57-C,3%(
M9$,T:3%*-#1P<F]O4DM9+W%X44I*3CA"-TAN5$98<T@U;TQQ#0IS;C5:86AB
M5U9T8UAM;S-514U#=U%2=DQ+5$DV0U-Q;T=B6D]68VYI<FE9>C501F9Y93AH
M*UIO=GI#,'4V,5A2<C9Z<W)5>7IT3F-7#0HP,%-C,6EB,'AZ9%%0=&M::S5:
M:F@R3%)J:6)F5"M95&MV;#)0>68U<S%R.#)"9C-U:#9H1' Q,7)(<GEZ>3)S
M-E)R8BMV>3-C<'A!#0HY355R;6)X9U$U.4A'-%-:3&1%.&XK8W16+TY/1%4W
M-U),-C-T-VI65W9:8FEE,6UJ:%922UIV:5IL0V=B57A-=TDQ86E*36UV2T@U
M#0IF961T4"]-87EN,6)2-WAK<V)L-WDT=7A&2DI&23%U1VU(1UI155EY36=#
M-S=K:D=C-&U/>%=-1'AB;W8X<"]+;FUY,3@K:EA.53!/#0HK:&IS;V)U."]F
M5W-S6655>$UQ;VY.44,U850T44XX1U=1-&%"5&II94MY<R]+5'E0-7 O-5=0
M<'0Y<D=J,S%P87=03&-Y,T9X8E-W#0IP-F=J67 X5'%&,VM)=S5::F@R2S0T
M;FES=EIF>F]J,5=F.$%,,U5,4%,W3V4Y=3=X;UE21F)2=DLT6#%&9'IX44UA
M8U5)*VY-8D18#0I&=3(U3U1W-U)02G9M*WHX:&5:061#,4%8,F]Z5U9P1D(Y
M5FXY57=O-WIY=44T8W502TY!5&U56FII1S=326YH3'1-.&TK8C=4.'5.#0IB
M:D=H-F@Y93%/+W,W9C9T.55M.5@P249K;5HK2$AL=S4X4E=L2S1$36-1,U52
M4$-61S(O3$QZ-"]K2S5U261,=3!C-F=P=61.94M3#0I/-&5/1T4K;DMS3$%-
M-G$P>F=51F-0:5(T;#1$=W(W:GE:-7=G+TQI>C K4%%T464W=F15;74W<49B
M4V-Y2DAB=TI&1'I52E915$Q*#0IX<C%X-'AX8S$T5'=V8V9Y5#!#-S!8.'9R
M2T,Y9VMT8C)E4V$T=4QE6D=J:U)M:TMQ1U9Q169!:6YF36).2S5.,DU51V0U
M57ID:7)S#0I69&ER<U9D:7%N8S(Q=F17.'1T8WA*4&)Z;S!C,$UI:#!D2$A&
M;%I7<4=69V%%2$962U149$]L4S)J:W196%-Y9%I,3E=J56E&,%5Q#0IJ4D%J
M-$=65TE"6&]-5F1Q3VPV6G%D=#E6,4MZ9W9R8FMR*VAC>'!,2'E1,59U3&AH
M54AO8U9224%!;TYG3V=X5C)+=7A6,DMU>%8R#0I+=7A6,DMO1%5V3"MG87!.
M8GIA;G!T<F945VIC-U=3-6=J;6%*<6<Q:DQQ>%4Q0399<6HX5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER#0IS5F1I<G-69&ER+R\R43T]/"]X87!'26UG.FEM
M86=E/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D\+W)D9CI!;'0^#0H)"0D\+WAA
M<#I4:'5M8FYA:6QS/@T*"0D\+W)D9CI$97-C<FEP=&EO;CX-"@D)/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&%P34T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX-"@D)
M"3QX87!-33I$;V-U;65N=$E$/G5U:60Z,C)$-#E$13@T0D8X13$Q,3@U-#8X
M-4)$.3=#0D,Q-C4\+WAA<$U-.D1O8W5M96YT240^#0H)"0D\>&%P34TZ26YS
M=&%N8V5)1#YU=6ED.C(S1#0Y1$4X-$)&.$4Q,3$X-30V.#5"1#DW0T)#,38U
M/"]X87!-33I);G-T86YC94E$/@T*"0D)/'AA<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D\<W12968Z:6YS=&%N8V5)
M1#YU=6ED.C@X-&0R.35F+3(Q,C M-&,Y-"UB.#,Q+6(X8S S-6%A9&%C.3PO
M<W12968Z:6YS=&%N8V5)1#X-"@D)"0D\<W12968Z9&]C=6UE;G1)1#YU=6ED
M.C-$-C5"041&.$)&-D4P,3%!-34Q0SDR.#8R.3E&,3$W/"]S=%)E9CID;V-U
M;65N=$E$/@T*"0D)/"]X87!-33I$97)I=F5D1G)O;3X-"@D)/"]R9&8Z1&5S
M8W)I<'1I;VX^#0H)"3QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM
M;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A
M=&]R+S$N,"\B/@T*"0D)/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R
M:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X-"@D)/"]R9&8Z1&5S
M8W)I<'1I;VX^#0H)/"]R9&8Z4D1&/@T*/"]X.GAM<&UE=&$^#0H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG
M=R<_/O_; $, "P@("@@'"PH)"@T,"PT1'!(1#P\1(AD:%!PI)"LJ*"0G)RTR
M0#<M,#TP)R<X3#D]0T5(24@K-D]53D940$=(1?_; $,!# T-$0\1(1(2(44N
M)RY%145%145%145%145%145%145%145%145%145%145%145%145%145%145%
M145%145%1?_" !$( $4 X0,!(@ "$0$#$0'_Q  ;   " P$! 0
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MS.T.U0E*<#RY6#R7O N)6]C>4M/0JK)<;85)7+$(?;=BR=;V]*] QL
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M P$!/P&9IC&.F3-,>$X]OI-1DA"$(1HT+U[\W__$ !\1  (!! (#
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MQMUBPG.^W_O_ /_:  P# 0 "  ,    0"U<VS,R$>IU'   ,A8I;D#D$0@W
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MQXA'5NWUY(43GFW*>/T'+H<VF7P^6)0Q_#__Q  I$ $  @(! P0" @(#
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M;*Y/8)GN1PR8VI^R90.1\*#[R-T,[ /N6[)UQXZ3>!A,(I9B6DC8]1]9_DF
M0U!V99M#Y 0)%5%CYQU9T?8"_P#W#TTG@D<.ZN H4ZD" *=<AA!FA+<8$J&
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AMAPO>G0*)FP\<X9&S-!P2Y)DN,?P2D22M%_PHG_C?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>exh411_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh411_1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  L(" H(!PL*"0H-# L-$1P2$0\/
M$2(9&A0<*20K*B@D)R<M,D W+3 ],"<G.$PY/4-%2$E(*S9/54Y&5$!'2$7_
MVP!# 0P-#1$/$2$2$B%%+B<N145%145%145%145%145%145%145%145%145%
M145%145%145%145%145%145%145%147_P@ 1" *& S0# 2(  A$! Q$!_\0
M&P !  ,! 0$!              (#! 4!!@?_Q  8 0$! 0$!
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M4H\U8>A2C5E(^Y]9'RFX0G4.A@W@$.5U>;VF9:]&:EHJZ./;SNP>74)PF
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M?NUQ.=;L'(K[<9>;VL.ZY?-_29^JV?*D=-S!TW,'39]'.A$)PF    0G"8
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M0(59\,=V'#Z-:9\+<7W\C2FRSD=E6?7RS:Y6N-3F6UJCDRG4W<SI@$)PF
M 0G"9@Y?4XY8V#&V#']!\K]6>3A,   S@C&\9=/MIFNA<03$,/1P%\>?;&[S
MGYJZT^5>:O,&DTLM)T)<WTZ<^1VDA3I+!,03$$Q!,03$$Q!,03$$Q5*8A&T0
M3$(70*J-O*.A#!M/+*;#/HR:CR_)N1CW\]=57/Z9'RFXC& ET.;TD!83A,
M  A.$QQ.WQ^TJ3>C,+Z[LWJ#QZA.$P  #."%=OIDVTWE=]-P P[L1&S/$OG5
M$WSSZ$!0               $)P*\?3YY:HTE-T9&/71(\VY=1/'LJ,=RXI]C
M,JJL\AT^=T; 6$X3    (3A,  8-^?<Y_8Q;=(3A/E0  ,X)U>3,?4SB5V6X
MLYN[$>+8133T(US]5HSVRL,<M'D<W=ZJ=%LC!U,VDY\]'D4UZ_:SZ,G0,F3I
M1,-]\"GS94:=.>PL5BQ6+%8L5BQ6+%8LAY$R\_K1C)H\OKD;;YG.]TV%._+>
ME>/H9URZ/;SGVZADCIK(=3#N (3A,    ^"?;5:GR3ZU7R3ZT?)<K]"E'FLS
M83A,   S@GBT1,_4S31=FN6: GQ>OE,>?M^G+CT[#)GZ=9S,_4L,-?6D<WWI
M#C.P.1[UX&3-T[#A7=<<&[K^G/\ =XXLNO".1+L^5:@)H": F@)H": G! \X
MO>S&#3M].3IU^G!VZ+8Y?:SVV7<3L95Y^[5X<ZW8.7'H^1C[&'=8"PG"8
M!BX7T\^T^4?5NL^4?5CY35]#BC:/+J$X3   ,X)U*RS5@THNS7+-7F-O&UR.
M9;OI.?HWP*(VZ3'#HT#;SJ3KL&PF@)H": F@)H": F@)H": F@)H": F@)H"
M<$"[*S%&O149+XW'-U^VF?I9;TNY>KQ>9T;J3/;[Z9O=%1'JX-X!"<)@   $
M)PF  /EOJ?CSZV?Q0^RG\4/M7Q0^U?%#[5\4/K6(="I26Z^;L%V:XGS.@,-'
M5YY"C5Z8I[?#%#I6)CTQJEMIE.J.OESG2<^LZC!Z;E?I- 30$T!- 30$T!-
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MTW0*-V?0D+J;E  PS\E$?%=1V9-177Y67/*C;'V@T9O/35?CV
M "$X$\6VDKMQWF7=7Z8]5%IGZ6+:3YW1QDF7<9[/)%=-D3SJ\[HH"PG"8
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M!YKP=(\R;^>:JN=U"/E-Q&N'D6]#E]2QP^YQ%ZUM5H   !"<)@   $)PF
M9P1IU^&'='09KH7&?)T,9[4]+TZR$J;A++MC%KHLLSPU5+EZD?2IY85>RK+J
M/!JIL@6U6YB^6:THT^4ED_:8A&WRK:_(FNFX7)B"8@F(0N@,70I*+<UY1<],
M.RF95NJT#G=3&>*-QG]]F41E[%74P[J A.$P   "$X3  'RGU>0T3"$X3
M,X)VY?#6R6B['I,_+[<#D6=*9P;^L.9/H>EJ F@)H": F@)H": F@)H": F@
M)H": F@)H": F@)H"<$"Y3 TH";/(N9?33"BPN9_2]"!<I%S-$LOQ[ "$X3
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MK"+]4K>$!=UDWC-\E:6'^FEALN[QJHFXYGD^"RTUC,MEXC+3XI=F$-^1_P#
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M67^;S.H_H_6VG:-*JK(A"\(L6W>2%L>9]R&K. HE?8'PS1/3QV T:=UXR_\
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M@JUJ]?[_ (1^]_Z8E^1J-5Q4$:UXJ<5.*G%3BIQ4XJ+^0*7:WC2P&J[^E<6
MS09H,T&:#.ZA<MP:#D)Z^U6_:LC)J@*S52^U>Y9*J*W!N#E$!$H*%ZK;WHX/
M)3IWHXMR*NA&ZT&:#-!F@S09H,T&:#-!F@S09H,T&:#-!F@S09H,T&:#-!F@
MS09H,$1U;[%$^AOM5428M*F^T+HL>VEX[>1$6T1B(S08!7M;4#,@NE);4]K-
M&I;3&L;:B&]U^O\ ?\(_?EF0+[G3N=.YL[G3N=.YT[G3N=.YT[G3"(C &!2V
M=+8/2)]H195-JFU3:IM4)($=XH798H%5H&XK'!1=8]O4/C>/5#6+0UXX<DF-
M&CG4/*\4%PL<2HL4#AH$@'40VJ;5-JFU3:IM4VJ;5-JFU3:IM4VJ;5-JFU3:
MIM4VJ;5-JFU3:IM4$JUV&5CA2[Q56:AZY:EE:EJ571&) YTAV453:H2Q*BQ0
M*F4+%:CV6A>W2%GT5SIH/K_?\(_>Y-.'P1G@C*PANO!&>",\$9X(SP1G@C/!
M&8RZ5%_QY1Z MQ%E1?W 1^3>0>X9>\K+,YCO(K;E$$+)L7*R3L$Y#"BG=LO-
MU$\K0LC),)WWW?\ 6'PF1OMY5 *'=U6;N"?_ ("-O6QED5,9<'T$C61YE!,H
MC'&MA5DF^[,66#:8PF@16/K_ '_"/XA^/WK^8&6EE=S>YV%%E<VN;7-KFUS:
MY_?0>:0L;Z0X$!&[2!7T!L&.L)20&)"U#:0L;2%EXZ^.H=MKFUS:YM<VN;7-
MKFUS:YM<VN;7-KFUS:YM<VN;7-KFUS:YM<VN;7-KFUS:X-WKM<+W3I7N ]=$
ML2FE=?CA&!31ZAHZNYM<L!*N@-2]X=8]A+$S6H57:0LK&@#U_O\ A'\0_'[U
M_-?\>90V"1XR8O[E:>9;6VU>49W3VE,4RV?D'R63=9&.Z],<RB&FVSRFB#,D
MQ/(=9UWEY/\ UA\)E*69WE6$Q6DT"']B9SBGU^,_4P'G<?2A6@F9AU697.)?
M%9CBY>&H9/ ^6K]D>O\ ?\(_B'X_>OYAOUL9:JIEV?\ DB]I[I[I[I[I[H)C
M;/WG%SB#>U?^)Q*NN!*BBUVL>+G%\W=!.+GNGNGNGNGNGNGNGNGNGNGNGNGN
MGNGNGNGNGNGNGNGNGNGNGNGNGNGN@\Z^Z,<"[K]Y574(QJMO\=N70,.@'M&S
MKF>Z"\&7Q<*]1LQII'0F)C9]H4>],7Z_W_"/XA^/WK^:_P"-XL(5),&Q?W8U
M,%G69-7W;"MG&.!@;A817OY&.+*I*SF-O<(74ME-['4;A]WD_P#6'PCJN[*W
M[8NVEJTATXL<A94<1C./</H5'4/N*LM?9B^^LE@L[4TX2HN7!5Z^O]_PC^(?
MC]Z_F 7UMLE")$3="BZN<7.+G%SBYQ<6VF%954YKFV!46=-HC$*YKD&TP!>!
M4("-;5.:Y8T53FN>+G%SBYQ<XN<7.+G%SBYQ<XN<7.+G%SBYQ<XN<7.+G%SB
MYQ<XN<7.+G%SBX->WBXUEK*OWJO=7>-B1ZJO)JJ<RD+WOMJIQ<!UF7-5',I"
M][[3;0,6VF%;AIG-FOU_O^$?Q#\?O7\U_P ;E$VA#4HO[EHL7^-_D7BL"#B$
M$3CVLV8K#,L=I/5B,&*Q37,0/V/#.ULQ3(SQFLKH9Y'_ %A\(T+.RQF%>,HE
M":+*>.?2>*9K8HB3:+\@?0TE='B-,7!;$6B[R#QV68XQ=K4V9"NUK]?[_A'\
M0_'[U_,%!:WC2P"Q)_4N+ 9H,T&:#-!F@S<K8LZM8O05^1C\%DK@FHE]R[(L
MA7'<&RWK9+-5+[4\TQ10<@"8LU-K09H,T&:#-!F@S09H,T&:#-!F@S09H,T&
M:#-!F@S09H,T&:#-!F@S09J,$1UT&.V NQ54%K95OX&N.JW%X[;U@Y&[1$9H
M, [VMJ!F072GLJ\EA:, KMUNX(#[%^O]_P (_B'X_>OY@P*6SI;!I GVA%E4
MVJ;5-JFU3:HQ>]T%='4'(8XC/'&H(B(KQQ"#BT%"@:+IZTV =/CKIHX]!08X
MKB%"F]JFU3:IM4VJ;5-JFU3:IM4VJ;5-JFU3:IM4VJ;5-JFU3:IM4VJ;5-JF
MU02K7:H="<O'$B0 I&PBUJ7.B&H+E8X"=%4VJ$L2HL4"IE"Q1!1,ZU\ FJEX
MX7=!H/K_ '_"/XA^/WK^:_X\H] 4T[RHO[F-:)*:58]91;5EW=7E,N@;9*')
M(R\LSGD$3$Y)%5OX1Y?^1>3O%9)L8A_=_P!8?"9&^WE4 H=W436U+R/\%M95
M.;6HY!6X?02-9'F4$RB,,?N+R3?=L6[4B;:W+9;$^O\ ?\(_B'X_>OY@9:67
M,VN=A197-KFUS:YM<VN$ G*6-+ZQY%"QG0N:UQ20J5C*JJ2%0L>NJQJPZQVZ
M XI(#%K%4VN;7-KFUS:YM<VN;7-KFUS:YM<VN;7-KFUS:YM<VN;7-KFUS:YM
M<VN;7!N]=KA5M.A>X#UU:Q*:#U="^&+ILT'FKN;7+ 2KH#4O>%K&V$L3,%BN
MZ2(E8T >O]_PC^(?C]Z_FO\ CRQHE*$O*B_N$AIB#UP*<W<,IIU;3. PK2#S
M,_))M=ML8AQ:$T_%\AG<O*NXEI$S%>3?^L/A,I2S.\JPF*TF@=7406R:K_3R
M"HK7?^8?2A6@F9;*K,KG$N^,QO)'7*\DR]R..OU_O^$?Q#\?O7\PWZS9:ZY+
M;_)%[3W3W3W3W3W2F+Y$MQXN<7+NAG[SCB7[:YH;(*<O]YQ?.O[?_M5=3W3W
M3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W3W0>=?=&.!=U^\
MJKJ$P1JF5:Z.K!AT ]@]E<SW07+9>L*]1MH4PF4)<^[L'LW$U>O]_P (_B'X
M_>OYK_CR )BP78NB_N;1,,=O'I;!,!:5=9W HZ2NBV&F$(TVS5NM9"SQ=74Y
M=L&E >V)O_UA\(ZKNRM^V+MIH2P<LJ40-('D8Q8VMH^A4=0^XJRU]F+=660P
M6=J@=3B_R$&W5Z_W_"/XA^/WK^8!?6XK2%%=MT*+JYQ<XN<7.+G%RWT,"[(>
M:N<U"< ROWKL#DF"-$S6ZM;I_P#G-7=712G!V5[IQ<XN<7.+G%SBYQ<XN<7.
M+G%SBYQ<XN<7.+G%SBYQ<XN<7.+G%SBYQ<XN#7MXN-9:RK]ZKW53MJ!FZ?)'
MK<RD+MM4VJG%P'69?M4<RD+)MBTV4!@VF';P%F_8'K_?\(_B'X_>OYK_ (VA
M;!6D@9%_<S'-I"DJQO%X->&=3Q#X%/"EX[!L,1M4.*='TECH)'.-XI=P8[AB
ML4UWBI-/_6'PC0L[+&85XRB4)).QU]Q8K.MBB)-H/O'T-)73,1IBX+8CKNWD
MHK@8[*MR+;= 8CZ_W_"/XA^/WK^8*"UO&EK&A[^I<UO51V[&%O.*O)KGO15>
M3C\'DI"UFIL[T459&/8J:!*[T0<I5MO*QZOR%45Y"8.0G@7(-CGK67?C["Y)
M3R\;CO1Q>3C5*R$P\M7'<CL4Y#KU&:C-1FHS49J,U&:C-1FHS49J,U&:C-1F
MHS49J,U&"-:M.E,7E;3O1JIE,3Y/&(P],8G$*\DK2OMJ\L1J/_QJ!HTOO1=O
M9TSMKRR9QE)*R:;R60GV*]?[_A'[W_J.8M_D?JD//SU7^F-:[&^]?S!@4MG2
MVAZ1/M"&-/3J7'CAUEAJNK1K/$'6\<>$I%+/#'GQ0@*$4^&-#6(-3Q@GB#KX
M@\^(' H 6'CB3?$7<ZKNO"#K/% [O#"Q+&JR\(.OQQ[$XX)+89L,V&;#-AFP
MS89L,V&;#-AFPS89L,V&;#-AFPS88)5KD+#(66,LF#B (I$4@6*HE=2^OHX)
MB:(J0L7T51FK%LQQ,:PUT;1%M>,KNM8]BD4 %CTRZ"EJ]?[_ (1^\\93&Q^.
MO)$*X#[U_-?\>45BI;K/*B_4<EEX]YFI^7P-Y1JC,@Z7Y'[CEE<\R]6OZB'*
MLJ'+WO'>;C9F=9^27(.+Q5Y1:^1?!Y=C"S-:K+LKK+NEUE%J678U_P H?!VW
M260<\RAM!F9=QC27;I[&WC-;6HY!VX?02-9'F4$RB,,8LC_:-MV0LL&O:Q)#
M9<>O]_PC]^=^ZNH8(51C\?O7\P,M+*[FY3L*+*YM<YN4A=3QU\DA9PL=9RT!
M=] ;4D*C,7>[&BLL>KE(71"L0N\=962A*=8]7CKJ="Y2%U5J&YUC/&7.A<Z%
MZ\W-KFUS:YM<VN;7-KFUS:YM<VN;7-KFUS:YM<VN;7-KFUP;O7:Y2@H>H;)8
M4J:C!]@= 0UTR=8\U=S:Y8"5= <%[PL!LRK:+4*KZ@VTI:_7^_X1^\@%E>,B
M5CIJQ^/WK^:_X\L:)21NLF9/'5W6DARF%?DDJ4^PE9C;O+,A:&4W4LQM4S)(
M4^6RY606]Y+=L1UN5_\ !#X?J'_H[V&1Y;(@S<DBL<!A;X5W,PELI8 6>,RQ
M$L7M\9-9K;9FU?';?U$_WS<4EC8T@FX]_P"KZ_W_  C^(?C]Z_F&_6;+75,N
MS_R0*NZU_;6 U;"UYE>ZKFLXYC%]E%Q0\7-9574$MZ]T]T]T]T_>>Z5=W/=/
M=*NRKW3F^=O=60!%5V5>Z>Z5=W/=*O:O=/=/=/=/=/=/=/=/=/=/=/=!YU_>
MYV!IK/WG,J]AMH53;$:[@HZYA%K7-6>O[E>HW?NN^+"QVW51=@F$>\,=0&+
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MD8)00-O'.X.,6_A,ZBQ>66B_&O$]Q8G!(22ZM+*@8K%F*3K*)!^4K&82 QB
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MKOH2$(6N_.QC&,>00A"%_6$X!X*_[LC:8^%MB__$ "H1  $" P<$ P #
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M.ZZ/W1:0Z#_)^Z:0U_+_ "__ +(NY[B-'[J"QV<Z?_V0U6_D_=20Z8C1^Z&
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M,9($SO*GUEJ8O_,?DA37I,4?Q;+_ %#;ASRZ)*(9ANT.%)9E;8H<AIPW<O\
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MH%@8G$)+C+K#*"L9U?(Q[8$;3'WP[D]S##ANFU.)8UAK$9D*'84/Y;5=42
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MQ+<V8ZK"?(- ,]J>7EHQ'&2\76._#+9> &SL@T@#F&\S?[ [OLP1(*=B"_\
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MGAK@8#K1T'>GS27,)@Q_+*+'/:.>*R.R5AO=FYL__2CN3V?Q"%Q1_P";U?\
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MR]WR6RV4V7NJDQ"V7N^2V6RV6RV6RV6RV6RV6RV0RR6R >]C54(NK0G7;;-
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M#P"'1U'V!W?=>/X+%^+Y!-[E =3UM*+B^H'L]#OB^TXD,;;8ZK[K$P^4%TP
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M5.(VY\/L#N^Z\?MM'\RT!,-/OM_J/N<7XOD$WU3LNQ7P7?I]5[%_Z?5>R?\
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MO:G%^&  P.MW3\T [@X9CWN\_1"IODV4 -_Y40QO*&@S$(.&&WADQV]ZG_\
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M'B&J)_D0' 4"9$(O.((Q  #0')!Q F3ZSR+K!XOX)(/S/*NLP?A9V?> !L#
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MH0OF"PR6$$;>1!:HX>>SJR9JQ C:/CQ@$"H%UZ?0M(2XKL6VYP67)IT6R/9
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MQ#R0_-LG^>TPYGT,UWR@2U0VJBP+M32S$:F95@C_ % ,8Q!R6 Z/],RF(+&
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M$"A JXH97EV$TL>L3:#1;&*A0+#I-@]E\OA-> !,M0:JU#QU#L&1-;PAB5?
MJF@C! <M6@>%CU_XO@HG? D:L0([* 8;/[$3#$* X1H6N$,O1YD%9VE^6=@
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M3I<@!<A4,:5/NSG]0Q=9!C8]IAS/H@DH"4L$=XJ17\$==CC!*=9(>%+C"RC
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M4:CVFGD2;9"4#\F)7@EB&8:\#?CSCR :&198FS58XYC+Y(4P*U&,2L*<[Z8
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M@&4&=+F827+0;B)Z$51(!$-ZY@TE#=QB'RCV )[%6;.7\0S(B&16FL;33D
M@)%ABU,L.P-L,JH*D("KLL 55YCL*S8!(,'_ +&M:UK6M:UK6M:UK6M:UK6M
M:,.<+3ZZT&&0&1 "=81M"$6"@;?.'8$+.@C]PUJ)<:CC'P<+2_>A'!@R+1&0
M+L2BFMX8"\IT^FC\LKL#T$OZ@YFHB#)RBJ '$PH6 -6Q@09@-JH4?FH,S $4
MVR^(<.;+$:[7_1!)!,#"#[#\C^?< 0#D+)CTYJ"_5PX_7 \WXL7X/@9#DW :
M<(3 !(@C,.2++)(A]3.Z(F6HYQYQYQYQY=S 0@+$  1[0HQ$ D7"$2\PA(E
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MZ]\AQ)GPBRQ @&V>4I3,5?6G!V!8.SOLP_(_GXL#S?BQ?@^!D.*DR6W.)P&
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M>Q@E)* AJ7FFH$BQ.2P2F2W]A^1_/Q!5$A!!&?KUUCK4+24 R,#!&OW8OP?
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M8-/#! R)S>R<WL@S%ZHT,J+-!H\3F]D'SAI'HVN1J:^3%I.;V0@@@"0#W,*
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M,@-%&?7ZXOP? R.!9(61@=>(P"94860CP+7!UQB>-Q$*0<>%GA9X6>%@<(H
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M("@FEZ?53=43FR5&:+PY@KK.X'2=P.D[@=)W Z3N!TG<#I.X'2=P.D[@=)W
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M(5N!192"_:"(.VE&*5>YA>B6:S_JB P;ALHM-@/^_P""CV6 <;!!^#*6?+,
M.@J>U-Z%>QQ $.C-@,N,; @S93]X3*R5"@")N&P%O!AUW 0/F&!1I@:F:0@(
MO"OB8'FB34!\1'JV<# &*X0U$MR(PC'HW&8>P"3>P:6@4<H!U,)! HP2@P/2
M!&5HR,O3+@UF]MS=S!\Q$P&-?8?D?S\6!YOO:8+>-T0" 0%  3A/:**^PG">
MTX3VG">TX3VG">TX3VG">THK9(P%$A9&8Z&=78!:S1F$QQ7'TPIX7$0I!QX"
M> G@)X")+L %E $_I"CA/8& =Q5>\()V4)E D2:H<8:W(8>0'12T@%JCNCX
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MLQUG9CK.S'6=F.L[,=8  "N$6,!K7B8CTU-"WV@B!  QJA3L\96 2J8CF<3
MHI !S&==XN^2"#6PC30F6! ;,V*!W'C$> DV2QGB,SW 1BN)M'"$3H SZPD;
MA)<V1G'"$\@D$%[4::$L@S.P7J'9 -ZPMALUD>,[,=9V8ZSLQUG9CK.S'6=F
M.L[,=9V8ZSLQUG9CK.S'6=F.L[,=9V8ZSLQUG9CK.S'6=F.L[,=9V8ZSLQUG
M9CK.S'6=F.L[,=9V8ZSLQU@U]3;K.S'6 #,_6!1]XXDK&"]@C34$2Q+):]R9
M2672TTL@U0A*ZFDQ^W#JP) (1LLXM P^!A*?<& (*# &TM2Q!@=P[=9V8ZQ8
MB0XH*\U@2M4!)S9>6<GQ@@VS@,6/>>HW:\--/C##.,TXAW<8.6('L8+0@(T;
MS36D"PS9;&FI+^P_(_GXL#S?BQ?@^!E\?^HQ;B 0#30/B)H]@C"XOI^U]P 1
M,<29HZUZPF/A@V(U,PMAU%;L$.'2-0]LHJ[+A 00 58HSZP$!3%$A-FP/I"P
MO2-1ZO8*-C,"LKKG7[A2@MK;(>\,%!".S;W@:L2(4 +(6#O2!Z4B@+!KMCV@
MP.(KFBBA$)076N0]B/\ L^"^A!>!@FD:@$,RBJT#I&2J 2U#<B#<331#E_D4
MDZ9@:=32>F()8RLG=\]C#.;!Q'[H']P=&(_Y[F8<R9A5E0(8'Y9,!386<"R
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M-V\ Y_8?D?S\6!YOQ8OP? R-!,2%D)CH9U-@%K%8*5K86N#KC"GC<0"D'I/
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MAIPTX:<-.&G#3AIPTX:<-!:V$X:&3*>_[<OF*==J-P/+C*A]A$%"CH= 7Q$
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MFG##./#B'=QA6=W7)FO2.H2)()$B?0CHP(8R1X_8?D?S\6!YOQ8OP? R^/\
MU'(9;G8LH?O2"%L#&#H/77EZ_3]K[BY% ;BL@%J"F)A($2RB<N#J*& *TYP0
M%LL<4RR%!^D# ,$V>$OA!-#>&4  !H!E&"!@.H(L LT;;507,5?M/:H.2BR*
M*Y70OX,# <S!0  /@Q>&$+@H<Q>D'5I,X ;5@A!=%#I$32YF% K>""7C@?\
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M9PLX6<+.%G"SA9PLX6<+.%G"SA9PLX6<+.%G"SA8.,AA-=@P'M^B83HV0Z,
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MK.S'6=F.L[,=8-?4VZSLQU@?E?T'WA*)$()<\Y*:MMDP=-3+B)EK$64M]A!
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M1Q:]D;_" 4 C8"6O6MOM "1R?I&#&BC]0&6A@C7Z"A-H$@=\Y43<":E-*^I
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M=F.D[L=(1D>U( !U_JA9$$K,T+:0P."@0B@ +5D^D%@'(!A\2LY;U/U/ZZ2
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M4A"E7S$A2D]FV^1"_>\ 'T_Y'P7T*"4F]D8.I()A+#LO[*VX8 1@#38VBE?
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M7X/@9?'_ *@12&[^D+SAS$.0P/I^U] [,X'"4%% )@"SN:F;!!M194>,F (
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MPYD R20@!K4H[-@"4JR]8-8'0D$N5ONV@D37R T1_J*6<0$T*(:K_3"@I+
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M<Q6#.--8#A$NMH788O$)[NM&K1QBLXE*;"P!@=5>\,PL'D@T442+N(MB)D2
MTTH<'#&R 4^< 7#F7J%I"(X* S0^8JMHB6.E1[:@38,%%59>D#V 6U!J859$
M!*AAM@9&(D YQ' ,V1M'J66H ]1#D0, 20V"X&-(,&BL@=58F<M]0!5%%(SQ
M4\5/%3Q4\5/%3Q4\5/%3Q4\5/%3Q4\5/%3Q4\5/%3Q4\5/%0]^)I/%0Q!&HZ
M-](!@PED+)P.L@B"D/0P9M5Q.@(_<6Z0JVHQ<1#  X$<.)AVX]8@(.8GU G.
MPMM(:#O-)XZ!O1!$LDA('/!@412RZH<<2Q68J@N)ARA3Z"A!B+FJJ'I+XE$
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M20PPPPPPPPPP!J<3[ X^3FL  !!K'N"      #S@@  0A*AQ;$ YH
M   !!3X2W(2A8D,   !/"<8      #QSC##04%"# #!!###########""CJC
MFN3C)L,      )$@     #R@"! H&:8!OGJM:J\&(7>W:<H!!+HS\ 9N!BH
M     #3#"@   #SBB@! 8!3  :-         "  ##QH#Q\13HVD      !8%
M8    #SQ"  3_P )   @             $TV05^ X&S!      (  !(    \
MDD,410CB7U<,C"2Z"U,,,,,,,(&H<\+4N@0H      IQQC@    \])( 41@J
MN$ LE01)X/6      $D2@/'$\.;#      B  5     \EC (<%&(L((
M         $ 4PX/8LLH@          ,$,,,\QH@ @](WR@&(
M  6+(@G(B$*C         !QYYYQ^]K   "^Q0L<<@@           P46$9Z0
M@YE)           @   .)1PPPV2YDH-6PPPPPPPPPPPPP@PR [J@TM%"
M           \X!@  ;J%H,C^             P F\H+4XPEH
M   \=I(  '"ALH=R             0 *T4XD<Q'#               \-)
M /*_ 2D6@            44FD]V4$.%C               \Q,,,,-*%82%^
M,,,,,,,,,,,,,(<*(,B(,%8(               \M (  "V?8B):@
M     $ *4M.$4I9K               \MG    2=Q21W(              2
M@DF8$M'C               \O#@*$-22QM:TJ,$$         , V84-,\$H+
M           (   \[CP2HPKXT]_=& YR         037@$R@0T0K
M 7,    \8PWCJ-5K10  02 PPPPPPPPPP@[DX'AL_<,K         2#    \
MX!0<,*;S,L"65 FXY,@      0QTLI3F8,0@8              \\A0\#R[&
M<096(Q(IPPPPPPPPP P.L%:@T2?+0H             \\( T=X(:3G8BL<AR
M\WN6<H   04F$]24<R>B         4     \L((T29>
M $$ $($($ ,H               \@I>)87K  $($(,,,,,,,,,,,,(M@(UC;
M:T4K,              \X   RUFKCN40!($          ,$ZQQ.D\&]#P
M   (       \\( 0DU_G8"2(S[\(.        04J0W10P.YK           (
M   \ \\\ ! \<<@@@\< @\\\\\\\\\@<@ \\<@\\\\\\\\\\\\@<\\\\_\0
M*A$  @$# @4$ P$! 0        $1(3%!$/ @,$!187&!T>&AL<&14/'_V@ (
M 0,! 3\0TI31WZ?'*Q)D=!TU?!&CHI,_\;OJ[C'JJ7,&17T8_'#,0S)%-[WY
M&B=Y(W[R-4,0361*(WF3,[O(ZJ##7<D5#$'83@5/P=O E'!A'8L->?V))-QX
M$.PW+;,LKCIG6A5UW4Q(ZJ6Z? W,K2.A[(5&FA0?J(N3+WO)%W[E:Z.!$B*7
M0M0)-T*Q.]U'??H2F-W@?D<E;[M\")A3NWP1&_<;A3NTCHI>\\K&BJTBIQNN
MF!WKO<$W1;1I,@0$DN:A:W(<C'W9:NE9+BH>-;J.5@?9GDB' M,U,2-5C2 :
M5TV8U=%)%8,3SW?2*F-,F!WZ>*G8P*]3&JAP8GH%?7)C@EC455>AIJA6'X'X
MZ!WTSP8Z9U4>H[4O]?([[[?(YI XAQNGSICS]'<Q_HFJ#B*;M_1S$>OT8,#W
M^#'MR,'85$;\_L2<U$=M]OL^!7DPUTR<"U=4T.KDD0J"YUZK3--<CL361*!K
M) @0Z%49@OI$L3ASY%1)/3SSV*M$-R]<R>!/(AJ2)$B)1T#K)+R97C^#K?'\
M)A[9DD[[@=Y%3V_\+J!Y\[_G-['85&FB,:.PZLC/N)M3OR+A:(B)SR\M<'DQ
M^22,$CE#+<_UTBNN1VJ9%PP(#> I/G14PB9X'6_0/SIFNN3!D7' V N6[#R1
M00E9=SMY%=3D56O8JB<C4?@S!A/T'1$43/@:A218BWD=IW:15@)TG=IU>#L*
MJ+U_9\:.PU#@RUU$&.!F>@MH[ZY,&1<B6-"JYO8726TSP8,BY3M01I5Y+L*)
M%9;[CC?I\Z.,%(\_7R8%Y*4,KVG^Z*G@812K'WR7@["HC=J_L7P([;[?>F>3
M*)1*)7&J"X)KIB!O?^Z(=BE=&YG6:\KTTS.C,CL9%QN6NN.IF@O&OJ3G>_HQ
MTF!U8JT1,O7,G@\]$N!UDK=C4J'Y(6_R>1>"<D<_L=A4::(K N_<FS[;_@E@
MF*D7]@N4W!$B1(D1.1"X.[TK,"[^Y9:3GGX'YTNX>N1VT7+@0($"&BX>X_X5
MDQ[#LB&F8\<_N/SHKF-,CL9Z)"X'DJ14Q.]_P=B*F$^@=-,ZYTST2\BX'G2D
MF!V(,3T#TSKDP4D5J]"O(N!1-16J9,#$+H'XTI.N3!21="N%1-16K<I)@8O(
MN@?C3.N2L=&N%.'45C(K0,0N@]-$ZSHS)\"8NA7"G#GR*T$UDQ Q,5N@==,S
MKG2LBM3H5,T%P3#D2A1[$UGR0U3=2[)@M3=2=,QS/Z-S JN"9>G8\G=$Q+8N
MA0HUB!]B=[]"Q-9W03<RBERQ$/>/@G.[_)=7>3SR^VBHYW<B*:21@M4\"Y3<
M(]/$JZ-6WW^!M;_TO/O^",Z7;>Z$K^=%%#LQ51>O[$Y>G;S]?))EK1<N%Q+@
M5='3\Z9KP1HZ*1CN.@[\EZ177)@=.B0M8,<#P4GA=+<QZ9X,%)%.>A6K'$N#
M _!G7([4.X_!G5^.#'$_&COKDQT[J.K8_P#G3%14,ID7\E$^_P"140E3I>PE
M#3]1*'*$=O'U\".[&I33R+I,&6*]!6'8JV+N>-T)H/ZYV!]WI5O1LR8*MB<]
M+W)2@O\ $&"LBL9?N,J8'DMS'YTK.N1VJ9%;II9B/^=__\0 *A$  @$# @0'
M 0$! 0        $1(3%!$/ P46'1($!Q@9&AX;'!\5#_V@ ( 0(! 3\0\"C/
MF.?@776-%5P89F#,:.PZ."*P9C1&!J''_CY7A5A:.YG1VIHO%=R4ACOO>^A1
MOIMB<;Z09'6N[SHW+G=H%11NT"HY%1)>GT*B@FD&6=!U<CJY'6>NE#GP<V9+
MT.KF]%1D6%;Y_P!,#J_(OP)14:C>^1$;Z$53W>2%R96^;%7R'0ZF/@;R^HQ.
M&0HWC_@J0A*R+"%MDHY]?^'0??8Z#[["TS3].*_!,T)DBF]X%6&MR3*G=I(K
MT;_TE(L.EQIVW?N-VWT&FFES[P--.-\N')B?3^#4?)@5Z$J-[R+$">_8=ZDC
M.)U220\\5^%N*E;"K1;H614TN.M7X,SQ%;X&\CTI&]X%@5AB=I4BWOT\@ ?A
M=%K!U%>#$^15O@=J#4/3 L"\DQ^"QS(K K:9@5ZCH9@5I'Q5;X'9P.,:8%@6
MK(^$?<H]/X?8]/X?8<:B?1]O)4TQO?\ P8NHL3Y''P,>JQY-ZJ).6\]C9[]B
MDU''H_>Q4;4[YD.@HCK3]TI&^OX+L4@<8W44YW<YL3]<'F8CT'7Y>F'OG^$&
MZ#M"$,2-I3'E>>DBIOJ*B&I4#<R^8^@[\=6CT'55T5S L&(&/D!_KN=#[1T/
MM'0^T/?)Q%?P8G=))AF4^0U*@;NR&D&ZM\R:R7XRTLG[#Y/17T6#?^#')7!T
M'WW.@^^YT'WW'/?/$5S&O^&80OZ.K;W44QMB/X;/47<=7.ZB;DBD;I_TQ'$Y
MF=[P8^"IMOGV,"=2*"E0D70_"M(E?7L=!]]B-DG/+A*YA/5%M\R2U-T)@0TX
MW05EOH7H5=?7C*]-%:G3^#HFQJ!7,"Q!@?A0)+0L:/3]0N'*O+]?"QX('S>O
M76W&5ST%;XTQ.F!8/T?CN9H8[8<=?^DPEC@XTR*7&GJ1+<CI/0=)'<EU&E7I
M)%7J'13O U4,H="L^YF!J&_<Z#4-+=X.8:LW>-9N17?0Q/H4.G,PA59(K290
M_+/1YC3\*0_(T%;XTQI@6.$R-CT?A]B1HF'AWXKM0?E5;X'K@6#'#4':2JST
MC@Y'-"Y?8[N-V_1VINO;13%=T[F$;KV'>AT;KV.9E\L#ANEBD5)K[_0NNZ=Q
M6KP.>]U,O?(Q'H5VZZ8>^?X0;H*W!OXSJ?AG4_#&M2V^.'F@^AS'$B<'(_-%
M2/?1420J*-51+@9)YBM'H.S&Q7,"P8'XUR)>_P",V7^&R_P4Q+US_/&QZI\A
MK'L+GZ&*%!OR*)_A9/V'UT7/14ABZ>6MOW(ATW!A(E1<H_")H-9>]P5=.7D.
M9G>\&/@;+(B@N6^7^C7,O3V.ON/A.2N3H/OL=!]]CH/OL=!]]CH/OL-:^*:8
MGP25GZ+[Y#L.4X>!/EHQ Z\57.@K#HI&H%<P<A57#>JX;4&U!M0;4&U QFUW
MXN6\BN8^1V&H9;W;Z,%9XZOI@=$-0XT=CD*TC\M-A&#&]_HU#:6]T$1Q\Z8'
M:=,Z<A6\O44&!V&E+CR.=%:O@P<BL+W_ -@?EZ2.P[T*172E=^O'SI@=J#C!
MG1&!^6P4DP/H)TTY[]>/G16'5#UY"\OB":F('5B=-)OQ\Z8'5,;D5]%C1^1B
M1^#DW<FLET.K%,&#G[<=7TFD^@[1HKZ<M'Y%QG6-,03DQ [UW!,)[L-0X)ON
MQ45;&_\ 2_#3Y8)9B?0:BC,'7>Z#I1BQ E9+=Q^1<9,3HI=%T$IJ*A#A+T_"
MW\&Y;G<C4S.23<[J1))5WR$HHMT["M3>!-K?MP[TT5OC^#YZ+EO=1N:L6$A<
MQ\*"G$FZOWQ6TF^^7<2K0FB]OL2I.[M$Y&XA;J)2OO\ SPSQ>NZ'0R:Z#46Y
MO2*-[W01T/F*J3XB;3E'5?/!YCT2GZ)W[P.U-&Q5T="*BK J_1B>&K? ]$I,
M2*L&/*K5VD:APA>!"XN=%;X'TUP+!@?E%>HL3HNHYAP.)^?P417H/H.)H+J7
M*3&F1=OTK!319\.=%;X'IG18T?E%>1"I'_GWT2N7H726Z$T'5Z2.E_)<SL&O
M/-C,1NS[C2GJ*B2WD3AIK>_Z/RF18WTT:;H_0Z[J.J,P8WDOO?(5*^05G[#H
MJC3$X=#$"P*P_*9T=JF???T*16INO<5S'Q^'05,TZ?FL<)7*BM3I_!T3D::N
M*Y@6(%8?EY<\#/\ XW__Q  J$ $!  (! P(%!0$! 0     !$0 A,4%18?#Q
M,'&!D=$0(*'!X;% 4/_:  @! 0 !/Q!6(:K*P\8@YE "<GI\LU>WN49LL1'J
M]'KGJ3^L%':2(4 H],.&9(&K*AD1H*I!Q\.@CRHMK&MATV&6=210W!$[G$IU
M#6/ %W"8BDU>X:?%:>(I Q!:*NND+DX34Z[ @*ART-(YZD_K/4G]9ZD_K/4G
M]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K
M/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9Z
MD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]9ZD_K/4G]8R@L65&^,]2?UGJ3^
ML32.]#F_C-#!2D-C@.LWO2;;)DDW0V.X'6^,6#ROB@]+GJ3^L]2?UGJ3^L>)
MP7B%.F>I/ZSU)_6;(<JY(JZUX[X#[W6D;II7@%-ZU7?.2OIA1'2A/.$Z5'@Q
MY)]G/4G]9ZD_K"KH"&0@FYR:^O[ H4*@32 Z0@_S/A!0H4*%"A0H4*6 EWAC
M\*%"A0H4*%"A2!!</P*%"A0H4*% .",8/JB>?KGIO9BCKU3H3D1X7+6E'])M
M5= <_I7.DJ[)'^'$]RV,0E(\(HG"<F%&)N1:D( 4R&;3;AH_O740*Z)#BNC(
M/8L-$$A$5V;VG#BHZ4N@:=>V9I8$@0JP*@JZ@_\ D^B=GZ@@"B(\.30;0!4%
MT%=.IUB@C38E9YIZ ^1@N .4!P55_9Z)W?K66Y7H)?LN#@24-HLZXE+7)SPB
MVE"FEG7.OD[.5R_JBR)6S+C$@MFE+WPD14H-: NR<K^I6EN91NB=^,JHPQ1*
M0!AX"_0R]G(.(XMD)(=9-8"DQOX%J&G94YWTPQ.!^/)6*FQ+P<2.%Y;BTYB7
MD#\W@QO'$8"'"!UHW_++C'0%U@$2Y:T'66W10(FP #4#OS^B/XX :I!^9-/4
MZWHQC65$NJ%+SL:N+]U&AQTD:#3=[TUVV("!1C8H-N7CKFT"[<<;'430^<W@
M,,0&,2*"IH#-\0J:IU! :$1V:Z\AB1@(<T52U3>C=D*C+0&BOEGZ0D8P4+(&
MB%T@<NC%04"G9HC:'?J0W$SM,XB8([E.KE4X<C'LTRTC:D:3RTX*1< DI"6Z
MN9TQDO"JUL)32KO3UX3S).!!2.$.UW^H@]-[/V>I^7_S_1.SX7HG=\$RPL*(
MW'$D;![%)H"&)YK$%]T@D0E*G)U8XW*%(LBDP)2KQL#> L2=3S#6@$4F[K66
MC]7(96%0VG62F) U;1A01!0!J]6MH8^@,+5X\'VQ0+)XW*4#:!>#?.%$P"2I
M:.LYIH76.S/NBH\<H11%@RZFHIOGKC<H4BR*2 2BKQL#>"J8(5M4.-B&6O\
M1R$5A4-IJR4PJTUY%R"6;.^*<[C4HUK#MA.6'VQIU2369"&S=.)RFYBF5=I
MMVV<9K<($UH XU.:MT<M; M223D#(\^<;E"D60))"45>-@;R1,H*I:EX 2DY
MX.O!=0BNK#<K5..3"Y;L:[ D!2MSHU6>36L.V$Y8?;#OT#4)4&]2S5A9A$U
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M=\;R+W"M2R2N8C'&]Z9;Z5>RZ0XX%YAO.^RG$B*HE.+XP%"2BJ$5I4B5K@R
M[+!FZV%9T4/.)'+A: ]PAPD\VF.KHQT@HCDVWIO28)5RD%PR"G*P<$_\Z"L
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M]*!\C<<Z><G^_P#G)_O_ )R?[_YR,HC2O7\YH0+%'N%=FS[F! $@T!:_G 9
MG9?G 0)!H5I^^;;:[U^<@(+'E9*R^3?G%$O<$O)U=XU* L1IWWQ<1@\E_G/^
MQS_.)V[PC^\HCQ^?YPJ@K6/;]\0ID!OH4TO"Z^F.DAT4"3J^.=T&K5_[G]O$
M_P"Y/]_\Y/\ ?_.3_?\ SD_W_P Y/]_\Y/\ ?_.3_?\ SD_W_P Y/]_\Y/\
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MZ^H(Q)QA4,-MJ!4L55@=\B9ALLH[#]%-_L&Z>2'?JY_:,/)9!O2?//0']YZ
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M"0LJMU0P* (%@@5=A-4+K /.0_-9%(U3QJX%$+!:H**#I-4.G_F],[8@,2R
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M^<_@P/+-+Q=8TV&A-2PWS!P^)LZR74X*;\XI&X%>92ET3=QI0@[+ 7EO2??
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M54A!YSP-\_"UM\9?8#H@6!/'R[S'NA=(!5TUX^N6W%FFEJS1IS2CEB!)%3?
M+=9(R(#0P\F#*!FGC*B'NI2;:.@Z?V#=/)#OU<_",USPAU>WZEL@:7H+'ZL.
M$E4'?IYYTZU8_>74E4'?IYYTZU8_>74E4._3SSIUJQ^\NI*H#$<$@@>JG7^2
M+L/T,USG4#KXU\%AZ;V8S&[_ "T_TP)) WH !XY?FOT";>F?M4NX"]0&%5<C
M3GMB7EL@1% 0I:K.D,,>RVT#5YB5$B;XP82"!X66B*QDD)RL(8#!+<*-T[2[
M<N/)KJ*BIH1')N8]UCCT:"3;2KH]F-\A'58E UN0<FL7J;?P;1II3R [8S4D
MJ(=1"-'IL>3'$]A"(0<Q2<D%UN9HL!RQ"P@O2UW6"ZMQ5H8]4*>'Z8 4 I$4
MM1$7:4W_ .WTSM@$F&<(D3#$?6L(#J4<9UWEAV,"ZL@,/FX-'15(QI3EO4[,
MF 1Z &!G$$[& 7'VX!'Y)XP0@G)+0EI=FKQQ;")T!D $'EUKFQ2R+130C2TZ
MZSU3O^B^U>0,;$95[!Y/EAHX3A!$24[!=AA(CRL% LZ;Q\Q#63X0'>^[S<.R
M"A)GI%TZ&'VKEZTCCN[5^DKS,:&:4 I*X&C7*' )>QHNQ4M&WZ_L&Z>2'?JY
M^$9KG@#J]OU#R3&T4*'A[2<D5<X_X#^4FL=ZXY(U>/\ @/Y2:QWKCDC5X_X#
M^4FL=ZXY(U0"2ES!W1K?3JR5OZ&:YSJ!U\:^"P2:VH*P\8@C8# 4\;YR T20
M&H:1MM&T;YST]_6&(08 AGM7/:N>U<]JXPH8(L7\0MFBO257.HD"+(P15T4W
MB[U:5$EN +!73B[5H(;D$/DFSC%I*Y*Z(<:K9)UQ$CX=@48EQ5JK\N>U<]JY
M[5SVKGM7/;N/,?S.>U<]JY[5SVKGM7/:N>U<]JY[5SVKGM7/:N>U<]JY[5SV
MKGM7/:N>U<]JY[5SVKGM7/:N>U<]JY[5SV3BF*HJ>V-7D!W%FCQDB'K7Z3D
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M<8J$ H4?NI?DR=T!8DCK@DSFX4@\S 5)%=B='EP8@M*D4=!P!RKRN: \)XD
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M:SLR>;Q 3P JI)T2[H?J-T\D._U>OE\(S7/ '5[>_P +77.>@=?&O@L <89
M=&REP@##@3P"B4">#]#RRFKJ;/&/<LO<LO<LO<LO<LA2.<8B$TT_>P($C#U%
M'^*<8H8 .FHZ0-"%XWK)C11%2H$O7U+NXSMQA@'/U@?^8ONMS-@WB:4!V[VX
M%"IHB @8@!0OG-+-N[G04@<!K?&'[XR- /,D$=/6X,A+".@"T AS@K*L7(ZD
M*IY5&&M9P@P!"@[$TH#M[N!I03=%%0O3SK-,9;Z(0E$-4+YSW++W++W++W++
MW++W++W++W++W++W++W++W++W++W++W++W++W++W++W++W++W++W++W++W++
MW++W++W+(2!&P=]8]RR4$%JH"778N-ELTCJ&5.=;R'#N',#:W@#GI@<H]-("
M!= TG\N)VE=V3OR6[MMW;B-.N$:!%2[5JPQ)QU3F)P78H[W<E86(!(/5$%E@
M9(7K:>_'N62V\( H "6@DDXO. C\VAT[ 042/4R89PE")2N,\]_+C9O1K2^<
MAUJ!#'0)AV48[,=&6];6K0#>L[X&R:10 1I* 4!9S@YFO$G5"T!\@_9V7DAW
M^KU\OA&:YX ZO;W^%KKG/0.OC7P6'IO9B[!#.T4*J7HYZFW%?XNB$@=-G')-
MS]/4_+]S^ET5%:5KL5P1QP -U0!S)K22<.,(X%R%BZ"IP\MX4R+ 8%+L*8^>
M,//1C%#:MT[23+I321V$=6Y)Q'BC^T@:VHM*(E>BVQU+R+1--? Z=:;,"!:4
MYVMI0V?([9,9/#O8-\ 1^&/^UB.&Q)O:HKV4<XW,P!*++:).SQ8M:^H.(\BL
M3C62])2;6W11-)!-\S_U^F=OT>>K<-NR<7<PH(>0/ #JPZ<.L9U:X138$:O7
MB./"DKYS  [#H)K&TQC9T $%:Z5SD@*W27(C)= ,U-8M(0M$/<8;T$M,O750
M].RZ#W%?E*YZAWQ (E'D<"5=,GY21$[<N-L0J@Q0(4=I76C&:B$C5M,LO,E^
M6/$*=4E%D5KN)OIDID4>6X TZ%V+BRL56P*,=MB(!W@LG(?2VR1 . R:Q4S5
M:0/,G\?L[+R0[_5_7\?",USP!U>WO\+MYST#KXU\%@.T?VN'G%0/$!65Z]L&
M-D) UN7R?<ST%_>'R%Q3IYR?[7YR?[7YR?[7YR?[7YR?[7YS> G@9K>^E^ES
M?>5O+G[X$  ANAVP 3& \IP&_MB%50.EL%O<W\L^6"1]3>,# ) !.)VQ+2HZ
M:S2/RRQ&B>:$3ZA^6(C(PU*JD/L& ! H%Z>^10C1K4^>2"-4AE/7H'Z8$ "A
MN'8\9/\ :_.3_:_.3_:_.3_:_.3_ &OSD_VOSD_VOSD_VOSD_P!K\Y/]K\Y/
M]K\Y/]K\Y/\ :_.3_:_.3_:_.3_:_.3_ &OSD_VOSD_VOSD_VOSD_P!K\Y/]
MK\Y/]K\Y/]K\Y/\ :_.3_:_.3_2_.#C#11[?/)_M?G(K$J"\A-^'"HP 'I-;
MR/#=%#"[ROQ0@VYW]Q@[BW$)KYYXF-<]<%',WTGTP.I0(TO.J_/ C;$I"43?
M4W\L/UHA[_/&!6)X?SA5O4"KKJ?*99%BCI>YB-8D"#JM< %K4;5_C3]L:Z*:
MR?5FU-W 1FX]'6+D]BL 5N^A'QA^<+LE<=\[OU_8-T\D._U?U_'PC-<\)W>W
MO\+77.>@=?&O@L/3>S*1$6ZG 2O5Z'&]@84J P($ [%V>OZ>I^7[DX$@P58F
MA.XA8ZPT\H'LD$ 2:;NK-8$O&V7B_7QIK+.1K3+YNK)HY3)5:HK*!UV&4VV8
M0K"3KD[ 8)&SPM129V:-U)R8EV71,BFC$ X"Z)?Y X$3OD*NTM$(O17BN(:X
M"D>_/:%\N^(++ C@: $'4?4N0$71'&^E8FA>>N1_>T!  H@T3JKWR1C#;-JJ
MTWD)763_ -GIG;]$4:+=#KXV8P(I>179L5(=$W,I=M&^ ;F?]$U,%.)K1H-1
M+42G'+BGQLY<20KT!M-<8,OC<(D4V-73JF'W:6_. )7!P/71EAR00D#='%2-
MMB.>H=_T-N=1>"0WH,.8F),N-BSL4G01XL&8&-MM#O>,,WW\!B FG8-7AM6D
M%+W0K> E=HAO&FE6FLL K$[Z+'6$IL0#*S#>@.UJU V(&':V* *#1HN^7]>R
M\D._U?U_'PC-?T3N]O?X6NN<] Z^-?!8%)UR":.]Y1@ .M%4@GUKT,=<\;+(
M.A%W(+'L_H+F*(:I;CVG+VG+VG+VG+VG+E8 D-^*P0:%HE,"M*"1W=<9R+]]
M0!-F:SS8R"Z-%,6$< "5(#*J8PXK0QEJ*_C!"W]=Q!-F;U\CH%([SH5R:)=A
M"%P,BW9]:*38(8#N!PW_ #B/(]-:Y\9$I5Z=Y)H\Y6O;4@=Z%X=!>,K<D_D
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MRNO^N 6J[MDJ)06;0KUSW7'@<C;\L]^SW[/?L]^SW[%RDCJU38[&=$Z8D3;
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M,1+DT ZK7&]!.O78'SQLP[,7P7%!!D,)=M\:CZXGAJ+J!=[NJ9$!C1JW_O\
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MWP#=9_T34P*-C2+"]Y2OAP^9#8@!N-37*X88(3*@K0A=H@E-97)P:YP!5<'
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M"!O&]"P3"!HM=[[';'E<*BBD6DNN_=[X)]U/-*56IU;DA>MI[\>Y9+9P@BD
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M_M<^?[7/G^USY_M<^?[7/G^USETZ*/;'@HY$4<T3RFVHB]&PSIMQB7O\\'0
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M&VT'>\84A"-]H5\MP.F!?2+IMXNPJ7Z8V63N)#J:*61=N3:P*9$XP:@7=JV
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M!P5.WA@Y3K )U'$W;V;@6CG7EBH[AIX8>^RNK#1B98F/X=H A%O6C<4<D2"
MT?-!\^,"M58KD-L**>N@W=RFI0(9!X)@/R. :1I>M!^5Q(XTONV XX)S=(!O
MK,'"8_)"?+ (I3 36>&5Q2*3(25?S/ICT8P)D3:TI:6Q.'!+O\!H3]2L3L Q
M%#=.6;NN,,'8%5*HN[5D[%36=HJ9!W=W>Z<&C YTX$D"YTDE"*-T@*<$),,'
M!0?)ROI Y*V<!<#""\VY,S! :R%(VIQ-<X)G(,6H7[XE9(7N*WB::-I$F: 7
MY*N;=*B;U.V:9>E]VP''!.;I!)0'Y2H7KM4^V3_E! *.H@:.II*XX<]4@E4"
MD#!V;V.H*"'-0WF-!86G)7+(#Q%Y$NK43SXP:=RP;&+L0)KCG&E&=!-KT\0P
M5-FMOIAH,&@H0A(?(Y1*A!)$-'1[],T:M:T#OGHOU^!Z9V_12$IA:!)@[E*@
MBOE<J:Z]< BJ[A0?P<J\]H%Y8!4+F$NOY87&8.H=*K+TL,(<6XD"392':WG'
MWLC@\V(C'>WF=L,J* 0(H'6RQK7F:SU#O^@0D"V;@ZE#]4R(T@V%L (A%OD<
M5*G$L(6?7 *+0=GJ8:Z3QAC$SHF"3IR<):<<[*4H0-!" 82-()K1A=0&BU=K
M@R;I,A)3-#K^SV1W^K^OX^%[<[O;W_?S;+?XIUCLO#^O_=V[^-?!8>F]G[/4
M_+]$*41A'C?(H3Y7:5/6->\YSM7B%Z:7!2EW#-7O45$@;<B=%Q63 HG$CT00
MR;A*?A2(7*OF1WHYQA46#1#3;:%[CTPAHF.0.DK(4K?;_P"+Z9V^%ZAW^*O]
MD=_J_K^/A>W.[V]_A?\ =V[^-?!8<HX^*X9>:X07MMSEJDC\TNL^?[,/4N"T
M%( 7JN>O>%%X9!WXP0&@::V#Y\!E_4)=*B,ZC<6!:J=]KKZXH!I%W.N;#8".
M8Z7OUQ8%&)W$D?IBA:!!JAVN>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>
M>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>>O>
M>O>>O>>O>>O>>O>=F-%O;'V_W8AM<#A^H3T+LUSGKWGKW@)IK'SPV$Q4:6<"
M+;Q)UP*(B-B\.V[XSA;KH^2ODQ&6*3RG.K=9_.M>^#$-FLOS<2E;PR_,^9GK
MW@*-Q*C /*],4=O;L'*',PH$@@#E#L86J0/DN+' 49K%G?=KA^V:P>H'3S]_
MV>R._P!7]?Q\+V[W>WO\+_N[=_&O@L/3>S EP3@"<B&^5I-.*SZ*+V86E,>3
M4_0 ><R@96= ZX1^MZ,J:@/T7BXD%CG;J0TK(!-%4F @9ER!K3I%X.H [C?Y
MC8,G2W;W;Y+C+MF\$'1ZHIT#' EXRS0MC;U74YS13P^ WK'AO!74<,?!,5A:
MA7OK_P"/Z9VP.;E#D4#QDN%*$6*ZC!=,QZR@EV^>CF)RLZX1QL:,MC7"-LZY
MNJ141(*E0-6.^$1"E8T4N'C;N:QY0,B23/M&[EX*ZR">G@RG0XY$.;QB&^\@
MA)>MA^C/4.^"5?6J7 \XY_WMEUG!I"\/4Q,#578Q"7=WL=F#TT82NX<:V>A?
M.#]$ZDWW-1>NTZ3.=4@I/0-:80K=5<N-1!V XV*EY#4S9/C=%GH@:;:4LRD<
M# @5;+S'>_V>R._U?U_'PO;O=[>_PO\ N[=_&O@L 4ZY!-&BMR"29$(L ,-S
M88,P>78-A;JQ_1)-60U%N/8LDQ19T#?">7-@Y0KVA9V3N9)&@# 2P*13@6TI
MD>%H&B(O5IKMS*7<KC,7=1BT733 @@Q!V1V@_9WXP4M J6@[S")D(G;04C1E
M7!% (\/@QPD+K<-<4X85."- %LF2\R18%%#PWSB?$]!  TTQ,&!=E!K.^#=$
M:I]BZU1$\)B4JVAU Y?#.8+FD-X!Y8V$D (=W6?-4&D[AT9LQPML5--*&>Q9
M>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9>Q9
M>Q9>Q9>Q9>Q9*0)T!KK'L639B>H2,)$F^>,1>5V:'=.!EH<5-@3IA"U>OJ!=
MP@^;QCYA2BA2_5FJ9.2L"(:*:+MQSAP:R7;"K8!.[\LXKR)&[*9 YO\ 3)"<
M+1WXJEL*IZM< *^#(,.YA0"+.2CQPF)O9VH^36\/P!1=98.3[L,><-RP*KT>
M,2)II>%KT&G&3("512+J#8<B4WCL-CB-M4;IV!1WBJV^P:6*1ECOFG(_I:@3
M6[?=[#OE= Z3Z(]7/9'?ZOZ_CX7MWN]O?X7_ &=N_C7P6'IO9D4PVZ)*PNNC
MFCJ+N5IO+8SM7FZP3T>GZL:,XY4&YR'3QB9#)4X4C;2JJAT %Y(\[*((G7SX
MUFB]W@Q*L#580[$ZXU=;(HJ6/!L+=.G'%2J*@?4;+*=CKG"RON6TGM#0%.N5
M'H N[V/-@^>\-V0E8EN$U/FF2Y,/OVJE< 4;7AK&<QH=(=!ZIK6'@4$!R5%'
M4JXX,T)#HUL%!+2&@:UK% 'D'0.R.1-)[Z/!LF0-%(2JJ.XU@4 L2*5-25RM
MZY62-*E$(C3FS7&&)RC2Y5I1=%MKNH!,R"/:MP1ZSI_ZO3.WZ!B<-O%2G$A^
M7&Q IT&"X!3=>&L72.E0'4G-6$ 0KD!@I)0WT,KDUY@$+M^SQCA-@0)[H XU
M;SCY V*KF:#PK4#2+0*I[81U-&@$?GHSU3OD46(I5P><-1N4BN'<L9J\.%8_
MJ4-HT4K#;HQ>PMJ% 7QO)5T5W6P(@UV=5W<*1SH@,U%TZ&&A,6*JH\ DY5XQ
M)^@FL^=1WFZ-&K7)3844"_-?TE8(S-OL]UVR @;3YI/4SV1W^K^OX^%[<[O;
MW^%_W=N_C7P6#AHU171B9&3CK;M[%<LBUPS>#@_OGM3#"(, :SVIC-EODR6*
M!TA1OH#MW7MDN]B2(UUHTCT3IC'W7J:4!*==R]TQP^!=@4\$1MU7I+E9R%VX
M! -H5TZUFDV2%B+2@#H73TN7 @?)]$6*:SLW].&INSJ#:<X 01E6Q1U0@P*,
MR01/7\( A Q><X+Z.W [C.05"KPY1 9I*DHD:)$&N4T\)(5L;J :8Y*D0$U.
M::U1[$<A<WB3( *[9QFCKBK( !U$"*BR9:*"#-0/9!L4.<)O(&X*#0USQ@#
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MX7MWN]O?X*1BN:2B>R"=^^D"4W-0>@P GM_RP^ P0A4031\\7(CR.S^<YB5
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>asher_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 asher_sig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $)R:61G970@
M06QL:7-O;@  !9 #  (    4   0J) $  (    4   0O)*1  (    #-#0
M )*2  (    #-#0  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1"  6 #(# 2(  A$! Q$!_\0
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:44 (Z+(NV10R^C#(I:** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
